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Abstract
Staphylococcus aureus biofilms represent a significant cause of morbidity and economic
burden and are often associated with nosocomial infections, including medically implanted
devices. In particular, prosthetic joint infections (PJIs) are a growing concern due to the continued
increase in orthopedic procedures. Staphylococcal species cause >50% of all PJIs, while S.
aureus represents the most invasive and associated with the most morbidity. S. aureus-associated
biofilm infections are recalcitrant to antibiotic therapy, due to both the acquisition of genetic
elements and metabolic dormancy. Furthermore, S. aureus biofilm infections remain chronic
because they cannot be cleared by the immune system. Recent studies from our laboratory have
demonstrated that S. aureus biofilms actively polarize the immune response associated with these
infections to promote biofilm persistence. Specifically, biofilm infections are characterized by an
influx of myeloid derived suppressor cells (MDSCs), paucity of T cells and neutrophils, and the
polarization of anti-inflammatory monocytes. Augmentation of monocyte pro-inflammatory
activity, either by adoptive transfer or MDSC depletion studies, promotes bacterial clearance,
highlighting a critical role for monocyte/macrophage inflammatory polarization in dictating
biofilm persistence. The inflammatory properties of leukocytes are linked to their metabolic
activity, where anti-inflammatory macrophages primarily rely on oxidative phosphorylation
(OxPhos), whereas pro-inflammatory macrophages utilize aerobic glycolysis. This suggests that
biofilm-associated monocytes likely shift their metabolism to favor OxPhos over glycolysis.
Therefore, we characterized the metabolic state of monocytes during S. aureus orthopedic implant
infection and whether the metabolic reprogramming of monocytes would promote proinflammatory activity and biofilm clearance. Specifically, nanoparticle targeted delivery of
oligomycin to inhibit monocyte ATP-synthase of the electron transport chain significantly altered
monocyte metabolism and increased pro-inflammatory gene expression, which resulted in a
significant reduction in S. aureus biofilm burdens. In addition, nanoparticle treatment acted
synergistically with antibiotics to clear the biofilm infection, suggesting that targeting monocyte
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metabolic activity may represent a novel therapeutic target during PJIs. Prior work from our
laboratory suggested that arginase-1 (Arg-1) expression, a marker of anti-inflammatory polarized
monocytes/macrophages, may also contribute to the inability of myeloid cells to clear S. aureus
biofilms. Using a conditional knockout mouse model of myeloid Arg-1, we show that while
myeloid-derived Arginase-1 does not influence S. aureus biofilm establishment and persistence, it
does play a significant role in controlling planktonic S. aureus infection. Collectively, these
studies reveal that monocyte metabolism is skewed towards OxPhos during the early stages of
biofilm formation that limits pro-inflammatory activity, effectively facilitating biofilm
establishment.
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Chapter 1: Introduction

Modified from:
Yamada KJ, Kielian T: Biofilm-Leukocyte Cross-Talk: Impact on Immune Polarization and
Immunometabolism. J Innate Immun 2018. doi: 10.1159/000492680
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1)

Staphylococcus aureus biofilm infection

a)

Methicillin-resistant Staphylococcus aureus (MRSA)
Staphylococcus aureus (S. aureus) is a gram-positive bacterial pathogen that is found to

permanently colonize the skin and nasal mucosa of approximately 30% of people worldwide
while transiently associating with another 60% without causing infection (1-5). Nevertheless, S.
aureus is regarded as a significant threat to human health, causing a range of diseases from
superficial skin and soft tissue infections (SSTIs) to more invasive infections such as sepsis,
osteomyelitis, or pneumonia (2, 3). Prior to the 1940s, S. aureus infections were routinely treated
with antibiotics. However, staphylococci have the capacity to acquire antibiotic resistance
determinants through horizontal transmission, which has been routinely observed following the
introduction of new antimicrobial agents into clinical practice (6, 7). In addition, the common
misuse and overuse of antibiotics has contributed to the ability of S. aureus to acquire resistance
to several antibiotics by the 1960s. Today, S. aureus has gained resistance to nearly all
antibiotics, including penicillin, erythromycin, and tetracyclines (6, 8, 9) giving rise to
methicillin-resistant S. aureus (MRSA) strains (10, 11). Therefore, significant efforts have been
made to improve clinical care by enhancing antimicrobial stewardship practices (12).
Due to the high pathogenic potential of S. aureus, the emergence of MRSA strains poses
a significant challenge to the treatment of S. aureus infections. The defining feature of MRSA,
over methicillin-susceptible S. aureus (MSSA), is the acquisition and insertion of staphylococcal
cassette chromosome mec (SCCmec) (6, 7, 13, 14). While there are currently 11 SCCmec types,
all of these mobile genetic elements carry the mecA gene which allows for broad-spectrum
resistance to β-lactam antibiotics (5, 15-17). This is because the mecA gene encodes for the lowaffinity penicillin-binding protein 2A (PBP2a), which β-lactam antibiotics are unable to inhibit at
physiologic concentrations, leaving cell wall synthesis uninterrupted (15, 16).
The acquisition of the SCCmec mobile genetic element and emergence of MRSA strains
has significantly complicated treatment of S. aureus infections (12-14, 18-21) and MRSA has
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now become the most frequent cause of hospital-acquired infections (15, 16, 22, 23). Over the
past three decades, MRSA infections have increased in incidence within healthy individuals who
lack classic epidemiologic risk factors, such as hospital exposure or chronic disease, which are
referred to as community-associated MRSA (CA-MRSA) infections (10, 15, 16, 22-24).
Furthermore, both healthcare-(HA) and community-acquired MRSA isolates have attained
resistance to non-methicillin antibiotics such as erythromycin (25), clindamycin (26),
ciprofloxacin (27), and tetracycline (28). While glycopeptides, like vancomycin, are commonly
used and effective against MRSA infections, clinical isolates have emerged that exhibit complete
resistance to vancomycin (VRSA), or intermediate-resistance (VISA) which are only susceptible
to extremely high vancomycin concentrations (29-31). While the prevalence of VRSA is
currently relatively low (<5%), the continued use of vancomycin will likely cause VRSA strains
to become more prevalent (2, 6, 32-34). MRSA infections are associated with significant
morbidity and mortality rates ranging from 15-60%, which now account for greater than 50% of
all nosocomial infection isolates (35). These increased infection rates ultimately result in an
estimated 18,000 deaths and 80,000 invasive infections annually in the United States alone (36,
37).
As stated above, until recently, MRSA infections were primarily the result of healthcareassociated (HA-MRSA) infections, and affected hosts with compromised immune systems,
chronically ill, or those who had implanted medical devices (5, 23, 38, 39). However, the
incidence of CA-MRSA has continued to increase over the past decades to affect healthy
individuals who lack the classic epidemiological risk factors (10, 15, 16, 22-24, 39). Populations
who are at risk for CA-MRSA infection include intravenous (i.v.) drug users, prison inmates,
athletes, residence in high-density populations, or those who come in contact with infected
individuals (40-44). In addition, CA-MRSA is molecularly distinct from HA-MRSA. CA-MRSA
more frequently harbors the smaller SCCmec IV, while HA-MRSA carries SCCmec II. CAMRSA is often associated with increased virulence, relative to HA-MRSA, due to its expanded
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repertoire of virulence genes, such as Panton-Valentine leukocidin (PVL) and staphylococcal
enterotoxins (39, 42, 45, 46). In addition CA-MRSA can more robustly inhibit immune-mediated
clearance through the expression of staphylokinase, staphylococcal complement inhibitor, and S.
aureus chemotaxis inhibitory proteins (CHIPS) (47-49). Of note, these molecular determinants
are species-specific, affecting human but not murine cells. Therefore, the emergence of CAMRSA has represented a costly and increasingly deadly challenge for the treatment of S. aureus
associated disease.
The Kielian laboratory utilizes a clonal complex 8 (CC8)/USA300 S. aureus clinical
isolate that was isolated from an outbreak in the Los Angeles County (LAC) jail in 2000. The
USA300 clade is the major cause of CA-MRSA infections in the US, Canada, and Europe (5052). USA300 strains are more closely related to S. aureus lineages CC30/USA200 and
CC1/USA400 as compared to CC5/USA100 and CC45/USA600, all of which frequently cause
disease globally (53-55). In general, USA300 isolates belong to a single pulsed-field subtype –
USA300-0114, indicating that the strain has become wide spread without acquiring significant
genomic changes (23, 50-52, 56, 57). USA300-0114 is the primary strain responsible for most
CA-MRSA infections in the US and predominantly carries the IVa SCCmec subtype, spa type
YHGFMBQBLO, msrA-mediated macrolide resistance, and a number of virulence genes,
including lukS-PV/lukF-PV (PVL), and arcA (arginine catabolic mobile element (ACME)) (45,
46, 57-59). In addition to its general stability and clinical prevalence, compared to isolates from
the 1960s, the USA300 LAC strain is significantly more virulent, invasive, and able to resist
immune-mediated killing (60, 61). To facilitate genetic manipulation, the USA300 LAC strain
utilized in Dr. Kielian’s laboratory was cured of the p01 (cryptic), p02 (confers tetracycline
resistance), and p03 (confers lincosamide, macrolide, mupirocin, and streptogramin B resistance)
plasmids, which is referred to as USA300 LAC13c (23, 56, 62). Unless otherwise noted, this
strain was used in all of the publications and in vitro and in vivo experiments described in this
dissertation, to strengthen the translational impact of our work.
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b)

Bacterial biofilms
Bacterial pathogens adapt to host tissues and immune defenses by shifting between

planktonic and biofilm modes of growth (63-67). In general, a bacterial biofilm can be
differentiated from planktonic infection by its association or attachment to a surface, which can
be biotic or abiotic (67-71). For example, infections of native damaged heart valves or implanted
medical devices are both classified as invasive biofilm infections. In contrast, skin and soft tissue
infections and sepsis encourage planktonic bacterial growth over biofilm (68, 69, 72). Biofilms
are multicellular communities of bacteria embedded in an extracellular matrix, which exhibit
altered growth, metabolism, and gene expression relative to planktonic cells of the same species
(67-69, 72-74). For example, biofilms are typically antibiotic tolerant compared to their
planktonic counterparts, which show susceptibility (71). This is due to the metabolic
heterogeneity of biofilms, which confers antibiotic tolerance, since most available antibiotics act
on dividing, metabolically active cells by targeting cell wall and protein synthesis machinery.
Therefore, most antibiotics are not effective against metabolically dormant cells in the biofilm,
which are also called “persister” cells (68-70, 75).
The biofilm community is encased in an extracellular matrix (ECM) that supports the
three-dimensional organization of bacteria, while providing protection from the environment,
antimicrobial killing, and immune-mediated clearance (68-70, 75). Unlike the growth of
planktonic bacteria in liquid culture, the spatial arrangements of bacteria within an anchored
biofilm shape their microenvironment, from intercellular relationships to concentration gradients.
The sum of these interactions influences bacterial growth rates, metabolism, gene expression, and
general biological activities within the biofilm (68, 73, 75). Furthermore, biofilms elicit unique
immune responses compared to planktonic infections, which will be discussed in the sections
below (69, 76, 77). These attributes are typically not shared with planktonic infections,
highlighting the distinctions between the two modes of bacterial growth.
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Biofilm gradients
Biofilm growth is driven, in part, by adaptive changes in bacteria in response to
environmental cues, which leads to the establishment of chemical gradients throughout its
structure (67, 68, 72, 75). The formation and persistence of these gradients are influenced by
diminished fluid flow within the biofilm, spatial relationships of bacteria, as well as rates of
solute production, consumption, and diffusion (78, 79). Generalizations can be made concerning
the direction of a concentration gradient for metabolic products and substrates based on ReactionDiffusion theory (67, 79-81). For example, metabolites produced by the biofilm, such as carbon
dioxide (CO2) and acids, can quickly diffuse at the biofilm-fluid interface but do so at a slower
rate in the interior, resulting in a CO2 gradient, which is greatest at the biofilm core (67, 82).
Conversely, the availability of metabolic substrates, such as glucose, oxygen, and other nutrients
is generally greatest at the fluid-biofilm interface and are slowly depleted as they diffuse towards
the center of the biofilm (79, 82). It also follows that the ability of antibiotics to penetrate a
biofilm and reach an effective concentration is dependent on diffusion (82, 83). This provides an
additional layer of protection to the “persister” cells at the center of the biofilm which already
exhibit increased antibiotic resistance (68-70, 75). Furthermore, biofilms can maintain a zone of
relative nutrient depletion and toxin accumulation that may affect leukocyte recruitment or
invasion into the biofilm core (67). These multi-faceted and dynamic gradients ultimately provide
a spectrum of unique microenvironments for biofilm-associated bacteria and the infiltrating
leukocytes that encounter biofilm infections.

Biofilm physiology
Bacterial biofilms are known to display increased resistance to stress and display general
differences in physiology compared to their planktonic counterparts (3, 60, 63, 74, 75, 84-87).
Besides the chemical gradients described above, the intercellular relationships of biofilmassociated bacteria and how they influence quorum sensing-mediated gene regulation are unique
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compared to planktonic organisms (73, 88-90). For example, transcriptomic analysis comparing
biofilm and planktonic S. aureus (91) demonstrated global differences in gene expression that
were clearly distinct between each mode of growth. Furthermore, small molecules like cyclic-diGMP have been shown to play a role in promoting biofilm formation and growth (92, 93). In
general, biofilms exhibit reduced metabolism adapted to microaerobic growth and favor the
production of ECM components. These attributes endow biofilm tolerance to metal, oxidative,
and antibiotic stress (94). In S. aureus biofilms, genes associated with responses to oxidative
stress, metabolism, and toxin production are upregulated in biofilms relative to their planktonic
counterparts (60, 91, 94-96). Some studies have shown that oxidative stress will also induce
biofilm formation, or allow a biofilm to better resist oxidative stress (96). In addition, an
abundance of small RNAs are differentially expressed between biofilm and planktonic growth,
which suggests that post-transcriptional regulation is another means of physiologic regulation (91,
97). Proteomic analysis of secreted proteins demonstrated that 108 of 301 proteins (36%) were
significantly enriched in S. aureus biofilms compared to planktonic cultures. This included
proteases and toxins, such as alpha-toxin (Hla) and leukocidin AB (LukAB) (60). Analysis of
>700 proteins from P. aeruginosa biofilms revealed that biofilm induced proteins could be
grouped by their function and temporal relationship with biofilm developmental stages (74).
Other studies have reported the induction of specific genes and proteins that coincide with
progressive stages of biofilm development (74, 98). Furthermore, changes in gene expression
patterns can contribute to biofilm topology. For example, P. aeruginosa can stochastically
express type IV pili to induce elevated stalks at specific foci within a biofilm (99). In addition,
stochastic expression of S. aureus nuclease during early biofilm growth has been implicated in
biofilm establishment (88). Together, this highlights the differences in biofilm physiology and
function compared to planktonic bacteria.
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Biofilm extracellular matrix (ECM)
Although the extracellular matrix (ECM) is a dynamic structure, especially during the
initial stages of biofilm development, this discussion will focus on the ECM components of a
mature biofilm (67, 68). In general, the bacterial biofilm ECM is composed of extracellular DNA,
polysaccharides, and proteins, where the contributions of each to biofilm structure continue to be
studied. Prior work has shown that proteinase K treatment leads to the dispersal of S. aureus and
S. epidermidis biofilms (100), but growth enhancement of P. aeruginosa biofilms (101). This
suggests that the protein components of a staphylococcal biofilm likely have direct structural
contributions, whereas the contribution of proteins to P. aeruginosa biofilms is more complex.
Tetz et al. found that DNase I treatment of biofilms from several bacterial species, including P.
aeruginosa and S. aureus, resulted in biofilm dispersal without affecting cell viability. They also
found that DNase I treatment acted synergistically with antibiotics by promoting antibiotic
penetration into the biofilm and subsequent killing of S. aureus biofilms (102). The clinical
implications of this finding suggest that antibiotic efficacy may be increased by disrupting the
biofilm structure.
The structural attributes of a biofilm promote adherence to biotic and abiotic surfaces
while maintaining intercellular contacts. In addition, host-derived proteins can be exploited to
facilitate biofilm establishment and maturation. For example, serum proteins including,
fibronectin, fibrinogen, and collagen, rapidly coat foreign devices and are recognized by bacterial
surface proteins, collectively referred to as Microbial Surface Components Recognizing Adhesive
Matrix Molecules (MSCRAMMs), which facilitate bacterial adhesion and accumulation (103). In
addition, host-derived soluble proteins or cell components released from necrotic eukaryotic cells
can also be incorporated into the biofilm ECM. For example, Pseudomonas biofilm growth is
enhanced by the incorporation of neutrophil components released via NETosis or toxin-mediated
neutrophil necrosis (104).
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Other ECM components do not directly contribute to the ECM biomass but instead
regulate the complexity and topology of the biofilm structure. For example, bacteria release
nucleases, proteases, and detergent-like molecules that remodel the ECM to form channels that
facilitate nutrient diffusion to the deeper biofilm layers. S. aureus (87) and P. aeruginosa (75)
produce detergent like molecules such as, phenol-soluble modulins (PSMs) and rhamnolipids,
respectively, which influence biofilm structure and dissemination. These molecules are multifunctional and contribute to the repertoire of virulence factors that allow biofilms to escape
immune-mediated clearance, which will be discussed in greater detail below.

c)

Prosthetic joint- and catheter-associated biofilm infections
The risk of infection is increased by the presence of a foreign material, such as indwelling

medical devices (69, 105-111), where bacteria usually establish biofilm infection (68, 69, 77, 110,
111). These infectious complications often occur during a narrow peri-operative window, with a
small number of organisms needed to colonize the implant. S. aureus invasion at the surgical site
and adherence to the indwelling device will then lead to the formation of a biofilm infection (69,
77, 112-114). The establishment of infection is likely aided by the small inoculum size that
affords escape from immune detection and clearance (69, 114). Furthermore, infection
establishment is likely promoted by trauma- or surgery-induced immune suppression, which is
characterized by a local anti-inflammatory milieu, dampening antimicrobial responses and
promoting biofilm growth (115, 116). However, in a few cases infecting pathogens can
hematogenously seed indwelling medical devices during states of transient bacteremia (117-120).
With the high asymptomatic colonization rates of staphylococcal species on the skin and
nasopharynx, it is unsurprising that staphylococcal species are the most common etiologic agents
of device-related infections (24, 107, 108, 110, 111, 120, 121), where S. aureus is the second
most common cause of prosthetic joint infection (PJI) only behind S. epidermidis (110, 111, 122124).
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The number of orthopedic procedures, such as total knee (TKA) and total hip (THA)
arthroplasties, continue to increase and are estimated to reach 572,000 and 3.48 million,
respectively by 2030 (125, 126). A devastating complication following arthroplasty is infection,
and the estimated incidence of prosthetic joint infections (PJIs) in the United States is 2.18% for
all THAs and TKAs. The current standard-of-care for treating PJI is to surgically remove the
infected device and fill the site with a temporary antibiotic-impregnated spacer to control the
infection in combination with systemic antibiotics. Weeks to months later, depending on the time
required to clear the infection, this is followed by a second surgery to replace the prosthesis.
Throughout this entire process the patient has limited mobility, leaving them with significant
morbidity and economic burden (107, 108, 111, 124). Patients diagnosed with PJI are prone to
infection recurrence, with some studies reporting initial success rates as low as 77% (127) and an
annual reinfection rate of up to 9% (128, 129).
Central venous catheters (CVC) and urinary catheters for vascular or bladder access,
respectively are utilized commonly in clinical scenarios. While CVCs and urinary catheters are
indispensable, they are often associated with a variety of complications. Central venous catheterrelated blood stream infections (CRBSIs) account for 90% of all blood stream infections, 51% of
which are due to staphylococcal species (117, 130). In addition, CRBSI carry a high rate of
morbidity due to the virulent nature of S. aureus. In the U.S., catheter-associated urinary tract
infections (CAUTIs) have an incidence of about 5 per 1000 catheter days (131, 132).
Furthermore, studies have shown that catheterization promotes the colonization and infection by
MRSA through the release of fibrinogen from the urothelium (133). Although S. aureus accounts
for only about 2% of these cases, MRSA-related CAUTIs have a 4-fold greater chance of
progressing to disseminated bacteremia, which carries significant mortality risks (133, 134). Like
all biofilm infections, these catheter-related infections require both the removal of the infected
device and concurrent antibiotic treatment (117).
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d)

Mouse models of biofilm infection
Currently, there are a limited number of animal models used to study the immune

response to S. aureus biofilm infections. Two well-described models include orthopedic implantand catheter-associated infection. These models have been used in various tissues to understand
the host-pathogen interactions during a biofilm infection, and were utilized in this dissertation
work.
In general, the orthopedic implant-associated biofilm infection model explores hostpathogen interactions under static conditions in close proximity to the bone marrow cavity (109).
In this model, a titanium pin is inserted into the shaft of the femur through a channel drilled at the
knee joint, which allows it to closely model a PJI following TKA. Furthermore, this model can be
used to examine the rising incidence of implant-associated osteomyelitis, of which S. aureus is
also a leading cause (135). This model was developed to accurately represent clinical disease,
with special attention given to the materials used and bacterial inoculum. Since titanium alloys
are the most commonly used material in THA and TKA, the Kielian laboratory utilizes a nickeltitanium alloy wire for their studies (136). The inoculating dose may also influence the course of
infection because higher initial burdens can alter the immune response to promote biofilm
formation. Furthermore, the 103 colony forming unit (cfu) inoculum used in this work more
closely models clinical scenarios where small numbers of bacteria are sufficient for establishing
infection (114, 137).
In contrast, the catheter-associated infection model allows host-pathogen interactions to
be explored in a variety of tissues throughout the body, under dynamic or static conditions.
Commonly used models include venous and CNS catheter-associated infection, in addition to the
subcutaneous catheter-associated infection model routinely employed in Dr. Kielian’s laboratory
and a portion of this dissertation (138-143). Furthermore, a catheter based endocarditis model has
been employed in rabbits (144). The subcutaneous catheter model does not recapitulate the
sheer/dynamic forces that a biofilm experiences on a venous catheter, but advantages include the
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use of a low infectious inoculum (103 CFU) compared to hematogenous models (~107 to 108
CFU) and a relatively straightforward device placement that is more high throughput compared to
the orthopedic infection model (109, 138). Furthermore, the accessibility of the infected device is
advantageous because it allows for real-time monitoring of infection by IVIS (139) and direct
administration of treatments which are not limited by volume, compared to the small joint space
in the orthopedic model (138).
Collectively these mouse models allow for the investigation of S. aureus biofilm-immune
crosstalk that are clinically relevant (145, 146). Furthermore, they provide a better mechanistic
understanding through the use of bacterial mutant strains and genetic knockout mice (60, 114,
138, 139, 146-149). Continued use of these models could help to identify critical determinants
during PJIs or therapeutic targets that could clinically translate and reduce patient morbidity and
mortality during S. aureus biofilm infection.

2)

Immune evasion during S. aureus biofilm infection
Bacterial biofilms are able to subvert the host immune response by several mechanisms,

which include interfering with humoral immunity, secreting toxins to impair recognition, and
regulating the inflammatory status of recruited leukocytes. Furthermore, S. aureus is able to
maintain biofilm infection in the host, even in the presence of a robust immune response. This
suggests that S. aureus is able to evade innate and acquired immune responses, making it difficult
to develop vaccine strategies for these infections. Indeed, several efforts towards vaccine
development for S. aureus have failed, although multi-valent vaccine approaches are still being
pursued (150-152). The failure to elicit an effective immune response results in a chronic S.
aureus biofilm infection, which typically requires physical dissociation and removal of infected
tissues/medical implants for treatment.
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a)

Evasion of innate immune recognition by pattern recognition receptors (PRRs)
Detection of invading bacterial pathogens requires recognition of pathogen-associated

molecular patterns (PAMPs) which occurs through pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs) (153, 154). There are thirteen human TLRs and ten mouse
TLRs currently identified (153, 154). Although they recognize a variety of ligands, they most
commonly signal through MyD88 and NF-κB pathways, leading to the activation of
inflammatory pathways and transcription and translation of pro-inflammatory cytokines and
chemokines (155-158). In the case of S. aureus, TLR2 is critical to recognize extracellular
peptidoglycan (PGN) and lipoproteins, while TLR9 detects the presence of unmethylated CpG
motifs on bacterial DNA (159). TLR9 discriminates between self and non-self, since mammalian
DNA is methylated at guanine residues. TLR-mediated recognition is critical for controlling
planktonic staphylococcal infections, as MyD88- or TLR2-deficient animals demonstrated
increased susceptibility to S. aureus-induced sepsis concomitant with decreased cytokine
production (160-162). TLR9 recognition of unmethylated bacterial CpG-DNA has also been
shown to stimulate an immune response from osteoblasts and dendritic cells (163, 164).
Bacterial cell death and lysis are essential processes during staphylococcal biofilm
development and prior studies have shown that mutations in genes involved in autolysis, such as
atlA, play a critical role in this process (96, 165-167). Furthermore, inhibition of autolysis with
polyethanol sulfonate (PAS) significantly impacted biofilm structure and development (167, 168).
Autolysis leads to the release of PAMPs, such as PGN and bacterial DNA, during biofilm growth.
Although it would be expected that these PAMPs would trigger pro-inflammatory responses
through TLR recognition, prior studies have shown that neither TLR2 nor TLR9 influence S.
aureus biofilm growth in vivo (139, 169). In contrast, MyD88 signaling is critical for S. aureus
biofilm containment, likely through the action of IL-1β, since biofilm burdens were higher in
MyD88 and IL-1R KO mice (147, 169). In conclusion, while autolysis is essential to biofilm
formation and liberates molecules that are capable of stimulating TLR-mediated signaling, TLRs
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do not have a significant effect on the detection and response to S. aureus biofilms, despite being
critical to controlling planktonic bacterial growth (139, 160-162, 169).

b)

Toxin production
Many S. aureus toxins are regulated by quorum sensing mechanisms that are effectively

enriched during biofilm growth, and can directly kill MФs, neutrophils, and other leukocytes to
inhibit immune recognition and microbicidal activity (54, 60, 170-173). Recently, our laboratory
has shown that MФ phagocytosis was inhibited following exposure to conditioned media from a
wildtype S. aureus biofilm (60). Phagocytic activity was restored following proteinase K
treatment, indicating that soluble proteins were partially responsible for inhibiting MФ
phagocytosis. In addition, conditioned medium from a S. aureus accessory gene regulator (agr)
mutant biofilm was unable to inhibit MФ phagocytosis, suggesting that the candidate protein(s)
were regulated by quorum sensing. This work went on to demonstrate that the responsible
proteins secreted from S. aureus biofilms that inhibit MФ phagocytosis were the toxins, αhemolysin (Hla) and leukocidin AB (LukAB) (60). Hla acts on red blood cells and leukocytes by
binding ADAM10, causing protein oligimerization, pore-formation, and osmotic cell death (69,
171). Furthermore, Hla facilitates immune evasion within phagosomes, preventing the
intracellular killing of phagocytosed bacteria (172). While LukAB has been shown to target and
bind CD11b, to kill neutrophils (174, 175). A S. aureus hla/lukAB mutant displayed significantly
reduced bacterial burdens and increased MФ recruitment in the mouse orthopedic implant biofilm
infection model compared to WT or the individual Δhla or ΔlukAB mutants, demonstrating a
complementary role for both toxins in vivo (60).

c)

Evasion of humoral components of immunity
Established biofilms utilize several mechanisms to protect against humoral immune

attack. The benefit of S. aureus-specific antibodies remains unclear since, previously infected
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patients who have high circulating antibody levels can experience recurrent S. aureus infections
(176, 177). Staphylococcal protein A (SpA) is a secreted protein that can bind the Fc or Fab
portion of IgG or IgM (178, 179). Binding of the Fc domain by SpA prevents opsono-phagocytic
killing, whereas Fab binding leads to clonal expansion of B cells (170, 180). Recent studies have
shown that staphylococcal biofilms do not prevent the diffusion of humoral components into the
biofilm, but instead their large biomass and antigen abundance, as compared to planktonic
bacteria, dilutes targeting antibodies and interferes with opsono-phagocytosis (181). This is
further supported by the finding that chronic S. aureus biofilm infections can induce antibodies
against a biofilm antigen (SA0486,) without reducing bacterial burden (182).
Other humoral components, including complement and antimicrobial peptides (AMPs)
are also targets of immune evasion during biofilm growth. Extracellular fibrinogen-binding
protein (Efb) produced by S. aureus binds complement protein C3, to inhibit the classical and
alternative pathways of complement. Specifically, Efb can inhibit complement-mediated opsonophagocytosis by saturating C3 molecules and preventing coordinated C3 deposition and
complement activation (183). AMPs, are amphipathic, positively charged molecules that disrupt
microbial membranes and inhibit cellular processes (184). Currently, very few AMPs have shown
efficacy against S. aureus biofilm development. However, a few AMPs like RNAIII inhibiting
peptide (RIP) and cathelicidin were able to inhibit biofilm development (185, 186). However,
most evidence suggests that leukocyte-derived AMPs are not sufficient to promote S. aureus
biofilm clearance.

d)

Immune polarization by biofilms
Previously, the complex biofilm matrix was believed to be the primary facilitator of

immune evasion (76, 77). However, our laboratory and others have shown that S. aureus biofilms
actively skew the immune response to an overall anti-inflammatory state (138, 139, 148, 187).
This is evident by limited T cell and neutrophil recruitment, abundance of MDSCs, and
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polarization of anti-inflammatory MФs/monocytes at the site of S. aureus biofilm infections (138,
148, 188, 189). Although the immunomodulatory properties of S. aureus biofilms have not yet
been fully elucidated, our laboratory has recently shown that one mechanism is through IL-10
production, as a result of MDSC recruitment (148). MDSCs are a heterogeneous population of
myeloid progenitors that alter leukocyte activation, and MDSCs are well recognized for their
immunosuppressive roles in chronic diseases, such as cancer, infections, and autoimmunity (190195). We have also demonstrated that MDSCs are enriched in subjects with PJI compared to
aseptic loosening, demonstrating the similarity between our mouse model and human disease
(145, 146). Our laboratory has demonstrated that MDSCs are integral to S. aureus biofilm
establishment and persistence as a result of their ability to polarize infiltrating MФs towards an
anti-inflammatory phenotype (146, 148, 187). Accordingly, our laboratory has shown that MDSC
depletion augments MФ pro-inflammatory activity, which translates into reduced biofilm burdens
(189). Biofilm clearance is also facilitated by the adoptive transfer of pro-inflammatory MФs at
the site of biofilm infection (138). Together this highlights the importance of MDSC and
monocyte/MΦ crosstalk in determining the outcome of S. aureus biofilm infection.

T cells
T-cell populations are limited in both mouse and human PJIs, as compared to tissues
recovered from aseptic revisions where T-cell populations were abundant (114, 146, 148, 187).
However, T-cells may play a role in preventing and controlling S. aureus infections, since HIV
patients are more susceptible to MRSA infections and T-cell deficient mice are more susceptible
to lethal challenge than immune-competent animals (196, 197). One mechanism whereby S.
aureus can inhibit an effective T-cell response is to secrete some of its repertoire of 23
superantigens, including toxic shock syndrome toxin 1 (TSST-1) (173, 198, 199). Superantigens
exert their actions by bypassing the classical pathway of antigen processing and presentation on
MHCII molecules on antigen-presenting cells (APCs). Instead they directly bind to the MHCII
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molecules of APCs and to T-cell receptor (TCR) without being processed, resulting in the
activation up to 20% of T-cell populations (200, 201). The overstimulation and activation of nonspecific T-cells can induce local depletion of IL-2 to limit the expansion of otherwise antigenspecific T-cells (200, 201). In addition, superantigen stimulation skews T-cells to a Th1 activation
type, to drive non-specific cytokine production, which delays the development and expansion of
S. aureus antibody producing B-cells (202). Of note, S. aureus superantigen action is mainly
restricted to human MHC, which has prompted the development of transgenic mouse models
which express human HLA (203-205).

Neutrophils
Neutrophils are an important part of the innate immune response during infection of
bacterial pathogens like S. aureus. Neutrophils rapidly migrate to sites of inflammation, and are
among the first responders to S. aureus infections, second only to resident macrophages (206209). Neutrophils respond to chemokines, such as CXCL1 and CXCL2, which are produced in
response to PAMPs, to direct their chemotaxis and extravasation from the vasculature (210-212).
Specifically, S. aureus components, including lipoteichoic acid (LTA), PGN, and TSST-1, can
elicit chemokine production from stromal cells and tissue MФs to recruit neutrophils to the
infection site (210-213). Neutrophils possess many of the PRRs that respond and recognize S.
aureus-associated molecules. PRR engagement allows neutrophils to phagocytose S. aureus and
activate pathways that increase their antimicrobial activity (210, 214, 215). Neutrophils are best
known for their ability to produce large amounts of reactive oxygen species (ROS) and
antimicrobial peptides, such as cathepsins and lysozyme (209, 216-218). In addition, neutrophils
secrete pro-inflammatory cytokines and chemokines, including CXCL2, CXCL11, IL-1β, and
TNF-α, to recruit and activate other immune effector cells (208, 210, 214, 215, 218).
However, S. aureus possesses several mechanisms to evade neutrophil detection and
killing. Major S. aureus toxins, like Hla and leukocidins, induce pore formation and osmotic lysis
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of numerous leukocytes, including neutrophils (60, 219). S. aureus produces chemotaxis
inhibitory protein of staphylococci (CHIPS), which blocks chemotaxis by directly binding
chemotactic receptors and inhibiting neutrophil recruitment (220-222). In addition, S. aureus
produces extracellular adherence proteins (Eap), that bind and inhibit intercellular adhesion
molecule (ICAM-1), which is a receptor on endothelial cells involved in leukocyte adhesion and
diapedesis from the intravascular space (223, 224). S. aureus can also block phagocytosis with
protein A, its capsule, or cause frustrated phagocytosis when growing as a biofilm. Finally, even
when neutrophils reach the site of infection and phagocytize S. aureus, neutrophils undergo
morphological changes that are consistent with cell necrosis (i.e. neutrophil extracellular trap
(NET) formation) and are unable to effectively clear the infection (207, 225).

Myeloid derived suppressor cells (MDSCs)
Another mechanism of active immune polarization by S. aureus biofilms is the
preferential accumulation of MDSCs (CD45+CD11bhighLy6GhighLy6C+). MDSCs are likely
recruited and expanded at the site of biofilm infections, in part, due to the robust
chemokine/cytokine milieu, which has been identified as a key signal for promoting MDSC
activation and expansion (146, 148, 187, 189, 226). MDSCs are a heterogeneous population of
immature myeloid progenitors, which in healthy individuals are transient and rapidly differentiate
into mature granulocytes and MФs. However, in chronic pathological conditions, such as cancers,
infections, or autoimmune disorders, MDSCs are arrested in an immature state where they can
suppress the immune system by interfering with leukocyte effector pathways (227-229). MDSCs
constitute the majority of leukocytes present during a S. aureus biofilm infection; however their
functional role and the mechanism by which S. aureus recruits is not well understood. Models of
planktonic and biofilm S. aureus infections have shown that S. aureus actively expand/recruit
populations of MDSCs (106, 146, 148, 187, 230, 231).
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In general, MDSCs inhibit T cell expansion and activation using many mechanisms (229,
232). Previous studies have shown that MDSC expression of Arginase-1 (Arg-1), NADPH
oxidase can inhibit T-cell activation via arginine depletion and reactive oxygen species (ROS)
production, respectively (233-238). MDSCs can also express unidirectional importers that
deplete cysteine from the microenvironment to inhibit T cell activation and function (239).
Furthermore, MDSCs have been proposed to produce numerous mediators, including IL-1β, IL-6,
IL-10, GM-CSF, M-CSF, stem cell factor (c-kit), TGF-β, and vascular endothelial growth factor
(VEGF) to modulate leukocyte activation in addition to promoting further MDSC expansion
(229, 232). During a S. aureus biofilm infection, many of these cytokines are abundant in the
extracellular milieu, and the expression of genes such as arg-1 and iNOS are upregulated in
MDSCs (146, 148, 187). However, studies using inhibitors or knockout animals of Arg-1 or
iNOS in S. aureus biofilm infections failed to show any detectable changes in bacterial burdens
from the biofilm. However, mice deficient in iNOS or myeloid arg-1 had significantly higher
bacterial burdens during planktonic S. aureus infections, suggesting that they are essential in
controlling planktonic infection but are dispensable for biofilms (240, 241). Recent work has
demonstrated that MDSCs are a primary source of IL-10 and maintain suppressive activity ex
vivo (146, 148, 187). Biofilm-associated orthopedic implant infections in IL-10 knockout mice or
following anti-Ly6G antibody depletion, resulted in a reduction of bacterial burdens and
reprogramming of monocytes to a pro-inflammatory state (146, 148, 187). In support of this, our
laboratory has shown that MDSCs are the primary source of IL-10 during S. aureus biofilm
infection, which can block MФ NF-κB activation and down-regulate cytokine expression (148).
However, the lack of complete clearance of the biofilm suggests that the biofilm possess
additional mechanism of immune inhibition.
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Macrophages (MФs)
MФs are innate immune effector cells that are critical to defend against bacterial
pathogens and scavenge cellular debris. While S. aureus employs a similar repertoire of immune
evasion mechanisms towards MФs as they do with neutrophils, MФs have additional roles in the
immune response. Neutrophils are known for their potent antibacterial activity and require
constant influx to maintain their numbers due to their short lifespan (209, 214, 218, 225). In
comparison, every tissue in the body has a resident MФ population, which along with newly
recruited MФs play a key role in maintaining tissue homeostasis by eliminating waste and cell
debris, secreting cytokines, and recycling nutrients to support the tissue microenvironment (242248).
MФs are derived from monocytes, which differentiate upon traversing the vascular
endothelium into tissues (243, 249). At the time of infection, S. aureus first encounters tissue
resident MФs. Upon stimulation of TLRs and scavenger receptors, MФs become activated and
can expand by local proliferation as well as continued monocyte recruitment and differentiation
(250-252). This is in stark contrast to neutrophils, which are not tissue resident cells and must be
recruited by chemokines (210-212). MФs can exhibit both pro- and anti-inflammatory properties,
and are generally characterized based on gene expression signatures, cytokine production, and
function. MФ polarization is dynamic and ultimately determined by their microenvironment and
cytokine milieu (244, 245, 252, 253). The concept of immune polarization originated from in
vitro studies of MФ activation, which led to the identification of M1 (classical) and M2
(alternative) states to describe pro-inflammatory versus anti-inflammatory attributes of MФs,
respectively (254). However, it is now well-recognized that in vivo, MФ activation exists in a
spectrum between pro- and anti-inflammatory states, which exhibits some degree of plasticity as a
result of integrating pro-/anti-inflammatory signals. Here, we will discuss the immune
polarization states of murine MФs following exposure to biofilm or planktonic bacterial
infections. Of note, there are important distinctions between murine and human MФs in terms of
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cytokines responsible for driving polarization states and effector molecules, such as inducible
nitric oxide (iNOS), which is more robustly expressed in murine compared to human MФs (254).
For more detailed information on MФ immune polarization states and corresponding metabolic
effects, the reader is referred to several excellent reviews (255, 256).
S. aureus biofilm infections are characterized by anti-inflammatory monocytes/MФs,
MDSC expansion, and paucity of T cells in both humans and mouse models (106, 138, 146, 148,
187). Specifically, Iba-1 MΦs upregulated arg-1 transcription, which is a marker of antiinflammatory activity (138). In contrast, planktonic S. aureus infections are generally cleared by
eliciting a robust pro-inflammatory response through the activation of MФ PRRs, neutrophil
recruitment, and T cell activation. MФs associated with S. aureus biofilm infections are
characterized by increased arg-1 and decreased iNOS expression (138, 146, 148, 187). In vitro
studies have shown that MФs are capable of phagocytosing S. aureus from a disrupted, but not
intact biofilm (104, 139). This suggests that the size of a biofilm likely represents a physical
barrier, inducing a phenomenon known as “frustrated phagocytosis” (60, 85, 139) and the release
of intracellular molecules from phagocytes that can lead to bystander toxicity of surrounding
immune and stromal cells. In addition, MΦ immune effector mechanisms differ in their utility
during biofilm and planktonic infections. Recent work presented in Chapter 4 of this dissertation,
demonstrates that despite the importance of myeloid-derived Arg-1 in controlling S. aureus
planktonic infection, Arg-1 does not play a significant role during implant-associated biofilm
infections (241). Hanke et. al. demonstrated that the MФ activation state was critical for biofilm
persistence. For example, as opposed to endogenous biofilm-associated MФs, which do not exert
any anti-bacterial activity, the adoptive transfer of activated pro-inflammatory MФs into S.
aureus biofilm infections in vivo, facilitated biofilm clearance. In addition, activated proinflammatory MФs were able to infiltrate and phagocytose S. aureus biofilms in vitro, which was
not observed with non-activated MФs (138). Furthrmore, depletion of MDSCs with a Ly6G
antibody significantly reduced biofilm burdens and increased the pro-inflammatory activity of
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biofilm-associated monocytes. The ability of monocytes/MФs to promote biofilm clearance in the
absence of MDSC action was indirectly demonstrated using a Gr-1 antibody, which resulted in
significantly increased S. aureus burdens, since effector Ly6C monocytes and by extension,
mature MФs, were also depleted. Taken together, these results support the conclusion that
biofilm-mediated MDSC recruitment regulates, in part, the anti-inflammatory polarization of
monocytes, effectively promoting biofilm persistence (187).

3)

Immunometabolism
The field of immunometabolism focuses on intrinsic changes in leukocyte metabolism,

which ultimately govern inflammatory phenotypes (256, 257). The link between metabolic
alterations and cellular function was first reported by Otto Warburg, when he observed that
proliferating tumor cells relied heavily on aerobic glycolysis (258, 259). It was also shown that
aerobic glycolysis is a primary feature of pro-inflammatory MФs and dendritic cells (256). This
metabolic shift is necessary to increase carbon flux through the pentose-phosphate pathway and
provide precursor molecules for anabolic processes and/or production of reactive oxygen species
(256, 257, 260). In contrast, MФs primarily rely on oxidative phosphorylation (OxPhos) to drive
their anti-inflammatory activity, with fatty acid oxidation also playing a role. In MФs, these
metabolic switches are facilitated by global changes in gene expression. For example, proinflammatory MФs express u-PFK2 (ubiquitous phosphofructokinase), a highly active PFK-2
isoform and down-regulate TCA cycle enzymes, facilitating intracellular accumulation of
glucose, succinate, and citrate (256, 257). In the mouse, pro-inflammatory MФs also generate
nitric oxide through upregulation of iNOS, which directly inhibits OxPhos (256).

a)

Biofilm factors influencing immunometabolism
Although biofilms are generally less metabolically active than planktonic bacteria, the

sheer number of organisms allows the biofilm to establish metabolic gradients by depleting
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glucose and oxygen from the surrounding microenvironment (261). Furthermore, host cell lysis
can increase the abundance of metabolic enzymes, such as hexokinase and indoleamine-2,3dioxygenase, which can deplete usable glucose and amino acids, respectively (262). Mammalian
intracellular metabolic pathways are sensitively regulated by nutrient availability, including
glucose, glutamine, and fatty acids. Local hypoxia and nutrient depletion from the
microenvironment can reduce glycolytic rates in MФs and promote anti-inflammatory
polarization (255, 256). Local nutrient depletion likely results from contributions of both the
biofilm and host cells, as it has been shown that neutrophils consume the majority of oxygen in
cystic fibrosis patients that often have biofilm infection (104). Although immune shifts are
possible during planktonic infections with highly metabolically active bacteria such as
Staphylococcus spp., it is unlikely that planktonic infections can deplete nutrients as quickly as
they are replenished in the host. Therefore, it is probable that the communal and relatively static
nature of biofilms allow these metabolic gradients and zones of micronutrient depletion to persist
over the course of infection, having a dramatic impact on leukocyte metabolism and
inflammatory phenotypes.
In addition to nutrient depletion, bacteria can generate metabolites that can alter the
activation and metabolism of host leukocytes. S. aureus is able to redirect its metabolism to
acidify the local microenvironment to encourage the release of iron from transferrin (263). S.
aureus lipoic acid synthase (LipA), blunts TLR activation by modifying the E2 subunit of the
metabolic enzyme pyruvate dehydrogenase (PDH) (264). To date, all of the work studying the
influence of S. aureus on host metabolism has used planktonic bacteria. Other bacterial biofilms
have been shown to produce metabolites that can influence the metabolism of host cells. Biofilms
collected from colon cancer patients show that polyamine synthesis from the host and polyamine
acylation from the biofilm act synergistically to promote glycolytic activity and oncogenic
transformation in colonic epithelial cells (265). Furthermore, the effects of planktonic S. aureus
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on leukocyte metabolism may be amplified during biofilm growth, due to the nutrient and
chemical gradients that are established during infection (67).

b)

Effect of metabolism on leukocyte development and lifespan
OxPhos is more efficient than glycolysis in extracting energy from glucose. However,

under conditions where glycolysis is enhanced, a concomitant increase in the pentose phosphate
pathway (PPP) is generally observed to provide NADPH and ribose phosphate, which are
required for biosynthesis, cell division, and other cellular functions (255, 256). An important
aspect of immunity is controlling cellular life span, such as memory lymphocyte populations and
terminally differentiated leukocytes responding to pathogens. Following the resolution of
infection, the life span of these effector cells must be tightly regulated to prevent potential
bystander pathology. Several studies have demonstrated that reliance on OxPhos metabolism
supports leukocyte longevity. For example, anti-inflammatory MФs that favor OxPhos have an
increased life span, whereas pro-inflammatory MФs, which rely more on glycolysis are shorter
lived (255). This relationship is most pronounced in memory T cells, where long-lived resting T
cells do not oxidize glucose but instead rely solely on fatty acid β-oxidation, whereas cytokine
stimulation promotes glycolytic metabolism, with cells undergoing rapid apoptosis following
cytokine withdrawal (255).
With regard to biofilms, recent studies have demonstrated that S. aureus biofilmassociated MФs exhibit anti-inflammatory profiles, despite elevated pro-inflammatory cytokines
in infected tissues (148, 187). Cytokine levels were significantly reduced during deviceassociated biofilm infection in MyD88-deficient mice; however, this resulted in increased
bacterial burden and dissemination, since MФs and neutrophils lacked major TLR effector
pathways necessary for killing planktonic bacteria following biofilm dispersal (147). It is possible
that elevated glycolysis-inducing cytokines could contribute to biofilm persistence by eliminating
effector cells by apoptosis in combination with biofilm-derived lytic toxins until nutrients are
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depleted, at which point newly recruited MФs and neutrophils are unable to be activated;
however, this remains speculative. Although cytokine-induced apoptosis of MФs and neutrophils
occur during planktonic infections, the static and chronic nature of biofilms facilitates continued
cytokine accumulation, likely accounting for the robust cytokine milieu associated with S. aureus
biofilm infections in vivo (106, 146, 148, 187).

c)

Effect of metabolism on leukocyte function
TCA cycle defects in pro-inflammatory MФs lead to the accumulation of TCA cycle

intermediates, namely citrate and succinate (Figure 1.1). Accumulation of succinate promotes
HIF-1α stabilization, epigenetic changes, and enhances IL-1β production through inhibition of αketoglutarate-dependent enzymes (255). Citrate can be used to generate itaconic acid, which is an
anti-microbial metabolite that has been shown to inhibit the growth of planktonic Salmonella
enterica and Mycobacterium tuberculosis (255). However, the antimicrobial actions of itaconic
acid have not yet been explored in the context of biofilm infections. Furthermore, citrate is used
as a precursor for nitric oxide, ROS, lipid, and prostaglandin production. Since biofilm-associated
MФs are anti-inflammatory in nature, it is likely that they primarily utilize OxPhos metabolism.
This has recently been established in S. aureus orthopedic biofilm infection (Chapter 3), where
infiltrating monocytes display significantly increased OxPhos and less glycolysis than monocytes
isolated from sham animals (i.e. sterile orthopedic implants)
In summary, biofilms are communities of organisms encased in a complex extracellular
matrix, which can colonize both biotic and abiotic surfaces. Biofilm infections are associated with
significant morbidity and economic burden, since they are recalcitrant to antibiotic therapy and
require physical removal and/or debridement of infected tissues for treatment. Biofilms can
subvert the host immune response by preventing immune detection, toxin production, and
polarizing monocytes/MФs towards an anti-inflammatory state, which promotes biofilm
persistence even in an immune competent host (Figure 1.1). Recent metabolic studies have shown
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that immune cell function and metabolism are intimately related. In terms of bacterial infection,
immunometabolism studies have primarily focused on MФs and neutrophils responding to
planktonic bacteria. Given the differences in inflammatory properties of MФs and neutrophils
responding to planktonic versus biofilm infections, future studies must also consider the
metabolic properties of biofilm-associated immune cells, which is addressed in Chapter 3 of this
dissertation.
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Figure 1.1

Metabolic profiles influence macrophage inflammatory status. Macrophages respond to
planktonic infections via sensing of pathogen-associated molecular patterns (PAMPs) through
Toll-like receptor (TLR) engagement. This favors aerobic glycolysis to provide TCA cycle
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intermediates for anabolic processes required for pro-inflammatory effector mechanisms. In
contrast, biofilm infections polarize macrophages towards an anti-inflammatory state and the
biofilm-derived signals that drive this process are largely unknown (indicated by question mark).
Since anti-inflammatory macrophages are typified by oxidative phosphorylation (OxPhos) it is
predicted that biofilm infections will bias cells towards this metabolic pathway and several
receptors associated with anti-inflammatory cytokines might be involved (i.e. CD36, IL-10R, IL4R, and IL-13R). The metabolic gradients present in the tissue microenvironment (i.e. nutrients,
oxygen) also influence the pro- versus anti-inflammatory profiles of macrophages that are
intimately linked to their metabolic state. G6P, glucose-6-phosphate; GLUT, glucose transporter;
HIF-1α, hypoxia inducible factor-alpha; IL-1β, IDH, isocitrate dehydrogenase; interleukin-1 beta;
IL-4R, interleukin-4 receptor; IL-10, interleukin-10; IL-10R, interleukin-10 receptor; IL-13R,
interleukin-13 receptor; iNOS, inducible nitric oxide synthase; NADPH, nicotinamide adenine
dinucleotide phosphate; NF-κB, nuclear factor-kappa B; NO, nitric oxide; PPARα, peroxisome
proliferator-activated receptor alpha; PPP, pentose phosphate pathway; ROS, reactive oxygen
species; SDH, succinate dehydrogenase; STAT3, signal transducer and activator of transcription
3; STAT6, signal transducer and activator of transcription 6; TCA, tricarboxylic acid cycle; TGFβ, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha; uPFK2, ubiquitous 6phosphofructo-2-kinase/fructose bisphosphatase 2; VEGF, vascular endothelial growth factor.
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4)

Overview of Dissertation
S. aureus biofilms are a major cause of chronic infections that cannot be cleared by the

immune system partially due to their ability to resist many immune mechanisms of killing. In
addition, prior studies from our laboratory have demonstrated that S. aureus biofilm infections
subvert immune-mediated clearance mechanisms by actively skewing the host innate immune
response towards an anti-inflammatory phenotype (138, 147, 187). Most notably, biofilms induce
anti-inflammatory MΦ polarization, which contributes to biofilm establishment and persistence.
Prior studies have also highlighted the importance of MΦ inflammatory state in dictating the
outcome of S. aureus biofilm infection (138, 187). Specifically, MDSC depletion to remove the
inhibition of MΦ activation, or adoptive transfer of pro-inflammatory MΦs promotes biofilm
clearance (138, 187). The inflammatory properties of leukocytes are linked to their metabolic
activity, where anti-inflammatory MΦs primarily rely on OxPhos, while pro-inflammatory MΦs
utilize aerobic glycolysis. Therefore, we hypothesized that biofilm-associated monocytes/MΦs
experience a metabolic shift to favor OxPhos over glycolysis, leading to anti-inflammatory
polarization and S. aureus biofilm persistence.
During the course of my dissertation research, we have studied the metabolic properties
of biofilm-associated monocytes, by targeting various aspects of metabolism in order to shift the
immune response. First, we utilized a novel nanoparticle-mediated drug delivery system to
specifically target monocyte metabolism and promote pro-inflammatory activation and biofilm
clearance (Chapter 3). Indeed, we have demonstrated that this approach attenuated biofilm growth
while highlighting the extensive nature of monocyte-MDSC crosstalk. However, preliminary
studies with a more global genetic approach targeting myeloid cell metabolism resulted in an
opposite outcome where bacterial burdens were elevated (Chapter 5). Comparing the disparate
results from these approaches suggests that leukocyte metabolism is differentially regulated
during S. aureus biofilm infection to dictate effector functions. Finally, we investigated the
functional importance of Arg-1 during S. aureus biofilm infection using myeloid-conditional KO
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mice, expecting it to be a key modulator of monocyte/MΦ polarization. While Arg-1 played a
significant role in limiting the growth of planktonic S. aureus in vivo, it had no impact on S.
aureus biofilm infection and did not act as a redundant mechanism to deplete arginine or produce
polyamines. This was unexpected given the robust increase in arg-1 expression in myeloid cells
during S. aureus biofilm infection. The overarching theme of my dissertation research was to
understand the role of monocyte metabolism during S. aureus biofilm infection. My results
demonstrated that the metabolic activity of monocytes modulates their inflammatory phenotype
and interactions other leukocytes during S. aureus biofilm infection. It also highlights the
complexity of leukocyte crosstalk and contrasts the immune mechanisms involved during S.
aureus biofilm vs. planktonic growth.
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Chapter 2: Materials and Methods
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1)

Mouse strains

A breeding colony of C57BL/6 mice was established in Dr. Kielian’s laboratory upon purchasing
animals from the National Cancer Institute (Frederick, MD) or Jackson Laboratories (Bar Harbor,
ME). Some animals were also ordered directly from Charles River Laboratories (Frederick, MD).
These studies were performed in strict accordance with recommendations found in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health (NIH) and were
reviewed by the Institutional Animal Care and Use Committee of the University of Nebraska
Medical Center.

Ndusf4fl/fl mice were obtained from the laboratory of Phillip G. Morgan, M.D. (Seattle Children’s
Research Institute, Seattle WA). These conditional knockouts were generated by Richard
Palmiter (University of Washington, Seattle, WA), by inserting loxP sites flanking exon 2 of the
NADH dehydrogenase (ubiquinone) Fe-A protein 4 (Ndusf4) gene, which is a subunit of
mitochondrial complex I. This line was backcrossed to C57BL/6 mice for ≥20 generations by Dr.
Palmiter’s laboratory, before donating to The Jackson Laboratory (Bar Harbor, ME, stock number
026963, B6.129S4-Ndufs4tm1Rpa/J). While published reports suggest that homozygous floxed mice
appear normal, our laboratory observed gross phenotypic differences (266, 267). This includes
loose skin and nasal abnormalities.

Arg-1fl/fl mice were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number
008817, C57BL/6-Arg1tm1Pmu/J). A targeting vector containing PGK-Neomycin cassette was used
to insert loxP sites flanking exons 7 and 8 of the Arg-1 gene of C57BL/6 embryonic stem cells.
These exons encode for two catalytic aspartic acid residues that are essential for gene activity.
Chimeric males were back crossed to C57BL/6 mice for ≥11 generations. Homozygous animals
display no phenotypic or functional impairments (268).
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LysMCre mice were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number
004781, B6.129P2-Lyz2tm1(cre)Ifo/J). A targeting vector containing frt-flanked neomycin cassette
was used to insert a nuclear-localized Cre-recombinase into the first coding ATG of lysozyme 2
(Lyz2) gene. Chimeric mice were backcrossed to C57BL/6 mice for ≥6 generations. While gene
activity is abolished in homozygotes, animals remain viable and fertile without displaying
physical or behavioral abnormalities. These animals express Cre-recombinase in activity in cells
of the myeloid lineage, including monocytes, MФs, and granulocytes (269).

Tie2Cre mice were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number
008863, B6.Cg-Tg(Tek-cre)1Ywa/J). Cre cDNA was inserted between the mouse Tek tyrosine
kinase (Tie2) promoter and enhancer in fertilized oocytes of B6SJLF1 mice. Chimeric animals
were backcrossed for ≥8 generations to C57BL/6 mice. These animals provide uniform
expression of Cre-recombinase in endothelial cells and macrophages (270). Hemizygous mice are
viable and fertile without displaying physical or behavioral abnormalities.

Ndusf4fl/fl;LysMCre mice were generated from breeding Ndusf4fl/flLysMnull female mice with
Ndusf4fl/flLysMCre male mice.
Arg-1fl/fl;Tie2Cre mice were generated from breeding Arg-1fl/flTie2null female mice with Arg1fl/flTie2Cre male mice.
Arg-1fl/fl;LysMCre mice were generated from breeding Arg-1fl/flLysMnull female mice with Arg1fl/flLysMCre male mice.

Mouse genotyping
Individual mouse genotypes were determined by PCR. Mice were ear tagged with 4-digit
numerical identifiers, and tail samples (1-2mm) were collected from non-weaned mice at 4 weeks
of age using sterile scissors. Tail samples were incubated with 250 μL of Alkaline Lysis Reagent
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(25 mM NaOH, 0.2 mM EDTA) at 95°C for 1.5 – 3.0 h on a heat block. Following incubation on
heat block, 250 μL Neutralization Reagent was added (40mM Tris-HCl), and samples were
vortexed to disrupt tissues. DNA preparations were either immediately used in genotyping PCR
reaction or stored at -20°C and thawed upon use. Following genotyping PCR reaction, samples
were run on an ethidium bromide containing 1.7% agarose gel at 90 volts until bands could be
resolved.
PCR Reaction (KAPA Taq PCR kit, KAPA Biosystems, Wilmington, MA):
10X buffer with loading dye - 1.2 μL  Final of 1X
MgCl2 (25 mM) 0.25 μL  Final of 0.52 μM
dNTPs (2.5 mM) 1.0 μL  Final of 200 μM
Primers (20μM) 0.6 μL  Final of 1.0 μM (each primer)
Taq (5 units/μL) 0.05 μL  Final of 0.25 units in 12 μL
DNA preparation
1.0 μL
PCR grade water
To 12 μL (reactions with 2, 3, or 4 primers received 7.3, 6.7, or
6.1 μL respectively)
Touchdown PCR cycling:
PCR cycler
1. 94.0°C for 2:00
2. 94.0°C for 0:20
3. 65.0°C for 0:15
decrease temperature by 0.5°C per cycle
4. 68.0°C for 1:00
5. Return to step #2 for 10 cycles.
6. 94.0°C for 0:15
7. 60.0°C for 0:15
8. 72.0°C for 0:45
9. Return to step #6 for 30 cycles
10. 72.0°C for 2:00
11. 4.0°C for 00:00 (forever)

The following primers were used in the reactions:
Ndusf4-flox forward: AGTCAGCAACATTTGGCAGT
Ndusf4-flox reverse:
GAGCTTGCCTAGGAGGAGGT
 201bp = homozygous for wildtype allele
380bp = homozygous for floxed allele
201bp & 380 bp = heterozygote for floxed allele
Arg1-flox forward:
TGCGAGTTCATGACTAAGGTT
Arg1-flox reverse:
AAAGCTCAGGTGAATCGG
 200bp = homozygous for wildtype allele
250bp = homozygous for floxed allele
200bp & 250bp = heterozygote for floxed allele
LysM-mutant:
LysM-wildtype:

CCCAGAAATGCCAGATTACG
TTACAGTCGGCCAGGCTGAC
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LysM-common:

CTTGGGCTGCCAGAATTTCTC
 350bp = homozygous for wildtype allele
350bp & 700bp = positive for LysM (Homozygote LysMCre animals were not
used)

Tie2-Cre forward:
GCGGTCTGGCAGTAAAAACTATC
Tie2-Cre reverse:
GTGAAACAGCATTGCTGTCACTT
Tie2-control forward: CTAGGCCACAGAATTGAAAGATCT
Tie2-control reverse: GTAGGTGGAAATTCTAGCATCATCC
 300bp = Control band
~100bp = Cre – positive

2)

Bacterial strains and microbiological techniques

Bacterial Strains
The USA300 LAC strain of S. aureus is a community-acquired methicillin-resistant (CA-MRSA)
isolate previously provided by Dr. Frank DeLeo (National Institute of Allergy and Infectious
Diseases Rocky Mountain Laboratories, Hamilton, MT). This strain was isolated from Los
Angeles county (LAC) jail inmates with skin and soft tissue infection and was also responsible
for the CA-MRSA outbreak of 2002 (62). This S. aureus strain contains two plasmids, p01 and
p03 and the USA300 LAC 13c strain used in the Kielian laboratory has been cured of both
plasmids (139). This will be referred to as USA300 LAC throughout the dissertation.
For in vitro imaging of biofilms, USA300 LAC was phage-transduced with the plasmid
pCM29 to express GFP driven by the sarAP1 promoter (USA300 LAC-GFP), and plasmid
expression was maintained with chloramphenicol selection (10 μg/ml) (271).

Bacterial storage
Bacterial strains were stored at -80°C in glycerol stocks, prepared from log-phase cultures
propagated in brain-heart infusion broth (BHI, Fisher Scientific, Pittsburgh, PA) followed by
centrifugation at 2,400 rpm for 10 min, 4°C. The pellet was resuspended in 10ml of ice-cold 1X
PBS and washed by centrifugation at 2,400 rpm for 10 min, 4°C. After discarding the
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supernatant, the pellet was resuspended in 25% glycerol in 1X PBS and this bacterial-glycerol
suspension was aliquoted into appropriately labeled cryovials and stored at -80°C. This stock was
used to prepare fresh bacterial streak plates before every experiment in an effort to avoid
accumulating bacterial mutations by prolonged storage at 4°C.

In vitro S. aureus biofilms
Prior to each experiment, S. aureus was freshly streaked on a TSA plate supplemented with 5%
sheep’s blood (Remel) from a glycerol stock using a sterile flamed loop, and grown overnight. A
single bacterial colony was selected from the plate and used to inoculate 2.0mL of complete
biofilm media (RPMI 1640, 10% FBS, L-glutamine, HEPES, 10µg/mL chloramphenicol [only for
GFP bacteria used in confocal experiments]) at 37°C, shaking at 250 rpm, overnight. Eight-well
glass-chamber slides (ThermoScientific, Waltham, MA) or sterile 96-well plates, were coated
with 20% human plasma in sterile carbonate-bicarbonate buffer (Sigma-Aldrich, St. Louis, MO)
and incubated overnight at 4°C. Plasma-coating buffer was removed the following day. The O.D.
of the overnight culture was measured (BioMate 3S Spectrophotometer, Thermo Scientific,
Waltham, MA) at 600nm. Chamber slides were inoculated with bacteria diluted to an OD600 of
0.05 in 400µL of complete biofilm medium. Individual wells of a 96-well plate were inoculated
with bacteria diluted to an OD600 of 0.05 in 200µL of complete biofilm medium. Following
inoculation, biofilms were incubated at 37°C under static aerobic conditions for 4 days. Media
changes were performed every 24 h by carefully removing ~35% volume from each
well/chamber and adding 50% volume of fresh biofilm media to account for evaporation.

Preparation of bacteria for in vivo experiments
Prior to each experiment, S. aureus was freshly streaked on a TSA plate supplemented with 5%
sheep’s blood (Remel) from a glycerol stock using a sterile flamed loop, and grown overnight. A
single colony was selected from the plate and used to inoculate 25 mL BHI in a 250 mL baffled
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flask to maintain a 10:1 flask:volume ratio. The culture was incubated at 37°C with shaking at
250 rpm overnight (12-16 h). The OD600 was measured (BioMate 3S Spectrophotometer, Thermo
Scientific, Waltham, MA) and 1.0 ml of the overnight culture was transferred into a 1.5 ml
Eppendorf microcentrifuge tube and centrifuged at 14,000 rpm, 4°C for 10 min to pellet the
bacteria. The supernatant was removed and the pellet was resuspended in 1.0 ml PBS and
subsequently washed twice by centrifuging at 14,000 rpm for 5 min, 4°C. The washed overnight
culture was resuspended in 1.0 mL PBS and estimated to be 5.0 x 109 CFU/mL based on several
pilot study experiments.
The desired inoculum for prosthetic joint infections was 1.0 x 103 CFU in 2.0 µL (5.0 x 105
CFU/mL). This was prepared by performing serial dilutions on the washed overnight culture:
10-1
10-2
10-3
10-4

1:10 dilution = 5.0 x 108 CFU/mL
1:10 dilution = 5.0 x 107 CFU/mL
1:10 dilution = 5.0 x 106 CFU/mL
1:10 dilution = 5.0 x 105 CFU/mL

The desired inoculum for catheter associated infections was 1.0 x 103 CFU in 20 µL (5.0 x 104
CFU/mL). This was prepared by performing serial dilutions on the washed overnight culture:
10-1
10-2
10-3
10-4
10-5

1:10 dilution = 5.0 x 108 CFU/mL
1:10 dilution = 5.0 x 107 CFU/mL
1:10 dilution = 5.0 x 106 CFU/mL
1:10 dilution = 5.0 x 105 CFU/mL
1:10 dilution = 5.0 x 104 CFU/mL

The desired inoculum for subcutaneous abscess infections was 1.0 x 107 CFU in 20 µL (5.0 x 108
CFU/mL). This was prepared by performing serial dilutions on the washed overnight culture:
10-1

1:10 dilution = 5.0 x 108 CFU/mL

The exact number of bacteria (CFU/mL) from the overnight culture was determined following
preparation of bacteria for infection by performing triplicate dilutions as shown below:
10-2
10-3
10-4
10-5
10-6
10-7

10 µL of the 1.0 mL washed overnight culture in PBS
10 µL of 10-2 dilution into 90 µL
10 µL of 10-3 dilution into 90 µL
10 µL of 10-4 dilution into 90 µL
10 µL of 10-5 dilution into 90 µL
10 µL of 10-6 dilution into 90 µL
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10-8
10-9

10 µL of 10-7 dilution into 90 µL
10 µL of 10-8 dilution into 90 µL

10 µL of each of the dilutions were plated onto blood agar plates using track dilutions and
counted the following day. The track with the largest number of resolvable colonies was counted
to determine the actual CFU used for infection. For example:
Track of 10µL of 10-8 had 42 colonies
Original culture: 42 x 108 = 4.2 x 109 CFU/mL
Prosthetic joint infection inoculum: (4.2 x 109 CFU/mL) x (0.002 mL) x (10-4) = 8.4 x 102
CFU
Catheter associated inoculum: (4.2 x 109 CFU/mL) x (0.020 mL) x (10-5) = 8.4 x 102 CFU
Subcutaneous abscess inoculum: (4.2 x 109 CFU/mL) x (0.020 mL) x (10-1) = 8.4 x 106
CFU

3)

Cell culture techniques

L929 Culture
Supernatant from L929 cells was used as a source of MΦ-colony stimulating factor (M-CSF) to
expand mouse bone marrow-derived MΦs. L929 cells were obtained from ATCC (Manassas,
VA) and immediately thawed and cultured in 25 mm2 vented flask in L929 medium (RPMI-1640,
containing 10% heat-inactivated FBS (Atlanta Biologicals, Atlanta, GA), 1% v/v HEPES (1 M
stock, HyClone, South Logan, UT), 1% v/v Glutamine (200 mM stock, HyClone), antibioticantimycotic solution (10,000 IU/ml Penicillin, 10,000 μg/ml Streptomycin, 25 μg/ml
Amphotericin B, final 1% v/v, Mediatech Inc., Manassas, VA)). Cells were grown at 37°C in a
5% CO2 incubator until confluency. Cells were expanded and subcultured by scraping and reseeded at a 1:20 density in 175mm2 vented flasks. Upon reaching confluency, cells were
subcultured once more by scraping and re-seeding into 8 - 175 mm2 vented flasks. Two weeks
after cells reached confluency, supernatants were harvested, filtered, and stored in 50 mL conical
tubes at -80°C. A mouse M-CSF ELISA (vendor, location) revealed that L929 supernatants
contained 20-40μg/mL M-CSF.
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Primary mouse bone marrow-derived macrophage (BMDM) culture
Adult C57BL/6, Ndusf4fl/fl;LysMnull, Ndusf4fl/fl;LysMCre, Arg-1fl/fl;LysMnull, Arg-1fl/fl;LysMCre, Arg1fl/fl;Tie2null, and Arg-1fl/fl;Tie2Cre, were euthanized with an overdose of inhaled isoflurane
(Isothesia, VetUS, Dublin, OH) using a euthanasia chamber and cervical dislocation was
performed as a secondary method to ensure death. The abdominal surface of the mouse was
flooded with 70% EtOH, to prevent fur from contaminating specimens and a subcutaneous
incision was made near the midline of the abdomen. Skin was separated from the peritoneum
until all hind limbs were exposed and excess muscle was dissected away. Hind limbs were
removed at the hip joint and immediately submerged in a petri dish containing 70% EtOH before
being stored in 1X PBS on ice. Excess connective tissue and muscle was removed from the bone
surface with Kimwipes and clean bones were placed in fresh 1X PBS.
At this point, the entire procedure was performed under aseptic conditions in a biological
safety cabinet with sterile autoclaved instruments. The bone marrow was flushed from the bone
into sterile RPMI-1640 serum-free medium, and washed once with sterile medium. The
supernatant was aspirated and red blood cells were lysed by briefly adding 900 μL of sterile water
immediately followed by the addition of 100 μL 10X PBS, and QS to 25 ml with sterile RPMI1640. Cell debris was removed by filtering through a 40 μm cell strainer, and the filtered cell
suspension was centrifuged at 1,200 rpm for 5 min, at 4°C. Cells were washed with medium,
centrifuged, and counted using trypan blue (Lonza, Walkersville, Germany) on a hemocytometer.
Cells were plated on 150 x 20 mm non-treated cell culture plates (USA scientific, Ocala, FL) at a
density of 5.0 x 106 cells/plate, in 20 mL of media. BMDMΦ media was composed of RPMI1640 containing 10% heat-inactivated FBS (Atlanta Biologicals, Atlanta, GA), 1% v/v HEPES (1
M stock, Hyclone, South Logan, UT), 1% v/v Glutamine (200 mM stock, HyClone), antibioticantimycotic solution (10,000 IU/ml Penicillin, 10,000 μg/ml Streptomycin, 25 μg/ml
Amphotericin B, final 1% v/v, Mediatech Inc., Manassas, VA), 0.1% v/v 50 mM Betamercaptoethanol (Fisher Scientific, Pittsburgh, PA), and 5% conditioned medium from L929
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fibroblasts (ATCC) as a source of M-CSF. Medium was replaced on cultures at days 3 and 5 after
initial plating and cells were harvested on day 7 for experiments. Flow cytometric analyses
revealed that > 99% of cells were macrophages based on CD11b and F4/80 staining after a 6-day
culture period.

4)

Confocal microscopy of Ndusf4fl/fl;LysMCre MΦ-S. aureus biofilm co-cultures

GFP expressing S. aureus biofilms transduced with pCM29 (chloramphenicol) were grown for 4
days in 8-well borosilicate chambered cover glass slides (ThermoScientific) coated with 20%
human plasma. Complete biofilm medium (RPMI 1640, 10% FBS, L-glutamine, HEPES,
10µg/mL chloramphenicol) was changed every 24 h. Our prior studies demonstrated that these
growth conditions resulted in mature S. aureus biofilms based on the presence of tower structures
and thickness (138, 139). Mature bone marrow-derived MΦs were labeled with CellTracker Blue
(Molecular Probes, San Diego, CA) and added to the biofilm at 2x105 per well, for an estimated
MOI of 500:1 (bacteria:MΦ). MΦs were allowed to settle for 2 h prior to imaging. MΦ-biofilm
interactions were visualized using a Zeiss laser scanning confocal microscope (LSM 710 META;
Carl Zeiss, Oberkochen, Germany). Z-stacks were collected from beneath the glass slide
extending to above the point where bacteria could no longer be detected. Three-dimensional
images of biofilms and measurements to demonstrate biofilm thickness were performed using
Zen 2012 software (Carl Zeiss).

5)

Gentamicin protection assay

Bone marrow-derived MΦs from Ndusf4fl/fl;LysMnull and Ndusf4fl/fl;LysMCre mice were prepared as
described above. On the day 6 in vitro (DIV), MΦs were harvested and re-plated in 96-well tissue
culture plates at a density of 5.0x104 MΦs/well and incubated at 37°C in a 5% CO2 incubator
overnight. Media was removed, and wells were rinsed with antibiotic-free biofilm medium twice,
and inoculated with S. aureus at an MOI of 1, 10, or 100 (5.0x104 CFU, 5.0x105 CFU, 5.0x106
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CFU, respectively), in 100μL. Plates were incubated at 37°C for 45 min. Medium was removed
and replaced with biofilm medium containing 100μg/mL gentamicin, and incubated at 37°C for
30 min to kill extracellular bacteria. Following gentamicin treatment, medium was replaced with
fresh biofilm medium containing 1.0μg/mL gentamicin. At 0, 2, 4, 6, 12, 24, 48, or 72 h
following treatment with gentamicin, supernatants were collected and stored at -20°C. Adherent
MΦs were lysed with 100μL of sterile H2O for 10 min. Track dilutions of lysates were made and
plated on TSA plates supplemented with 5% sheep blood. The tracks with the largest number of
resolvable colonies were counted to determine the number of surviving intracellular bacteria.

6)

Seahorse Biosciences Assay

The bio-energetic profiles of bone marrow-derived MФs were assessed using a XF96
extracellular flux analyzer (Seahorse Biosciences, North Billerica, MA). Briefly, MФs were
seeded in XF96 plates at 5x104 cells/well 24 h prior to assay, whereupon cells were treated with
10ng/mL rmIL-4, S. aureus PGN + IFN-γ (10μg/mL and 10ng/mL, respectively), or CTO (Cy5labeled, tuftsin-conjugated, oligomycin) nanoparticles (1μg/mL) for 24 h at 37°C. One hour prior
to assay, MФs were incubated in bicarbonate-free DMEM (Sigma-Aldrich) supplemented with
2mM L-glutamine and 1mM pyruvate at 37°C without CO2. Glucose was included at 10mM for
mitochondrial stress tests. For mitochondrial stress tests, oxygen consumption rate (OCR) was
measured following sequential exposure to oligomycin (1μM), carbonilcyanide ptriflouromethoxyphenylhydrazone (FCCP, 1μM), and rotenone (0.5μM) (all from SigmaAldrich). By sequentially blocking different steps of the electron transport chain, well-established
algorithms were used to calculate basal and maximal respiration (272, 273). To measure
glycolytic activity, MФs were pre-incubated for 1 h in medium lacking sodium bicarbonate,
serum, and glucose prior to initiating the assay to reduce intracellular glucose stores. Next, cells
were sequentially exposed to glucose (10mM) and oligomycin (1μM; both from Sigma-Aldrich),
whereupon extracellular acidification rate (ECAR) was measured. Total protein was quantified
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from each well following Seahorse assays to confirm lack of differential MФ toxicity to the
metabolic inhibitors.

7)

Mouse models of S. aureus infection

Subcutaneous S. aureus abscesses
Age- and sex-matched mice (8-10 weeks old) were used to examine the immune response to S.
aureus subcutaneous abscess infection. Arg-1fl/fl;Tie-2Cre conditional KO and Arg-1fl/fl;Tie-2null
control mice were weighed and anesthetized with ketamine/xylazine (100mg/kg and 5mg/kg,
respectively) by intraperitoneal (i.p.) injection. Once anesthetized, the left flank was shaved using
clippers, and the surgical site was cleaned and disinfected with povidone-iodine. Mice received
subcutaneous injections of S. aureus (107 CFU in 20μL sterile PBS) using a 27-gauge x ½”
needle. Eye ointment (LubriFresh™ P.M., Major Pharmaceuticals, Livonia, MI) was used for all
mice before they were returned to clean cages and kept under heat lamps to maintain core body
temperature until fully recovered from anesthesia. Cages were labeled with orange biohazard
cards and monitored daily throughout the course of infection. Abscess sizes were measured daily
with calipers (accuracy of 0.001”, and repeatability of 0.0005”, iGaging, Los Angeles, CA),
throughout the course of infection.

Subcutaneous catheter-associated biofilm infection
Age- and sex-matched mice (8-10 weeks old) were used to examine the immune response to S.
aureus subcutaneous catheter infection. Arg-1fl/fl;Tie-2Cre conditional KO and Arg-1fl/fl;Tie-2null
control mice were weighed and anesthetized with ketamine/xylazine (100mg/kg and 5mg/kg,
respectively) by intraperitoneal (i.p.) injection. Once anesthetized, the left flank was shaved using
clippers, and the surgical site was cleaned and disinfected with povidone-iodine. Next, a small
subcutaneous (s.c.) incision was made in the left flank and a blunt probe was used to create a
pocket for the insertion of a sterile, 16-gauge Teflon coated intravenous catheter, 1 cm in length
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(Exel International, St. Petersburg, FL). The incision was sealed using Vetbond Tissue Adhesive
(3M, St. Paul, MN) and 103 CFU USA300 LAC in 20 μL of sterile PBS was injected through the
skin, directly into the catheter lumen using a 27-gauge x ½” needle. Eye ointment (LubriFresh™
P.M., Major Pharmaceuticals, Livonia, MI) was used for all mice before they were returned to
clean cages and kept under heat lamps to maintain core body temperature until fully recovered
from anesthesia. Cages were labeled with orange biohazard cards and monitored daily throughout
the course of infection.

S. aureus biofilm-associated orthopedic implant infection
Age- and sex-matched mice (8-10 weeks old) were used to simulate infectious complications in
patients following orthopedic implant placement. Animals were weighed and anesthetized with
ketamine/xylazine (100 mg/kg and 5 mg/kg, respectively) by i.p. injection. Once anesthetized,
right leg was shaved using clippers, and the surgical site was cleaned and disinfected with
povidone-iodine. A medial incision was created through the quadriceps with lateral displacement
of the patella tendon to access the distal femur. A burr hole was made in the femoral
intercondylar notch through the intramedullary canal using a 26-gauge needle, whereupon a precut 0.8-cm orthopedic-grade Kirschner wire (0.6mm diameter, Nitinol [nickel-titanium]; Custom
Wire Technologies, Port Washington, WI) was inserted into the intramedullary canal, leaving
~1mm protruding into the joint space. The exposed wire surface was inoculated with 103 CFU of
S. aureus USA300 LAC in 2μL of sterile PBS. The quadriceps-patellar complex was reduced to
the midline and the fascia was sutured with 6-0 metric absorbable sutures before the skin of the
surgical site was closed with 6-0 metric nylon sutures (both from Covidien, Mansfield, MA).
Animals received s.c. Buprenex (0.1mg/kg; Reckitt Benckiser, Hull, U.K.) for pain relief, and
returned to clean cages under a heat lamp to ensure maintenance of core body temperature until
fully recovered from anesthesia. Cages were labeled with orange biohazard cards and monitored
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daily. A second dose of Buprenex was administered 24 h after surgery and after this interval, all
mice exhibited normal ambulation and no discernable pain behaviors.

8)

Nanoparticle synthesis and characterization

Polymeric nanoparticles based on an amphiphilic block copolymer of poly(ethylene glycol)-bpoly(L-glutamic acid) (PEG-b-PGA) with pendant phenylalanine functionalities were synthetized
as previously described (274, 275). Briefly, PEG-b-PGA (Alamanda Polymers, Inc., Madison,
AL; block lengths were 114 and 150 repeating units for PEG and PGA, respectively) was first
modified with L-phenylalanine methyl ester via carbodiimide chemistry. The degree of grafting
was 50% as determined by 1H-NMR analysis. Polymeric micelles were then prepared by mixing
the solution of copolymer in dimethylformamide with water (1: 1 v/v) following dialysis against
water for 48 h. The formed micelles were cross-linked using 1,2-ethylenediamine in the presence
of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) with a targeted crosslink density of 20% (based on the molar ratio of cross-linker to carboxylic groups of the GA
residues). Tuftsin peptide with a cysteine residue at the C-terminus (TKPRC) was synthesized on
an automated solid-phase Liberty microwave peptide synthesizer (CEM, Matthews, NC)
employing standard Fmoc chemistry using a Rink Amide resin (Nova Biochem). Sample
purification (≥ 95%) was performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250
× 4.6 mm C12 column using a water (0.1% formic acid)–acetonitrile (0.1% formic acid) gradient.
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system equipped with a
Waters 2489 absorption detector and a Waters Q-Tof Micro electrospray ionization mass
spectrometer.
Tuftsin targeting moieties were conjugated to nanoparticles via a heterobifunctional
maleimide-PEG-amine linker (MAL-PEG-NH2, 7.5 kDa, JenKem Technology, Plane TX). First,
MAL-PEG-NH2 (0.27 µmol, 0.15 eq with respect to the amount of carboxylic groups) was
conjugated to the free carboxyl groups (1.75 µmol) of EDC-activated nanoparticles. Resulting
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constructs were puriﬁed using repeated ultraﬁltration (MWCO 30,000, Millipore) at 2200 rpm for
15 min (3 washes). Purified peptide (0.31 µmol) was subsequently reacted with MAL-PEG
functionalized nanoparticles in PBS at pH 7 for 2 h. Unreacted MAL groups were quenched by βmercaptoethanol and targeted nanoparticles were purified by dialysis against distilled water using
a dialysis membrane (MWCO 3500 Da). The amount of peptide conjugated on the surface of the
nanoparticles was 126.3 ± 6.3 µg per mg of polymer (n=3) as determined by a BCA protein
assay. Oligomycin-loaded nanoparticles were prepared by adding an ethanol solution of
oligomycin (2 mg/mL) dropwise into the aqueous dispersion of tuftsin-coated nanoparticles (1
mg/mL) and mixed overnight at RT in an open-air system to allow for the slow evaporation of
ethanol. The residual ethanol was then removed at reduced pressure. Unincorporated oligomycin
was removed by ﬁltration with 0.8 μm syringe ﬁlters (Thermo Scientiﬁc). Oligomycin content
was determined by HPLC analysis under isocratic conditions using an Agilent 1200 HPLC
system with a diode array detector set at 226 nm (276). A Nucleosil C18 column was used as
stationary phase (250 mm × 4.6 mm), and the mobile phase was comprised of an
acetonitrile/water mixture (80/20, v/v) applied at a ﬂow rate of 1 mL/min. The resulting
nanoparticles had an average hydrodynamic diameter of approximately 80 nm (ζ-potential = -8.4
mV) and were characterized by narrow size distributions using dynamic light scattering (Zetasizer
Nano ZS, Malvern Instruments Ltd., Worcestershire, UK). The loading capacity of tuftsin-coated
nanoparticles for oligomycin was 5.2 ± 0.9 % (w/w). Finally, fluorescently labelled non-modified
(C), tuftsin-coated empty (CT) and tuftsin-oligomycin-loaded (CTO) nanoparticles were
synthesized by adding Cy5 amine (Lumiprobe Corporation, Hunt Valley, MD) in DMSO to the
aqueous dispersion of nanoparticles (equivalent to 0.16% of carboxylic groups in nanoparticles)
in the presence of EDC and the mixture was incubated for 4 h in the dark. Unbound dye was
removed by dialysis and fluorescence emission spectra of labelled nanoparticles were
characterized using a FluoroMax-4 spectrofluorometer (HORIBA Scientific). Oligomycin release
from CTO nanoparticles was determined using a PBS dialysis method with a 3.5 kDa membrane
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cutoff. The kinetics of oligomycin release was determined by HPLC and concentrations are
expressed as a percentage of the total oligomycin available vs. time. Over 90% of oligomycin was
released from CTO nanoparticles within a 24 h period at physiological pH (Supplemental Figure
3.1).

9)

In vivo drug administration

Nanoparticles
Animals were placed in an induction chamber without restraint and anesthetized with 2.5%
isoflurane. A total of 10μg control (C or CT) or oligomycin (CTO) nanoparticles were
administered by a single intra-articular injection (in 10μL of PBS) at either day 3 or 7 postinfection. Nanoparticle injection and length of retention was evaluated in the same cohort of mice
using an In Vivo Imaging System (IVIS Spectrum; PerkinElmer, Waltham, MA) under isoflurane
anesthesia, with excitation and emission wavelengths of 640nm and 680nm, respectively.

Antibiotics
Mice received daily systemic antibiotic treatments by i.p. injections (25 mg/kg/day rifampin and
5 mg/kg/day daptomycin) dissolved in 100 μL sterile PBS with a 26-gauge x 5/8 needle. In some
experiments, 100 ng or 50 ng oligomycin (in 10 μL of PBS) was directly injected into the knee
joint to assess antibiotic effects.

ROS, iNOS, and ODC inhibitors
Mice received i.p. injections of apocynin (6 mg/kg/day), N6-(1-iminoethyl)-L-lysine (L-NIL; 40
mg/kg/day), α-difluoromethylornithine (DFMO; 50 mg/kg/day), or vehicle beginning at 5 h prior
to S. aureus infection. All small molecule inhibitors were administered i.p. once daily until
sacrifice at 3 or 7 days post-infection (DPI).
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10)

Recovery of abscess- or implant-associated tissues for S. aureus enumeration

Recovery of subcutaneous abscess tissues
Animals were sacrificed by an overdose of inhaled isoflurane, followed by cervical dislocation.
The surgical site was flooded with 70% ethanol to prevent potential sample contamination with
skin microflora. The subcutaneous abscesses were excised, weighed, and collected in 0.5 mL of
homogenization buffer (sterile PBS supplemented with a Complete™ protease inhibitor cocktail
tablet (Roche Diagnostics, Indianapolis, IN)) on ice. Tissues were dissociated using the blunt end
of a 3.0 mL syringe. An aliquot was filtered through a 35 μm filter (BD Falcon, Bedford, MA)
and analyzed by flow cytometric analysis as described below. A second aliquot was centrifuged
at 14,000 rpm for 10 min and the supernatants were transferred to a new 1.5mL centrifuge tube
and stored at -80°C until Milliplex analysis. A final aliquot of homogenate was serially diluted
and plated on TSA plates supplemented with 5% sheep blood to determine bacterial counts.
Bacterial titers were expressed as Log10 (CFU/g wet tissue weight).

Recovery of subcutaneous catheters and surrounding tissues
Animals were sacrificed using an overdose of inhaled isoflurane, followed by cervical
dislocation. The surgical site was flooded with 70% ethanol to prevent potential sample
contamination with skin microflora. The section of the flank containing the catheter and
associated tissue was removed, whereupon the catheter was separated from the surrounding host
tissue, weighed, and placed in 0.5 mL of homogenization buffer (sterile PBS supplemented with a
Complete™ protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN)) on ice.
Catheters were sonicated for 5 min on ice while catheter-associated tissues were dissociated using
the blunt end of a 3.0 mL syringe. An aliquot was filtered through a 35 μm filter (BD Falcon,
Bedford, MA) and analyzed by flow cytometric analysis as described below. A second aliquot
was centrifuged at 14,000 rpm for 10 min and the supernatants were transferred to a new 1.5mL
centrifuge tube and stored at -80°C until Milliplex analysis. A final aliquot of homogenate was
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serially diluted and plated on TSA plates supplemented with 5% sheep blood to determine
bacterial counts. Bacterial titers were expressed as Log10 (CFU/ml) for catheters or Log10 (cfu/g
wet tissue weight) for catheter-associated tissues.

Recovery of orthopedic implant and surrounding tissues
Animals were sacrificed by an overdose of inhaled isoflurane, followed by cervical dislocation.
The surgical site was flooded with 70% ethanol to prevent potential sample contamination with
skin microflora. An incision was made in the skin of the right leg so that the skin could be
carefully removed. The subcutaneous tissue overlying the patellar tendon was excised, weighed,
and placed in 0.5 mL of homogenization buffer (sterile PBS supplemented with a Complete™
protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN)) on ice. The tissue was
dissociated with the blunt end of a 3.0 mL syringe. An aliquot was filtered through a 35 μm filter
(BD Falcon, Bedford, MA) and analyzed by flow cytometric analysis as described below. A
second aliquot was centrifuged at 14,000 rpm for 10 min and the supernatant was stored at -80°C
until Milliplex analysis. A final aliquot of homogenate was serial diluted and plated on TSA
plates supplemented with 5% sheep blood to determine bacterial counts. The tibia and fibula were
transected distal to the knee joint, and the femur was disarticulated at the hip joint and removed.
The remaining muscle and tendon tissues were removed from the bones using Kimwipes. The
knee joint was separated from the femur to allow for collection of the titanium implant into 0.2
mL sterile PBS on ice, followed by vortexing at 2,000 rpm for 10 min to dislodge bacteria
adherent to the implant. The knee joint and femur were weighed and placed into 0.5 mL
homogenization buffer before being homogenized with a Polytron homogenizer at the highest
setting for approximately 20 sec. Serial dilutions of the homogenates from the knee, femur, and
implant were plated on TSA plates supplemented with 5% sheep blood to determine bacterial
counts. Bacterial titers were expressed as Log10 (cfu/g wet tissue weight) for implant-associated
tissue, knee joint, and femur, or Log10 (CFU/ml) for implant-associated titers. The remaining
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homogenates from the knee and femurs were centrifuged at 14,000 rpm for 10 min and the
supernatants were transferred to new 1.5mL centrifuge tubes and stored at -80°C until Milliplex
analysis.

11)

Western blot for arginase-1

MΦs were expanded from the bone marrow of Arg-1fl/fl;Tie-2Cre MΦ conditional KO, Arg1fl/fl;LysMCre myeloid conditional KO, and Arg-1fl/fl;Tie-2null control mice. At day in vitro 6, MΦs
were harvested, re-plated, and treated with 10 ng/mL recombinant mouse (rm)IL-4 (BioLegend,
San Diego, CA) for 24 h, whereupon cellular extracts were prepared with RIPA buffer (1%
Triton-X, 0.1% SDS, supplemented with a Complete™ protease cocktail, Roche Diagnostics).
Blots were probed with an anti-Arg-1 antibody (goat anti-mouse 1:200, sc-271430, Santa Cruz
Biotechnology) followed by a rabbit anti-goat IgG-HRP (Abcam, Cambridge, MA).

12)

Arginase assay

Arginase activity was measured in MΦs expanded from Arg-1fl/fl;Tie-2Cre conditional KO, Arg1fl/fl;LysMCre, and Arg-1fl/fl;Tie-2null control mice following stimulation with 10 ng/mL rmIL-4. To
determine arginase activity in MΦs and MDSCs recovered from S. aureus catheter-associated
biofilm infections, MΦs and MDSCs were isolated by FACS. Following isolation of in vitro
stimulated or ex vivo isolated MΦs and MDSCs, cells were lysed in 100 μL of lysis buffer (10
mM Tris-HCl, pH 7.4, 1.0 μM pepstatin A, 1.0 μM leupeptin, 0.4% Triton X-100). Arginase
activity assays were performed using an Arginase Activity Assay Kit (Sigma-Aldrich, St. Louis,
MO) according to the manufacturer’s instructions. Arginase activity was reported as units/L.

13)

Hydroxyproline assay

To determine the relative collagen content in S. aureus catheter-associated tissues,
hydroxyproline assays were performed using a Hydroxyproline Assay Kit (Sigma Aldrich).
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Briefly, samples were prepared by homogenizing 10mg of infected tissue in 100μL of water,
transferred to a pressure-tight vial with 100μL of 12M hydrochloric acid, and hydrolyzed at
120°C for 3 h. A total of 10-50μL per sample was transferred to a 96-well plate and evaporated at
60°C. Following the addition of reaction buffer the plate was read at 570nm using an iMark
Microplate Absorbance Reader (Bio-Rad, Hercules, CA). Results were calculated based on a
standard curve, and reported as µg hydroxyproline/mg tissue

14)

Metabolomic analysis

Monocytes and MDSCs were recovered by FACS from animals with S. aureus orthopedic
implant infection that received CT or CTO nanoparticles and polar metabolites were extracted.
Briefly, monocytes and MDSCs were lysed using an 80% methanol/water mixture pre-chilled to 80°C. Cellular debris was removed by centrifugation at 13,000 rpm for 5 min at 4°C, whereupon
supernatants containing metabolite extracts were collected and dried at room temperature using a
speed vacuum concentrator (Eppendorf, Hamburg, Germany). Samples were resuspended in a
50% methanol/water mixture and analyzed using LC-MS/MS (Liquid Chromatography with
tandem mass spectrometry). A single reaction monitoring (SRM) LC-MS/MS method was used
with positive/negative ion polarity switching on a Xevo TQ-S mass spectrometer as described
previously (277). The metabolite peak areas were calculated using MassLynx 4.1 (Waters Inc.)
and normalized to the respective cell counts of each sample. The resultant peak areas were
subjected to relative quantification analyses by utilizing MetaboAnalyst 3.0
(www.metaboanalyst.ca). Fold-change values of metabolites were expressed as CTO relative to
CT treated mice. Individual values exhibited a normal distribution and outliers were identified by
Grubb’s test, followed by a Student’s t-test to determine significance. Principal component
analysis, heat map, and pathway impact analysis were also performed using MetaboAnalyst 3.0
software.
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15)

Flow cytometry

Flow cytometric analysis was used to characterize leukocyte infiltrates in inflamed subcutaneous
tissues from abscesses or soft tissues surrounding subcutaneous catheter or orthopedic implants
during S. aureus biofilm infection. Animals were sacrificed with an overdose of inhaled
isoflurane and tissues were excised as previously described and placed in 500 µl FACS buffer
(2% FBS in PBS) on ice. Tissues were dissociated with the blunt end of a plunger from a 3.0 mL
syringe, and passed through a 35 µm filter (BD Falcon, Bedford, MA). Following removal of an
aliquot for bacterial quantitation and Milliplex analysis, the filtrate was washed with FACS buffer
and cells were collected by centrifugation (1,200rpm, 5 min, and 4°C). RBCs were lysed using
BD Pharm Lyse (BD Biosciences, San Diego, CA) for 5 min at room temperature. After lysis,
cells were washed with FACS buffer and resuspended in 250 μL FACS buffer supplemented with
2 μL Fc-block (TruStain FcX, BioLegend, San Diego, CA) for 5 min at 4°C to minimize
nonspecific antibody binding. Compensation and isotype controls were made by pooling 50 μL of
each sample to identify gating thresholds and assess the degree of nonspecific staining. The
remaining 200μL was divided into two wells of a round-bottom 96-well plate to assess innate and
adaptive leukocyte infiltrates using the panels described below. To exclude dead cells from
analysis, cells were stained with Live/Dead Fixable Blue Dead Cell Stain (Invitrogen, Eugene,
OR).
General innate immune panel:
CD45-APC
Ly6G-PE
Ly6C-PerCP-Cy5.5
F4/80-PE-Cy7
CD11b-FITC
Innate immune panel for nanoparticle experiments:
CD45-PacBlue
Ly6G-PE
Ly6C-PerCP-Cy5.5
F4/80-PE-Cy7
CD11b-FITC
Nanoparticle-APC (not an antibody)
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General adaptive immune panel:
CD45-PE-Cy7
CD3-APC
CD4-PacBlue
CD8a-FITC
γδ-TCR-PE
Adaptive immune panel for nanoparticle experiments:
CD45-PE-Cy7
CD3-PE
CD4-PacBlue
CD8a-FITC
Nanoparticle-APC (not an antibody)
All fluorochrome-conjugated antibodies were purchased from BioLegend (San Diego, CA). For
individual samples, 10,000-100,000 events were analyzed using BD FACSDiva software with
cell populations expressed as percentage of total viable CD45+ leukocytes.

JC-1, BODIPY C12, and 2-NBDG staining
Staining with JC-1 (5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide),
BODIPY-12C (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid),
and 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose) were used to
assess the metabolic activity of leukocytes from the inflamed subcutaneous tissues surrounding
orthopedic implants during S. aureus biofilm infection. Tissues were homogenized in 1.0 mL of
PBS and passed through a 35 µm filter (BD Falcon). Unwashed cells were divided into three
tubes and incubated with either JC-1 (100 ng/mL), BODIPY-12C (200 ng/mL), or 2NBDG (10
µM) for 30 minutes at 37ºC. Single stain controls, with or without FCCP treatment were made
from pooled aliquots of each sample. Cells were washed with FACS buffer and resuspended in
250 μL FACS buffer supplemented with 2 μL Fc-block (TruStain FcX, BioLegend, San Diego,
CA) for 5 min at 4°C to minimize nonspecific antibody binding. Cells were stained in a 96-well
round bottom plate to assess innate leukocyte infiltrates using the panel described below. To
exclude dead cells from analysis, cells were stained with Live/Dead Fixable Blue Dead Cell Stain
(Invitrogen, Eugene, OR).
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General innate immune panel:
CD45-APC
Ly6G-PacBlue
Ly6C-PerCP-Cy5.5
F4/80-PE-Cy7
CD11b-AF700
All fluorochrome-conjugated antibodies were purchased from BioLegend (San Diego, CA). For
individual samples, 10,000-100,000 events were analyzed using BD FACSDiva software.
Oxidative Phosphorylation activity (JC-1) was expressed as the ratio of the number of green to
red cells of a specific cell population. Β-oxidation (BODIPY C12) and glycolytic (2-NBDG)
activity was expressed as the percent of a specific cell population.

16)

RNA isolation and real-time quantitative polymerase chain reaction (RT-qPCR)

Gene expression analysis of in vitro bone marrow derived MΦs
MΦs were expanded from the bone marrow of C57BL/6 mice as described above. At day in vitro
6, MΦs were harvested and seeded at 5x104 cells/well in a 96-well plate. Following a 24 h
adherence period, MΦs were treated with 10 ng/mL recombinant mouse (rm)IL-4 (BioLegend,
San Diego, CA) + various concentrations of oligomycin (Sigma-Aldrich, St. Louis, MO) for 4 h
at 37°C, whereupon a Cells-to-Ct kit (ThermoFisher Scientific, Waltham, MA) was used to
isolate RNA and synthesize cDNA for TaqMan qPCR (ThermoFisher Scientific). qPCR was
performed using TaqMan primer/probe sets for Arg-1, TNF-α, and GAPDH (Glyceraldehyde 3phosphate dehydrogenase). Gene expression levels were normalized to GAPDH expression and
are presented as the fold-induction (2-ΔΔCt) value relative to untreated MΦs.
Gene expression analysis of FACS-purified leukocytes from Arg-1fl/fl animals
Viable monocytes (CD45+Ly6G-Ly6C+F4/80±) or MDSCs (CD45+Ly6GhighLy6C+F4/80-) were
purified from S. aureus-infected tissues by FACS on a FACSAria (BD Biosciences), whereupon
total RNA was isolated using the cells-to-Ct TaqMan gene expression kit (ThermoFisher).
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Reverse transcription (RT) and pre-amplification reactions were conducted according to the
manufacturer’s instructions using a Bio-Rad CFX Connect™ thermocycler. TaqMan
primer/probe mixes (Applied Biosystems, Foster City, CA) for Arg-1, iNOS, and GAPDH were
used to evaluate monocyte and MDSC gene expression. Gene expression levels of monocytes and
MDSCs from Arg-1fl/fl;Tie2Cre animals were normalized to GAPDH and are presented as the foldinduction (2-ΔΔCt) value relative to monocytes and MDSCs isolated from Arg-1fl/fl;Tie2null animals.

Gene expression analysis of FACS-purified leukocytes from nanoparticle treated animals
Viable monocytes (CD45+Ly6G-Ly6C+F4/80-) and MDSCs (CD45+Ly6G+Ly6C+CD11bhighF4/80) from the soft tissue surrounding the infected knee were sorted by FACS on a FACSAria (BD
Biosciences), whereupon RNA was immediately isolated on spin columns using an RNeasy Plus
Micro Kit (QIAGEN, Hilden, Germany). cDNA was synthesized using the iScriptTM cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Pre-amplification reactions were conducted according to
the manufacturer’s instructions using a Bio-Rad CFX Connect™ thermocycler. Pre-amplified
cDNA samples were diluted 1:2 in PCR molecular grade water and RT-qPCR was performed
using TaqMan primer/probe mixes (Applied Biosystems, Foster City, CA) for the following
genes: Arg-1, IL-10, IL-4, triggering receptor expressed on myeloid cells 2 (Trem2), hypoxiainducible factor-alpha (HIF1-α), inducible nitric oxide synthase (iNOS), TNF-α, and Trem1. The
housekeeping gene GAPDH was used to normalize expression levels. Primer/probe sets were
optimized to PCR cycling conditions (95°C, 10 min; 95°C, 15 s; 60°C, 1 min – 40 cycles of steps
2 and 3). The cycle threshold for a particular gene in monocytes and macrophages was
normalized to GAPDH cycle threshold to calculate the ΔCt value. The ΔΔCt value was derived
by comparing the ΔCt values of monocytes and MDSCs from CTO treated animals to the ΔCt
values of monocytes and MDSCs from CT treated animals to determine fold induction (2-ΔΔCt).
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17)

Statistics

Significant differences between experimental groups were determined by an unpaired two-tailed
Student t-test or a one-way ANOVA with Bonferroni’s multiple comparisons using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA). For all analysis p < 0.05 was considered statistically
significant.
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Abstract
Biofilm-associated prosthetic joint infections (PJIs) cause significant morbidity due to their
recalcitrance to immune-mediated clearance and antibiotics, with Staphylococcus aureus (S.
aureus) among the most prevalent pathogens. Our previous studies demonstrated that S. aureus
biofilm-associated monocytes are polarized to an anti-inflammatory phenotype and the adoptive
transfer of pro-inflammatory macrophages attenuated biofilm burden, highlighting the critical
role of monocyte/macrophage polarization in dictating biofilm persistence. The inflammatory
properties of leukocytes are linked to their metabolic state, where anti-inflammatory macrophages
primarily rely on oxidative phosphorylation (OxPhos) and pro-inflammatory macrophages utilize
aerobic glycolysis. Here we demonstrate that biofilm-associated monocytes exhibit a metabolic
bias favoring OxPhos and less glycolysis to facilitate their anti-inflammatory activity and biofilm
persistence. To shift monocyte metabolism in vivo and reprogram cells to a pro-inflammatory
state, a novel nanoparticle approach was utilized to deliver the OxPhos inhibitor oligomycin to
monocytes. Using a mouse model of S. aureus PJI, >85% of oligomycin nanoparticles were
internalized by monocytes, which significantly reduced S. aureus biofilm burden by altering
metabolism and promoting the pro-inflammatory properties of infiltrating monocytes as revealed
by metabolomics and RT-qPCR, respectively. Injection of oligomycin alone had no effect on
monocyte metabolism or biofilm burdens, establishing that intracellular delivery of oligomycin is
required to reprogram monocyte metabolic activity and oligomycin lacks antibacterial activity
against S. aureus biofilms. Remarkably, monocyte metabolic reprogramming with oligomycin
nanoparticles was effective at clearing established biofilms in combination with systemic
antibiotics. These findings suggest that metabolic reprogramming of biofilm-associated
monocytes may represent a novel therapeutic approach for PJI.
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Introduction
The frequency of orthopedic procedures, such as total knee and total hip arthroplasty
(TKA and THA, respectively), continues to increase and is predicted to reach an annual rate in
the United States by 2030 of 572,000 and 3.48 million, respectively (125, 126). Although most
surgeries are successful, devices may fail following prosthetic joint infection (PJI), a
complication that can cause sustained disability and increased health care costs attributable to
prolonged antibiotic treatment and multiple surgeries. The estimated annual incidence of
prosthetic joint infection (PJI) in the United States is 2.18% for all THAs and TKAs; however,
the infection rate following revision surgery is even higher (i.e. 3.2-5.6% for both THA and
TKAs). The current standard-of-care for PJIs includes removal of the infected hardware,
placement of an antibiotic-impregnated polymethylmethacrylate spacer for 4-6 weeks until the
infection has resolved, followed by a second surgery to insert a new prosthesis. This demonstrates
the importance of developing novel therapeutic approaches to treat biofilm-associated infections
without requiring multiple surgical interventions (107, 108, 110, 111, 124).
Staphylococcus aureus (S. aureus) is a leading cause of PJI that is characterized by
biofilm formation (111), and with the increased prevalence of methicillin-resistant S. aureus
(MRSA) this pathogen has become an even greater therapeutic challenge (10). Biofilm infections
persist despite antibiotic therapy due, in part, to decreased metabolic activity of biofilmassociated bacteria and evasion of the immune response (86, 111, 278). Our laboratory was the
first to demonstrate that S. aureus biofilms skew the host immune response towards an antiinflammatory state (139). This is evident by the polarization of anti-inflammatory
monocytes/macrophages (MΦs) and abundance of myeloid-derived suppressor cells (MDSCs)
(138, 148, 188, 189). MDSCs are a heterogeneous population of immature myeloid progenitors
with the capacity to differentiate into mature granulocytes or MΦs given the appropriate
environmental cues (227-229, 232). However, during chronic pathological conditions, such as
cancer, infection, or autoimmune disorders, MDSCs are often arrested in an immature state where
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they can inhibit T cell activation and monocyte/MΦ pro-inflammatory properties (227-229). We
have demonstrated that MDSCs are integral to S. aureus biofilm establishment and persistence
and polarize infiltrating monocytes towards an anti-inflammatory phenotype (146, 148, 189).
These effects are mediated, in part, via IL-10 production by MDSCs, which can block NF-κB
activation in monocytes and MФs and down-regulate cytokine expression (106, 148, 189). In
addition, MDSC depletion augmented monocyte pro-inflammatory activity, which translated into
reduced biofilm burden (148, 189). Biofilm clearance is also facilitated by the adoptive transfer of
pro-inflammatory MΦs at the site of biofilm infection (138). Therefore, the immune polarization
state of monocytes and MΦs plays a key role in dictating biofilm persistence and this is
influenced, in part, by MDSC-derived factors.
Recent studies have shown that the inflammatory phenotype of MΦs is intimately tied to
their metabolic state. For example, anti-inflammatory MΦs rely primarily on oxidative
phosphorylation (OxPhos) to drive their suppressive activity (256, 257, 260, 279). However, upon
exposure to pro-inflammatory stimuli, MΦs favor aerobic glycolysis (256, 257, 260, 279-281). In
vitro studies have shown that MΦ metabolic switches are facilitated by global changes in gene
expression. Pro-inflammatory MΦs express the highly active PFK-2 isoform, u-PFK2 (ubiquitous
phosphofructokinase) and down-regulate TCA cycle enzymes, promoting intracellular
accumulation of glucose, succinate, and citrate (256, 260). In contrast, anti-inflammatory MΦs
express the less active PFK-2 isoform PFKB1 and upregulate CD36 to facilitate triglyceride
uptake to fuel the TCA cycle (256, 260, 282, 283). Of note, monocytes outnumber MΦs in our
mouse PJI model and we have shown that monocytes are also polarized toward an antiinflammatory state during S. aureus biofilm infection (106, 146, 148, 189). However, it is not
known whether these anti-inflammatory monocytes can be metabolically reprogrammed to induce
pro-inflammatory activity and biofilm clearance.
Monocyte metabolism and inflammatory phenotypes exist within a spectrum and shift in
response to environmental stimuli. Here we show that monocytes infiltrating S. aureus biofilms
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shift their metabolism towards OxPhos, and away from glycolysis. To demonstrate that the
metabolic profile of biofilm-associated monocytes can be modified to promote their proinflammatory activity, we utilized novel cell-targeted nanoparticles containing the OxPhos
inhibitor, oligomycin (284). Nanoparticles were conjugated with tuftsin, a tetrapeptide derived
from the Fc domain of the IgG heavy chain, to target FcR-mediated uptake in monocytes (285,
286). In vivo, Cy5-labeled oligomycin nanoparticles were preferentially internalized by
monocytes, with minimal uptake by MDSCs or neutrophils. Using a mouse model of S. aureus
PJI, oligomycin nanoparticles inhibited monocyte OxPhos activity and shifted cells to a proinflammatory state concomitant with increased neutrophil and monocyte recruitment, resulting in
significant reductions in S. aureus burden. Remarkably, combined treatment with oligomycin
nanoparticles and systemic antibiotics reduced the titer of established biofilms below the limit of
detection, a finding that to our knowledge has never been achieved for a mature biofilm in vivo.
Collectively, monocyte metabolic reprogramming could represent a novel therapeutic avenue for
circumventing the two-stage revision protocol for patients with PJI by treating an infected
implant in situ and alleviating a second surgery, which would represent a significant reduction in
patient morbidity.

86
Results
S. aureus biofilm infection promotes a shift towards OxPhos metabolism in monocytes.
Previous work from our laboratory has shown that S. aureus biofilms promote monocyte antiinflammatory activity (146, 148, 187). To determine whether this anti-inflammatory bias is
associated with a metabolic shift favoring OxPhos over glycolysis, the metabolic profiles of
monocytes associated with S. aureus infected vs. sterile orthopedic implants were compared.
OxPhos metabolism was evaluated with the bi-potential dye JC-1, which fluoresces red in
mitochondria with large membrane potentials and green in depolarized mitochondria. Therefore,
cells exhibiting increased OxPhos activity display a larger green:red ratio (287). OxPhos was
significantly increased in monocytes recovered S. aureus biofilm infection compared to sterile
implants at later time points (i.e. days 5-7; Fig. 3.1A), which our prior studies have demonstrated
coincides with biofilm maturation as measured by antibiotic tolerance (226). Interestingly,
monocyte OxPhos activity was significantly reduced during the first two days of infection (Fig.
3.1A), which may reflect an initial pro-inflammatory response that transforms over time to an
anti-inflammatory state. Glycolysis was evaluated by the uptake of the fluorescent glucose analog
2-NBDG (288), which revealed significant and persistent reductions in glycolytic activity in S.
aureus biofilm-associated monocytes compared to sterile implants (Fig. 3.1B). Collectively,
increased OxPhos concomitant with reduced glycolysis in biofilm-associated monocytes
corresponds with their known anti-inflammatory properties (256, 289, 290).
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Figure 3.1

S. aureus biofilm infection promotes a shift towards OxPhos metabolism in monocytes.
Leukocytes associated with tissues surrounding the knee joint of mice with S. aureus-infected (I)
or sterile (S) orthopedic implants were collected at the indicated time points (days 1-7),
whereupon cells were stained with (A) the bi-potential dye JC-1 or (B) 2-NBDG as measures of
OxPhos and glycolysis, respectively, and analyzed by flow cytometry. (A) OxPhos was
calculated as the ratio of green:red monocytes (CD11bhighLy6G-Ly6C+F4/80-) following JC-1
staining and is reported as a percentage relative to animals receiving sterile implants. (B)
Glycolytic activity is reported as the percentage of monocytes that were 2-NBDG+ relative to
mice with sterile implants. Data are presented as the mean ± SD (n = 5-10 animals/group)
combined from two independent experiments (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p <
0.0001; students t-test).
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Inhibition of OxPhos by oligomycin promotes MФ pro-inflammatory activity.
Since biofilm-associated monocytes displayed an OxPhos bias, we explored whether this could be
attenuated to promote their pro-inflammatory activity. Oligomycin inactivates mitochondrial ATP
synthase of the electron transport chain to inhibit OxPhos (284, 291-293). Prior work has
demonstrated that oligomycin shifts MФs towards aerobic glycolysis, which coincides with proinflammatory gene expression (284). To establish the efficacy of oligomycin in MФ metabolic
reprogramming and inflammatory capacity, mouse bone marrow-derived MФs were treated with
IL-4 in the presence/absence of oligomycin. Oligomycin decreased arginase-1 (Fig. 3.2A) and
increased TNF-α expression (Fig. 3.2B) in a dose-dependent manner, hallmark genes of anti- and
pro-inflammatory MФs, respectively (138, 189, 260, 280). Total protein levels were similar
between MФs + oligomycin treatment, indicating that alterations in gene expression were not the
result of differences in cell numbers (Fig. 3.2C).
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Figure 3.2

Inhibition of OxPhos by oligomycin favors MФ pro-inflammatory activity. Bone marrowderived MФs were treated with IL-4 (10 ng/mL) + various concentrations of oligomycin for 4 h,
whereupon RNA was isolated for RT-qPCR analysis. (A) Arg-1 and (B) TNF-α expression was
calculated after normalization to GAPDH and is presented as the fold-change relative to
unstimulated MФs. (C) Protein concentrations following oligomycin treatment confirming
equivalent cell numbers between treatment groups. Data is presented as the mean ± SD (n = 4-6)
combined from two independent experiments.
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Oligomycin nanoparticles shift MФ metabolism.
Given the ability of oligomycin to promote MФ pro-inflammatory activity, we designed a
nanoparticle delivery approach using tuftsin as a targeting moiety, to deliver oligomycin to
biofilm-associated monocytes in vivo to enhance their pro-inflammatory activity and promote
biofilm clearance. Tuftsin is a peptide derived from the Fc portion of IgG, which has been shown
to facilitate nanoparticle internalization by MФs through its interaction with Fc receptors (285,
294). Previous studies have utilized tuftsin-conjugated nanoparticles to deliver a variety of
biomolecules to monocytes and MФs in the context of arthritis, HIV, and other inflammatory
diseases (285, 286, 294, 295). We utilized three nanoparticle types, namely Cy5 (C), Cy5/Tuftsin
(CT), and Cy5/Tuftsin/Oligomycin (CTO), where the former two represented control
formulations and all three harbored the Cy5 fluorochrome to identify nanoparticle localization in
vivo (Table 3.1). Although oligomycin has been shown to affect MФ respiratory capacity by
inhibiting mitochondrial ATP synthase (284), to our knowledge no studies have examined the
efficacy of oligomycin in a nanoparticle formulation. To establish the effects of oligomycin
nanoparticles on MФ metabolism, bone marrow-derived MФs were treated with prototypical antiinflammatory (IL-4) or pro-inflammatory (peptidoglycan (PGN) + IFN-γ) stimuli or CTO
nanoparticles for 24 h, whereupon OxPhos and glycolytic status was examined using Seahorse
Bioscience assays (Fig. 3.3). Oligomycin nanoparticles (CTO) significantly reduced MФ basal
and maximal respiratory rates compared to untreated and IL-4-stimulated cells (Fig. 3.3A, C, and
D), which coincided with significantly higher glycolytic rates (Fig. 3.3B and E). The metabolic
profile of CTO treated MФs was most similar to pro-inflammatory MФs polarized with IFN-γ +
PGN, suggesting that oligomycin nanoparticles are capable of re-programming MФ metabolism.
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Table 3.1 Nanoparticle features

Abbreviations

Composition

Description

C

Cy5

fluorochrome

CT

Cy5/Tuftsin

fluorochrome + targeting

Cy5/Tuftsin/Oligomycin

fluorochrome + targeting + ETC inhibitor

CTO
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Figure 3.3

Oligomycin nanoparticles shift MФ metabolism towards glycolysis. Bone marrow-derived
MФs were treated with IL-4 (10 ng/mL), peptidoglycan (PGN) + IFN-γ (10 μg/mL and 10
ng/mL, respectively), or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles (1 μg/mL) for 24 h,
whereupon Seahorse Bioscience assays were performed to assess (A) OxPhos and (B) glycolysis.
(C) Basal and (D) maximal respiration, and (E) glycolytic rates were calculated using welldefined algorithms. Data is presented as the mean ± SD (n = 3). (*, p < 0.05; **, p < 0.01; ****, p
< 0.0001; One-way ANOVA).
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Tuftsin-conjugated nanoparticles are preferentially internalized by monocytes during S. aureus
PJI.
As mentioned earlier, monocytes outnumber MФs in our mouse PJI model (146, 148, 187, 226);
therefore, to determine whether tuftsin-conjugated nanoparticles are targeted to monocytes in vivo
during S. aureus PJI, mice received a single intra-articular injection of C or CT nanoparticles at
day 7 post-infection, a time point corresponding to biofilm establishment (146, 148, 187, 226).
Mice were sacrificed at 1, 2, or 3 days post-injection to evaluate Cy5 signal stability (Fig. 3.4A).
IVIS imaging demonstrated nanoparticle retention in the joint at day 3 post-injection with signals
detected out to day 12, suggesting that nanoparticles may act as a depot for continued action (Fig.
3.4B and Supplemental Fig. 3.2, respectively). Flow cytometry revealed that >85% of all Cy5+
cells were monocytes (CD45+Ly6G-Ly6C+F4/80-), whereas minimal uptake was detected in
MDSCs or neutrophils (Fig. 3.4C). Importantly, uptake of tuftsin-conjugated (CT) nanoparticles
by biofilm-associated monocytes was significantly higher compared to non-coated (C)
nanoparticles, where at 24 h after injection, approximately 15% of biofilm-associated monocytes
were Cy5+, which steadily declined to < 3.5% by 72 h post-injection (Fig. 3.4D). Collectively,
these data demonstrate that tuftsin conjugation confers a high degree of specificity in targeting
nanoparticles to monocytes and augments nanoparticle uptake.
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Figure 3.4

Preferential nanoparticle uptake by monocytes during PJI. (A) C57BL/6 mice received a
single intra-articular injection of Cy5 (C) or Cy5/Tuftsin (CT) nanoparticles (10 µg) at day 7
post-infection and were analyzed on three consecutive days. (B) IVIS imaging of CT labeled
nanoparticles in the infected joint at day 3 with representative flow plots (C). Left panel shows all
CD45+ cells and the right panel depicts Ly6G-Ly6C+ gated cells, where Cy5+ monocytes (Ly6GLy6C+F4/80-) are highlighted in black. (D) Mice receiving C or CT nanoparticles were sacrificed
at 1-3 days following nanoparticle treatment, whereupon Cy5+ monocytes were quantified by
flow cytometry. Data is presented as the mean ± SD (n = 4-5 mice/time point). (*, p < 0.05; ***,
p < 0.001; Student’s t-test).
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Oligomycin-containing nanoparticles re-program biofilm-associated monocytes towards a proinflammatory phenotype in vivo.
To determine whether the selective uptake of CTO nanoparticles by monocytes in vivo translated
into metabolic re-programming, metabolomics was performed. For these studies, mice received a
single intra-articular injection of CT or CTO nanoparticles at day 7 post-infection and were
sacrificed 3 days later, whereupon polar metabolites were isolated from FACS-purified
monocytes (CD11bhighLy6C+Ly6G- F4/80-) and analyzed by LC-MS/MS. This interval was
selected because our earlier studies determined that CTO nanoparticles had no impact on bacterial
burden at day 3 post-injection (Supplemental Fig. 3.3), ensuring that any differences in monocyte
activation reflected effects of CTO nanoparticles rather than alterations in bacterial abundance,
which was significantly altered by day 7 (Supplemental Fig. 3.3). All biofilm-associated
monocytes were analyzed, since Cy5+ monocytes were less frequent at 3 days following
nanoparticle injection (Fig. 3.4D), which precluded FACS enrichment. Principle component
analysis (PCA) using unsupervised hierarchical clustering revealed distinct metabolic patterns of
monocytes recovered from CT and CTO treated mice (Fig. 3.5A and B). Pathway impact analysis
of differentially expressed metabolites revealed that arginine, proline, and branched chain amino
acid metabolism were most significantly impacted (Fig. 3.5C). Despite these significant pathway
changes, analysis of individual metabolites only identified a few significant differences, most
notably decreased NAD+ levels in monocytes recovered from CTO treated animals (Table 3.2),
indicative of OxPhos inhibition by oligomycin. To examine whether the shift in monocyte
metabolism in response to oligomycin translated into enhanced pro-inflammatory properties, RTqPCR was performed on FACS-purified monocytes using a panel of pro- and anti-inflammatory
genes. Monocytes isolated from CTO treated mice displayed increased pro-inflammatory (HIF1α, iNOS, TNF-α, and Trem1) concomitant with reduced anti-inflammatory (arginase-1, IL-10,
IL-4, and Trem2) mediators compared to monocytes exposed to control (CT) nanoparticles (Fig.
3.6). The magnitude of metabolic and inflammatory mediator changes elicited by oligomycin
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nanoparticles were likely modest because <5% of recovered monocytes were Cy5+ (Fig. 3.4D),
which further emphasizes the significance of these findings. Earlier intervals following
nanoparticle injection were not examined to allow sufficient time for oligomycin to metabolically
re-program monocyte metabolism following nanoparticle uptake. Collectively, these results
establish that targeting oligomycin to monocytes using tuftsin nanoparticles induces a metabolic
shift that promotes their pro-inflammatory properties.
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Figure 3.5

Oligomycin-containing nanoparticles induce a metabolic shift in biofilm-associated
monocytes in vivo. C57BL/6 mice received a single intra-articular injection of Cy5/Tuftsin (CT)
or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles (10 μg) at day 7 post-infection (n = 5
mice/treatment group). Mice were sacrificed 3 days following nanoparticle injection and
monocytes (CD11bhighLy6G-Ly6C+F4/80-) were recovered from each individual animal by FACS,
whereupon intracellular metabolites were isolated for analysis by HPLC-MS/MS. (A) A principle
component analysis (PCA) plot was generated using an algorithm in MetaboAnalyst with mean
intensities and pareto scaling distribution. Ellipses represent a 95% confidence interval of the
normal distribution for each cluster. (B) The heat-map depicts the top 25 metabolite differences in
monocytes recovered from CTO and CT treated mice. The color key indicates log2-fold changes
of normalized-mean peak intensities for metabolites in monocytes from CTO treated animals
normalized to the CT nanoparticle treated group. (C) Identification of the most significantly
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altered pathways in monocytes isolated from CTO treated animals as determined by pathway
impact analysis.
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P-value
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Table 3.2. Intracellular metabolites from CT and CTO treated MDSCs and monocytes*
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0.93
0.8259
23328.76
0.81
0.5316
24382.54
0.88
0.6404
1265529.03
0.99
0.9590
1050524.89
0.82
0.5022
448887.04
0.87
0.6085
339231.95
0.72
0.3317
391813.14
0.80
0.4420
133416.41
0.65
0.1979
12507.33
0.74
0.2566
127836.07
0.93
0.7911
1739095.78
0.86
0.5847
9508.84
0.90
0.6461
70330.71
1.07
0.8062
786.69
0.96
0.9399
2815.83
0.97
0.9045
1048365.28
0.83
0.5155
684.59
1.24
0.5719
1500330.74
0.78
0.3511
8862.38
0.89
0.7446
12592.39
0.67
0.2539
1898.86
0.60
0.3293
110072.95
1.04
0.8923
4892.55
0.88
0.6752
4142.85
1.00
0.9971
778520.79
1.07
0.8037
123118.45
0.94
0.8476
33451.71
0.90
0.7631
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Table 3.2 (cont.). Intracellular metabolites from CT and CTO treated MDSCs and monocytes*

MDSCs
CT
CTO
Fold Δ
P-value
methylcysteine
162442.78 30426.18
0.19
0.0071
tryptophan
179625.10 33535.58
0.19
0.0046
glucose
42435.23
7658.38
0.18
0.0028
Ng,NG-dimethyl-L-arginine 311055.15 56018.05
0.18
0.0049
D-gluconate
5531.46
977.45
0.18
0.0037
acetylglutamine
1991829.48 351228.24
0.18
0.0062
myo-inositol
82324.23 14296.03
0.17
0.0054
xanthosine
55213.12
9201.99
0.17
0.0000
allantoin
8097.74
1299.27
0.16
0.0006
valine
30293.38
4833.61
0.16
0.0056
kyneurinine
12216.08
1884.32
0.15
0.0054
nicotinamide
148691.12 22747.25
0.15
0.0013
pantothenate
103332.69 15649.02
0.15
0.0093
methylmalonic acid
8013.86
1210.10
0.15
0.0104
acetyllysine
10319.45
1532.13
0.15
0.0092
cytidine
300405.65 43954.29
0.15
0.0082
xanthurenic acid
3490.77
490.47
0.14
0.0125
hypoxanthine
3681.43
448.85
0.12
0.0185
2-dehydro-D-gluconate
3741.68
417.12
0.11
0.0088
beta hydroxybutyrate
993.14
44.63
0.04
0.0157
CT
141086.24
133199.94
33657.50
305985.17
5885.43
1653195.62
63890.10
74332.18
7292.10
31134.19
7923.02
92465.86
94030.70
5162.45
11230.10
221483.90
4869.40
4291.35
3126.74
550.54

Monocytes
CTO
Fold Δ
P-value
127112.91
0.90
0.7304
137709.31
1.03
0.9210
32159.00
0.96
0.8825
265305.75
0.87
0.6235
4126.70
0.70
0.3181
1708981.37
1.03
0.9040
59667.70
0.93
0.7999
65463.52
0.88
0.7029
8242.82
1.13
0.7087
26913.39
0.86
0.6077
10551.98
1.33
0.4320
106831.39
1.16
0.7327
86732.95
0.92
0.7991
6284.79
1.22
0.5080
7776.12
0.69
0.2379
166574.21
0.75
0.3849
5399.37
1.11
0.7607
3793.19
0.88
0.6975
2136.40
0.68
0.3685
375.74
0.68
0.5021
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Table 3.2 (cont.). Intracellular metabolites from CT and CTO treated MDSCs and monocytes*

*Fold-change values are expressed as CTO relative to CT.
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Figure 3.6

Oligomycin-containing nanoparticles polarize monocytes towards a pro-inflammatory
phenotype in vivo. C57BL/6 mice received a single intra-articular injection of Cy5/Tuftsin (CT)
or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles (10 μg) at day 7 post-infection (n = 5
mice/treatment group). Mice were sacrificed 3 days following nanoparticle injection and
monocytes (CD11bhighLy6G-Ly6C+F4/80-) were sorted from pooled samples (n = 5) by FACS,
whereupon RNA was immediately isolated for RT-qPCR. Gene expression levels in monocytes
recovered from CTO-treated animals were calculated after normalizing signals to GAPDH and
are presented as the fold-change relative to monocytes isolated from mice receiving CT (control)
nanoparticles. Data is presented as the mean ± SD (n = 3) combined from three independent
experiments.
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Monocyte targeted oligomycin nanoparticles induce metabolomic and gene expression changes
in MDSCs, indicative of cellular crosstalk.
Prior studies have identified a significant role for MDSCs in promoting monocyte antiinflammatory activity during S. aureus orthopedic biofilm infection (146, 148, 189). Although
<0.01% of MDSCs internalized tufstin nanoparticles (Fig. 3.4C), we were interested in
determining the degree of cross-talk between metabolically altered monocytes and MDSCs.
MDSCs (CD11bhighLy6C+Ly6G+F4/80-) were purified from CT and CTO treated animals,
whereupon metabolomics and inflammatory gene expression were examined. Remarkably,
although nanoparticle uptake was negligible in MDSCs, their metabolic profile was dramatically
affected by CTO treatment (Fig. 3.7A and B), with the number of significant differentially
expressed metabolites far outnumbering those for monocytes (Table 3.2). Metabolic pathway
analysis revealed significant increases in glutathione, nicotinamide, taurine, and purine
metabolism, whereas arginine, glutamine, and cyclic chain amino acids were significantly
reduced (Fig. 3.7C). In contrast, RT-qPCR analysis was less straightforward, since anti-/proinflammatory mediator expression in MDSCs following CTO nanoparticle treatment did not
display a discernable gene expression pattern consistent with a specific function (Fig. 3.7D).
These results are the first to demonstrate that metabolic re-programming of monocytes can impact
MDSC metabolism, which supports our earlier work of MDSC-monocyte crosstalk (146, 148,
189).
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Figure 3.7

Oligomycin-containing nanoparticles targeted to monocytes induce metabolomic and gene
expression changes in MDSCs. C57BL/6 mice received a single intra-articular injection of
Cy5/Tuftsin (CT) or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles (10 μg) at day 7 post-infection
(n = 5 mice/treatment group). Mice were sacrificed 3 days following nanoparticle injection and
MDSCs (CD11bhighLy6G+Ly6C+F4/80-) were recovered from each individual animal by FACS,
whereupon intracellular metabolites were isolated for analysis by HPLC-MS/MS. (A) A principle
component analysis (PCA) plot was generated using an algorithm in MetaboAnalyst with mean
intensities and pareto scaling distribution. Ellipses represent a 95% confidence interval of the
normal distribution for each cluster. (B) The heat-map depicts the top 25 metabolite differences in
MDSCs recovered from CTO and CT treated mice. The color key indicates log2-fold changes of
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normalized-mean peak intensities for metabolites in MDSCs from CTO treated animals
normalized to the CT nanoparticle treated group. (C) Identification of the most significantly
altered pathways in MDSCs isolated from CTO treated animals as determined by pathway impact
analysis. (D) MDSCs were sorted from pooled samples (n = 5 mice/group), whereupon RNA was
immediately isolated for RT-qPCR. Gene expression levels in MDSCs recovered from CTOtreated animals were calculated after normalizing signals to GAPDH and are presented as the
fold-change relative to MDSCs isolated from mice receiving CT (control) nanoparticles. Data
shown as the mean ± SD (n = 3), combined from three independent experiments.
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Nanoparticle-mediated delivery of oligomycin to monocytes attenuates established S. aureus
PJI.
We next examined whether the observed metabolic re-programming and pro-inflammatory
properties of biofilm-associated monocytes following oligomycin nanoparticle administration
would impact biofilm clearance during S. aureus PJI. Two treatment paradigms were designed to
examine the effect of monocyte metabolic re-programming during acute tissue infection versus an
established biofilm (days 3 and 7 post-infection, respectively). Mice received a single intraarticular injection of control (C and CT) or oligomycin (CTO) nanoparticles on either day 3
(Supplemental Fig. 3.4) or day 7 post-infection (Fig. 3.8), whereupon bacterial burden and
leukocyte infiltrates were examined over a 28 day period. In both settings, bacterial burdens were
significantly reduced in the soft tissue, joint, femur, and implant between 7 and 28 days following
nanoparticle injection (Supplemental Fig. 3.4 and Fig. 3.8, B-E). Interestingly, despite the
reductions in bacterial titers at day 7 with CTO nanoparticles in both treatment paradigms, no
significant differences in MDSC (CD11bhighLy6C+Ly6G+F4/80-), PMN
(CD11blowLy6C+Ly6G+F4/80-), monocyte (CD11bhighLy6C+Ly6G-F4/80-), or MФ
(CD11bhighLy6C-Ly6G-F4/80+) infiltrates were observed (Supplemental Fig. 3.4 and Fig. 3.8, FI). However, at later time points (i.e. days 14 to 28 after nanoparticle treatment) mice receiving
CTO nanoparticles had significantly fewer MDSCs concomitant with increased PMN, monocyte,
and MФ infiltrates, reflective of a more pro-inflammatory milieu (Fig. 3.8 and Supplemental Fig.
3.4, F-I).
To establish that the ability of oligomycin nanoparticles to attenuate S. aureus biofilm
burdens resulted from monocyte metabolic reprogramming rather than direct antibacterial
activity, mice were treated with free oligomycin only, empty nanoparticles (CT) with free
oligomycin (not loaded), or oligomycin loaded nanoparticles (CTO). Free oligomycin was
administered at a dose that was equivalent to the nanoparticle formulation (100 ng). Only CTO
nanoparticles led to significant reductions in monocyte OxPhos activity, as revealed by JC-1
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staining (Fig. 3.9A and C). This was independent of bacterial burdens, since CTO nanoparticles
reduced monocyte OxPhos as early as day 3 post-treatment when no differences in biofilm titers
were observed (Fig. 3.9B). Overall, no changes in glycolytic activity were observed with CTO
nanoparticles (Fig. 3.9A and C); however, the reductions in OxPhos support a net glycolytic bias
in monocytes following CTO treatment, which agrees with their enhanced pro-inflammatory
activity (Fig. 3.6). Importantly, no changes in monocyte OxPhos or biofilm burdens were
observed in animals treated with free oligomycin or CT nanoparticles + free oligomycin (not
loaded) at either 3 or 7 days after intra-articular injection (Fig. 3.9). Furthermore, oligomycin
delivery by direct intra-articular injection into the infected joint in either one bolus or two
sequential doses also had no effect on bacterial burdens (Supplemental Figure 3.5). Finally,
oligomycin displayed no bactericidal activity against S. aureus during early biofilm formation or
mature biofilms in vitro (Supplemental Figure 3.6), which agrees with prior reports demonstrating
that oligomycin does not possess any direct anti-bacterial activity against S. aureus (296, 297).
Collectively, these results establish that the anti-biofilm effects of oligomycin are dependent on
targeted intracellular delivery to monocytes and their subsequent metabolic re-programming to
elicit pro-inflammatory activity, and not as an antibiotic.
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Figure 3.8

Nanoparticle-mediated delivery of oligomycin to monocytes reduces established biofilm
infection. (A) C57BL/6 mice received a single intra-articular injection of Cy5 (C), Cy5/Tuftsin

109
(CT), or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles at day 7 post-infection, and were analyzed
at 7, 14, 21, or 28 days following nanoparticle treatment. Bacterial burdens were quantified in the
(B) surrounding soft tissue, (C) knee, (D) femur, and (E) implant, where the red and dotted lines
represent the mean and limit of detection (LOD), respectively. Infiltrating leukocytes were
analyzed by flow cytometry and (F) MDSCs, (G) PMNs, (H) monocytes, and (I) MФs are
reported as the mean percentage of live CD45+ leukocytes ± SD. Results are combined from three
independent experiments (n = 15 mice/group/time point). (*, p < 0.05; **, p < 0.01; ***, p <
0.001; ****, p < 0.0001; One-way ANOVA).
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Figure 3.9

Nanoparticle-mediated delivery of oligomycin attenuates OxPhos metabolism in biofilmassociated monocytes. C57BL/6 mice received a single intra-articular injection of free
oligomycin only, empty nanoparticles (CT), empty nanoparticles (CT) with free oligomycin (not
loaded), or oligomycin loaded nanoparticles (CTO) at day 7 post-infection, and were analyzed at
day 3 (A, B) or 7 (C, D) after treatment. (A, C) OxPhos was calculated as the ratio of green:red
monocytes (CD11bhighLy6G-Ly6C+F4/80-) following JC-1 staining and glycolytic activity was
calculated as the % of 2-NBDG+ monocytes. (B, D) Bacterial burdens were assessed in the
surrounding soft tissue, knee, femur, and implant, where the dotted lines represent the limit of
detection (LOD). (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; One-way
ANOVA).
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Synergistic action of oligomycin nanoparticles and systemic antibiotics to clear established S.
aureus biofilm infection.
Based on the finding that oligomycin nanoparticles transformed the biofilm milieu by promoting
monocyte pro-inflammatory activity and effector leukocyte recruitment, we envisioned that
residual bacteria may have less biofilm characteristics and increased susceptibility to systemic
antibiotic treatment. To address this possibility, mice received CT or CTO nanoparticles on day 7
post-infection, whereupon systemic antibiotics (25 mg/kg/day rifampin and 5 mg/kg/day
daptomycin) were administered 7 days later for a one week duration after which mice were
sacrificed (corresponding to day 21 post-infection). Remarkably, bacterial burdens were largely
below the limit of detection in animals that received CTO nanoparticles and antibiotics, whereas
bacteria remained in the tissue and knee of mice treated with control CT nanoparticles and
antibiotics or CTO nanoparticles alone (Fig. 3.10, A-D). These changes were reflected by
significant reductions in MDSCs and increased monocyte and macrophage recruitment (Fig. 3.10,
E-H), which our results show are reprogrammed towards a pro-inflammatory phenotype by
intracellular oligomycin delivery (Fig. 3.6). To our knowledge, this is the first demonstration of
an approach capable of clearing an established biofilm infection, which was achieved through the
combined action of modulating monocyte metabolism to transform S. aureus biofilm
susceptibility to antibiotics.
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Figure 3.10

Monocyte metabolic reprogramming with oligomycin-containing nanoparticles synergizes
with antibiotics to clear established S. aureus biofilm infection. C57BL/6 mice received a
single intra-articular injection of Cy5/Tuftsin (CT) or Cy5/Tuftsin/Oligomycin (CTO)
nanoparticles (10 μg) at day 7 post-infection. Seven days later, animals received daily i.p.
injections of antibiotics (25 mg/kg/day rifampin and 5 mg/kg/day daptomycin) or vehicle for one
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week, whereupon mice were sacrificed at day 21 post-infection. Bacterial burdens were
quantified from the (A) surrounding soft tissue, (B) knee, (C) femur, and (D) implant, where the
dotted line represents the limit of detection (LOD). Infiltrating leukocytes were analyzed by flow
cytometry and (E) MDSCs, (F) PMNs, (G) monocytes, and (H) MФs are reported as the mean ±
SD percentage of live CD45+ leukocytes. Results are combined from two independent
experiments (n = 7-10 mice/group/time point). (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p
< 0.0001; One-way ANOVA).
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Figure 3.11

Metabolic reprogramming of monocytes promotes pro-inflammatory properties, MDSC
crosstalk, and S. aureus biofilm dispersal. Nanoparticles containing the ATP synthase inhibitor
oligomycin are targeted to Fc-receptor positive monocytes with tuftsin. Upon internalization,
oligomycin inhibits ATP-synthase of the mitochondrial electron transport chain and induces
metabolic reprogramming to shift monocyte metabolism and promote pro-inflammatory gene
expression. Metabolically reprogrammed monocytes also influence MDSC metabolism and gene
expression. Collectively, these changes promote biofilm clearance and a shift towards planktonic
growth, as evident by increased antibiotic susceptibility and clearance of established biofilm
infection. ADP, adenosine diphosphate; ATP, adenosine triphosphate; Fc-Receptor, fragment
crystallizable region receptor; HIF-1α, hypoxia-inducible factor 1-alpha; iNOS, inducible nitric
oxide synthase; MDSC, myeloid-derived suppressor cell; Pi, inorganic phosphate.
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Supplemental Figure S3.1

Kinetics of oligomycin release from tuftsin-modified nanoparticles. Oligomycin release from
Cy5-tuftsin-oligomycin (CTO) nanoparticles was determined using a PBS dialysis method with a
3.5 kDa membrane cutoff. The kinetics of oligomycin release were determined by HPLC and
concentrations are expressed as a percentage of the total oligomycin available vs. time (in hours;
h).
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Supplemental Figure S3.2

Longevity of nanoparticle retention at the site of S. aureus biofilm infection. C57BL/6 mice
received a single intra-articular injection of Cy5 labeled nanoparticles at day 3 post-infection,
whereupon the same animal was imaged over a two-week period to demonstrate the extent of
nanoparticle retention and distribution. Results are representative of 5 individual mice.
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Supplemental Figure S3.3

Oligomycin-containing nanoparticles do not significantly affect S. aureus biofilm burdens
until 7 days post-infection. C57BL/6 mice received a single intra-articular injection of Cy5 (C),
Cy5/Tuftsin (CT), or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles at day 7 post-infection,
whereupon animals were sacrificed 3 or 7 days following nanoparticle treatment. Bacterial
burdens were quantified from the (A) surrounding soft tissue, (B) knee, (C) femur, and (D)
implant. Results are from one experiment (n = 5 mice/group/time point). (*, p < 0.05; **, p <
0.01; ***, p < 0.001; One-way ANOVA).
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Supplemental Figure S3.4
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Nanoparticle-mediated delivery of oligomycin 3 days post-infection to monocytes reduces
biofilm burden. (A) C57BL/6 mice received a single intra-articular injection of Cy5 (C),
Cy5/Tuftsin (CT), or Cy5/Tuftsin/Oligomycin (CTO) nanoparticles at day 3 post-infection, and
were analyzed at 7, 14, 21, or 28 days following nanoparticle treatment. Bacterial burdens were
quantified in the (B) surrounding soft tissue, (C) knee, (D) femur, and (E) implant, where the red
and dotted lines represent the mean and limit of detection (LOD), respectively. Infiltrating
leukocytes were analyzed by flow cytometry and (F) MDSCs, (G) PMNs, (H) monocytes, and (I)
MФs are reported as the mean (red line) percentage of live CD45+ leukocytes. Results are
combined from three independent experiments (n = 15 mice/group/time point). (*, p < 0.05; **, p
< 0.01; ***, p < 0.001; ****, p < 0.0001; One-way ANOVA).
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Supplemental Figure S3.5

Oligomycin does not directly affect S. aureus biofilm bacterial burdens. C57BL/6 mice
received intra-articular injections of oligomycin at 7 day post-infection (100 ng), or two
sequential doses at days 7 & 8 post-infection (50 ng/day), or vehicle (PBS) and were sacrificed at
day 14 post-infection. Bacterial burdens were quantified from the (A) surrounding soft tissue, (B)
knee, (C) femur, and (D) implant. Results are from one experiment (n = 5 mice/group/time point).
(*, p < 0.05; One-way ANOVA).
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Supplemental Figure S3.6

Oligomycin has no antibacterial activity against S. aureus during early or established
biofilm growth. S. aureus biofilm formation was assessed in 96-well plates + oligomycin
treatment. Oligomycin (10 µg/mL) was added to (A) planktonic S. aureus at time 0 or (B) mature
biofilms for 4 days to determine effects on bacterial growth at the indicated time points following
oligomycin treatment. Cultures were replenished daily with fresh medium containing oligomycin.
Results are presented as Log10 colony forming units (CFU) per well (mean + SD).
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Discussion
Approximately one million knee and hip arthroplasties are performed in the United States
annually, with PJIs representing the most common complication (110, 111, 122-126). These
infections are associated with significant morbidity and medical expenses, since the current
standard-of-care requires multiple surgical interventions over a period of months, during which
patient mobility is limited (107, 108, 110, 111, 124). S. aureus is the second most common cause
of PJI behind S. epidermidis (110, 111, 122-124) and biofilms cannot typically be cleared by
antibiotics without removing the prosthesis, since the metabolic dormancy of biofilm-associated
bacteria decreases their antibiotic susceptibility (86, 88, 110, 111). Further compounding this
issue is the ability of S. aureus to promote an anti-inflammatory milieu typified by the
polarization of anti-inflammatory monocytes and abundance of MDSC infiltrates (138, 146, 148,
188, 189). Monocytes can be a key effector cell during PJI in a permissive microenvironment,
such as during MDSC depletion, where their pro-inflammatory activity is augmented leading to
reduced biofilm burden (138, 148, 189). This study is the first to demonstrate that biofilmassociated monocytes are metabolically skewed towards OxPhos to support their antiinflammatory properties. Interestingly, monocyte OxPhos activity was significantly lower during
the first two days of S. aureus infection compared to sterile implants, whereas cells transitioned to
favor OxPhos at later stages (i.e. days 5-7). These findings coincide with the kinetics of biofilm
development in vivo, where our prior studies have shown that biofilm maturation is evident by
day 7 post-infection as revealed by antibiotic tolerance (226). By extension, the early reduction in
OxPhos activity suggests that monocytes may initially exhibit pro-inflammatory properties but
transition to an anti-inflammatory phenotype that we have characterized with mature biofilms
(146, 148, 187, 226). This potential early pro-inflammatory activity may explain the conundrum
of heightened pro-inflammatory mediator production at the site of biofilm infection, which has no
impact on the intrinsic anti-inflammatory properties of biofilm-associated leukocytes or biofilm
burdens (146, 148, 187, 226). Furthermore, this study is the first to demonstrate that biofilm-
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associated monocytes can be metabolically reprogrammed to inhibit OxPhos, transforming cells
into a pro-inflammatory state capable of attenuating established S. aureus biofilms. Importantly,
we provide several lines of evidence demonstrating that oligomycin lacks direct antimicrobial
activity against S. aureus, including the failure of free oligomycin to alter biofilm burdens in vitro
or in vivo. Furthermore, oligomycin needed to be loaded into nanoparticles to inhibit monocyte
OxPhos, demonstrating the requirement for intracellular delivery.
Prior studies have shown that oligomycin promotes MΦ pro-inflammatory activity by
inhibiting ATP synthase and OxPhos (284). We selected oligomycin over other metabolic
inhibitors because it is less potent and would dampen but not completely block OxPhos, whereas
stronger inhibitors, such as rotenone, are extremely toxic and have been shown to inhibit MΦ
viability and function (298-301). Furthermore, a nanoparticle-directed method was preferred in
vivo because of potential toxicity associated with a non-targeted systemic delivery approach (292,
293, 299, 300). In this study, nanoparticles were conjugated with tuftsin to facilitate FcRmediated uptake in monocytes (285, 286, 294), which are the most abundant mononuclear
phagocyte population during S. aureus PJI (106, 146, 148, 189). Although other FcR+ cells
infiltrate S. aureus biofilms, they are either of low abundance (i.e. PMNs) or express less FcR
(i.e. MDSCs) compared to monocytes (302). We established that the tuftsin modification
enhanced nanoparticle uptake by monocytes approximately 4-fold compared to non-conjugated
nanoparticles.
Importantly, oligomycin nanoparticles were capable of metabolically re-programming
biofilm-associated monocytes, which coincided with their polarization to a pro-inflammatory
state, typified by increased pro- and reduced anti-inflammatory gene expression. These effects
were remarkable given the finding that <5% of monocytes displayed direct evidence of
nanoparticle uptake (i.e. Cy5+) at the time of analysis. However, it is also possible that a greater
number of monocytes had internalized nanoparticles but were no longer Cy5+, since fluorescence
is likely quenched in the phagosome as has been reported for other fluorochromes (303).
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Metabolic pathway analysis of significantly downregulated metabolites showed that arginine,
proline, and branched chain amino acid metabolism were most significantly altered in monocytes
isolated from CTO treated mice. Decreased amino acid abundance may reflect increased protein
synthesis to satisfy the need for metabolic intermediates during immune activation (289, 290,
304). Citrate and succinate accumulation was expected due to a glycolytic shift induced by
oligomycin treatment and block in TCA cycle enzymes; however, both were less abundant in
CTO monocytes (256, 289, 290, 305). Glucose and glucose-6-phosphate were also decreased in
CTO monocytes, which prior in vitro studies showed were increased in pro-inflammatory MΦs
(306). Nevertheless, secondary metabolites of the TCA cycle, such as aconitate and 2hydroxyglutarate, were increased in CTO monocytes (260, 306-310), indicating an inhibition of
the TCA cycle that supports a glycolytic bias. The endogenous macrophage activator uric acid
and its metabolite, allantoin, were also more abundant in CTO monocytes (311, 312) as were
methyl-malonic acid and uridine, consistent with prior in vitro studies of LPS stimulated
monocytes with potent pro-inflammatory properties (313).
Although these metabolite patterns do not follow the strict definition of glycolytic or
OxPhos metabolism that has been described in vitro (304, 314), we convincingly demonstrated
that oligomycin nanoparticles induced a metabolic shift in biofilm-associated monocytes in vivo
as reflected by significantly lower levels of OxPhos activity, suggesting a net shift towards
glycolysis. It is important to recognize that the metabolomic signatures defined for pro- vs. antiinflammatory MΦs are based on in vitro studies, where cells are polarized to activation extremes
(304, 314). In vivo, monocytes/MΦs receive a complex array of signals and exist in a spectrum of
activation states, with phenotypic and metabolic plasticity (249, 250, 252, 254, 315). Therefore, it
is not unexpected that the metabolic profile of biofilm-associated monocytes possessed attributes
of both OxPhos and glycolysis, which may be further explained by the milder OxPhos inhibitory
activity of oligomycin as discussed earlier (284, 316). Importantly, transformation of biofilmassociated monocytes to a pro-inflammatory state following oligomycin nanoparticle treatment
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was confirmed by RT-qPCR, where monocytes recovered from CTO treated animals displayed
increased pro- and reduced anti-inflammatory gene expression as compared to monocytes from
mice receiving CT control nanoparticles. These changes in monocyte metabolism and proinflammatory activity were independent of bacterial burden, which was equivalent between
animals receiving oligomycin and control nanoparticles at day 3 post-treatment, and increased
monocyte pro-inflammatory activity is likely responsible for the reduction in S. aureus titers from
day 7 onward. Furthermore, monocyte OxPhos was unaffected following treatment with free
oligomycin, establishing the requirement for intracellular delivery, which was facilitated by
tuftsin-modified nanoparticles. This study is the first demonstration of the utility of nanoparticledirected metabolic re-programming to modulate monocyte activation in vivo in the context of
biofilm-associated infection.
An unexpected finding in this study was that biofilm-associated MDSCs displayed
marked alterations in their metabolome, despite that fact that <0.01% cells exhibited evidence of
nanoparticle uptake. To our knowledge, this is the first demonstration of monocyte-MDSC
metabolic crosstalk during biofilm infection (Fig. 3.11), which supports our earlier observations
where MDSC depletion led to enhanced monocyte pro-inflammatory activity (146, 148, 189).
Metabolic pathway analysis revealed that MDSCs recovered from CTO treated mice had
significant increases in glutathione, nicotinamide, taurine, and purine metabolism, whereas
arginine, glutamine, negatively charged, and cyclic chain amino acids were down-regulated. It is
difficult to predict the impact of these metabolic changes, since few studies have explored MDSC
metabolism, especially in vivo; however, this metabolic signature would generally be consistent
with a glycolytic preference. Similar to monocytes, a decrease in amino acids likely corresponds
to an increase in protein synthesis or need for metabolic intermediates (289, 290, 304). An
increase in GSH/GSSH has been shown to prime T cells for glycolytic metabolism and Th1 proinflammatory activity (317, 318) and the increase in NADH/NAD+ (2.489-fold higher in MDSCs
recovered from CTO compared to CT treated mice) corresponds to a reduction in electron
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transport chain activity (314, 319). While elevated NADH/NAD+ should increase lactic acid
fermentation and lactate production, intracellular lactate levels were 4-fold lower in MDSCs from
CTO treated animals. One potential explanation to account for this finding is that lactate is
exported from the cell by monocarboxylate transporters (MCTs), which are enhanced following
immune activation (260).
Major challenges pertaining to PJI treatment are the inability to clear infection without
removing the prosthesis and preventing infection recurrence. Based on our findings that
oligomycin nanoparticles augmented monocyte pro-inflammatory activity, we examined how this
impacted biofilm burden. Remarkably, S. aureus titers were significantly reduced in mice
receiving oligomycin nanoparticles out to 28 days post-injection. This was accompanied with a
reduction in MDSCs concomitant with increased monocyte, PMN, and MΦ infiltrates, which
were likely responsible for biofilm clearance. These findings are significant for several reasons.
First, only a single injection of CTO nanoparticles was required reflecting sustained action, which
is a desirable feature for potential therapeutic interventions. Second, nanoparticle treatment was
not initiated until a mature biofilm was established (i.e. day 7 post-infection), which represents
the most challenging treatment scenario. Third, combined treatment with CTO nanoparticles and
systemic antibiotics reduced infectious burden to below the limit of detection. We propose that
the shift in monocyte pro-inflammatory activity by oligomycin promotes biofilm disruption and
transforms metabolically dormant biofilm-associated bacteria into a planktonic mode of growth,
which is more susceptible to antibiotic action (Fig. 3.11). To our knowledge, this is the first
demonstration of an in vivo approach that is capable of clearing established biofilms without
removal of the infected implant.
Understanding the complex and dynamic interactions between S. aureus biofilm and the
host immune response is critical to developing novel therapeutic approaches to reduce the
morbidity associated with PJI. This study is the first to demonstrate that biofilm-associated
monocytes can be metabolically reprogrammed using a novel nanoparticle targeted approach to
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promote their pro-inflammatory properties, which results in biofilm clearance. A similar strategy
might represent a therapeutic for PJI by modulating host immunity to facilitate the transition from
biofilm to planktonic growth, which can be resolved by systemic antibiotic treatment and
alleviate the need for removal of the infected prosthesis, resulting in less patient morbidity.
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Chapter 4: Arginase-1 expression in myeloid cells regulates S. aureus planktonic but not
biofilm infection
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Abstract
S. aureus is a leading cause of device-associated biofilm infections, which represent a
serious health care concern based on their chronicity and antibiotic resistance. We previously
reported that S. aureus biofilms preferentially recruit myeloid-derived suppressor cells (MDSCs),
which promote monocyte and macrophage anti-inflammatory properties. This is associated with
increased myeloid arginase-1 (Arg-1) expression, which has been linked to anti-inflammatory and
pro-fibrotic activity that are observed during S. aureus biofilm infections. To determine whether
MDSCs and macrophages utilize Arg-1 to promote biofilm infection, Arg-1 was deleted in
myeloid cells using Tie-2Cre mice. Despite Arg-1 expression in biofilm-associated myeloid cells,
bacterial burdens and leukocyte infiltrates were similar between wild type (WT) and Arg-1fl/fl;Tie2Cre conditional knockout (KO) mice from days 3 to 14 post-infection in both orthopedic implant
and catheter-associated biofilm models. However, inducible nitric oxide synthase (iNOS)
expression was dramatically elevated in biofilm-associated MDSCs from Arg-1fl/fl;Tie-2Cre
animals, suggesting a potential Arg-1-independent compensatory mechanism for MDSCmediated immunomodulation. Treatment of Arg-1fl/fl;Tie-2Cre mice with the iNOS inhibitor N6-(1Iminoethyl)-lysine, hydrochloride (L-NIL) had no effect on biofilm burdens or immune
infiltrates, whereas treatment of WT mice with the Arg-1/ornithine decarboxylase inhibitor
difluoromethylornithine (DFMO) increased bacterial titers, but only in the surrounding soft
tissues that possess planktonic attributes. A role for myeloid-derived Arg-1 in regulating
planktonic infection was confirmed using a subcutaneous abscess model, where S. aureus burdens
were significantly increased in Arg-1fl/fl;Tie-2Cre compared to WT mice. Collectively, these results
indicate that the effects of myeloid Arg-1 are context-dependent and are manifest during
planktonic, but not biofilm infection.
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Introduction
S. aureus is a leading cause of community-acquired and nosocomial infections in humans
(24, 36, 37, 110, 111, 320, 321), and the presence of foreign materials increases infection risk due
to the ability of S. aureus to form biofilms (24, 120, 121). Biofilms are heterogeneous bacterial
communities that are difficult to eradicate based on their chronicity and recalcitrance to antibiotic
therapy (24, 120, 121). In addition, previous work from our laboratory has shown that S. aureus
biofilms actively skew the host immune response toward an anti-inflammatory phenotype that is
characterized by the preferential recruitment of myeloid-derived suppressor cells (MDSCs) and
anti-inflammatory monocytes and macrophages, whereas neutrophils and T cell infiltrates are
minimal (138, 139, 146, 148, 187, 188). MDSCs recruited to the site of biofilm infection express
IL-10, which is one contributing mechanism of immune suppression (148). In addition, biofilmassociated MDSCs and macrophages upregulate arginase-1 (Arg-1) expression, suggesting that
Arg-1 could further potentiate the anti-inflammatory and pro-fibrotic cellular responses that are
favored during S. aureus biofilm infections (138, 147, 189).
Arg-1 catalyzes the hydrolysis of arginine to ornithine and urea (322). During an immune
response, myeloid-derived Arg-1 is an important enzyme involved in the regulation of arginine
availability (322-326), and previous studies have demonstrated that myeloid-derived Arg-1 can
inhibit pro-inflammatory immune responses (268, 322, 327-330). Arginine is a substrate for both
Arg-1 and inducible nitric oxide synthase (iNOS), which are characteristic markers for anti- and
pro-inflammatory macrophages, respectively (268, 331-333). In myeloid cells, ornithine
generation by Arg-1 is used for proline or polyamine synthesis through ornithine decarboxylase
(ODC), which promotes fibrosis by collagen formation (322). A previous study demonstrated the
importance of host-derived polyamines for S. aureus clearance and wound healing in a
subcutaneous abscess model that represents planktonic infection (149); however, a role for Arg-1
action in the context of biofilms has not yet been explored. Of note, biofilm infections are often
encompassed by a fibrotic response, which coincides with robust Arg-1 expression (10, 15, 16).
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Arg-1 activity also inhibits NO-mediated killing of pathogens by macrophages, since arginine is
the primary substrate for iNOS (331-333). Furthermore, extracellular arginine depletion leads to
reduced CD3ζ chain expression and the inability to augment cyclin D3 and cdk4, which leads to
T cell hypo-responsiveness and cell cycle arrest, respectively (323-327, 329, 334). However, the
effects of MDSC Arg-1 on inhibiting T cell proliferation may be context-dependent, as some
studies have not demonstrated a role for the enzyme (335, 336). Previous work has demonstrated
that myeloid-derived Arg-1 expression has a pathologic role in several cancers, Alzheimer’s
disease, and bacterial and helminth infections, establishing it as a key enzyme in dictating disease
pathogenesis and immune outcomes (268, 322, 337, 338). Therefore, elevated Arg-1 expression
by MDSCs and/or macrophages could participate in preventing an effective immune response to
S. aureus biofilm infection through the depletion of extracellular arginine and suppression of proinflammatory responses.
The objective of this study was to examine the functional role of myeloid-derived Arg-1
in promoting device-associated S. aureus biofilm infection. Using a conditional knockout (KO)
mouse to delete Arg-1 in myeloid cells (Arg-1fl/fl;Tie-2Cre) (268, 339) we established that Arg-1
expression was significantly reduced in myeloid cells in vitro and in MDSCs and macrophages
isolated from S. aureus biofilm infections ex vivo. Utilizing two device-associated S. aureus
biofilm infection models, we found that bacterial burdens were not dramatically different between
wild type (WT) and Arg-1fl/fl;Tie-2Cre myeloid conditional KO mice. Further investigation showed
that MDSCs from Arg-1fl/fl;Tie-2Cre conditional KO animals upregulated iNOS expression,
suggesting a possible compensatory mechanism for arginine depletion and immunomodulation.
However, treatment of Arg-1fl/fl;Tie-2Cre mice with a small molecule inhibitor of iNOS did not
affect S. aureus biofilm burdens or leukocyte infiltrates. Additive effects were also not observed
when mice were treated with a small molecule inhibitor of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase. However, in the orthopedic implant model treatment of WT mice
with the arginase and ODC inhibitor DFMO increased bacterial titers, but only in the surrounding
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soft tissue that possesses some planktonic attributes and not in the joint or femur that model
biofilm growth. Indeed, a role for myeloid-derived Arg-1 in regulating planktonic infection was
confirmed using a subcutaneous abscess model, where S. aureus burdens were significantly
increased in Arg-1fl/fl;Tie-2Cre compared to WT mice. Collectively, these results demonstrate that
myeloid-derived Arg-1 controls S. aureus growth during planktonic, but not biofilm growth in
vivo. By extension, the lack of Arg-1 involvement during biofilm formation represents another
immune-evasion mechanism leading to infection persistence.
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Results
Arginase-1 expression and enzyme activity are significantly reduced in myeloid cells from
Arg-1 conditional KO mice. Arginase-1 is a marker of anti-inflammatory macrophages and
inhibits inflammatory responses through depletion of available arginine stores (260, 268, 322,
326, 337, 340). Our laboratory previously reported increased Arg-1 expression in MDSCs,
monocytes, and macrophages infiltrating tissues surrounding a S. aureus biofilm infection (138,
146-148, 187). Although MDSC depletion improved biofilm clearance by enhancing monocyte
pro-inflammatory activity (148, 187), the mechanism of action and whether Arg-1 was involved
remained unclear. This was an important issue to address, since Arg-1 activity has been
implicated in several types of cancers, Alzheimer’s disease, and infection (268, 322, 337, 338). In
the current study, we used two mouse models of device-associated S. aureus biofilm infection to
determine the role of myeloid-derived Arg-1 in shaping leukocyte infiltrates and promoting
biofilm persistence. Prior reports have demonstrated that LysM-driven expression of Crerecombinase is inefficient at flox-mediated Arg-1 deletion (268, 270). This was confirmed in the
current study, where significant Arg-1 activity remained in Arg-1fl/fl;LysMCre macrophages
compared to wild type cells (Figure S4.1). As an alternative approach, we utilized Arg-1fl/fl;Tie2Cre mice, which have been shown to efficiently delete Arg-1 from myeloid cells (268). We first
confirmed efficient Arg-1 deletion in myeloid cells from Arg-1fl/fl;Tie-2Cre conditional KO mice.
Both Arg-1 expression and enzyme activity were significantly increased in wild type Arg1fl/fl;Tie-2null macrophages in response to IL-4 (Figure 4.1A and B). In contrast, bone marrowderived macrophages from Arg-1fl/fl;Tie-2Cre mice displayed significant decreases in Arg-1
expression and activity relative to Arg-1fl/fl;Tie-2null control cells, both at baseline and following
IL-4 treatment, confirming effective gene deletion (Figure 4.1A and 4.1B). Arginase activity in
Arg-1fl/fl;Tie-2Cre macrophages may result from mitochondrial Arg-2 expression that can also
catalyze the substrate used for the arginase assay (341).
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Figure 4.1

Arginase-1 expression and enzymatic activity are significantly reduced in Arg-1fl/fl;Tie-2Cre
bone marrow-derived macrophages. Bone marrow-derived macrophages were unstimulated or
treated with rmIL-4 (10ng/mL) for 24 h, whereupon whole cell protein extracts (20 µg) were used
for Western blot (A) and arginase activity (B) assays. Arginase activity in whole cell extracts was
measured by the amount of enzyme that converted 1.0 µmol of L-arginine to ornithine and urea
per minute. **, p <0.01; ****, p < 0.0001; one-way ANOVA with Bonferroni’s multiple
comparison (ns, not significant).
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Myeloid-derived arginase-1 does not dramatically affect S. aureus device-associated biofilm
infection. Based on our in vitro studies demonstrating that Arg-1 activity was significantly
reduced in Arg-1fl/fl;Tie-2Cre conditional KO macrophages, we next examined the role of Arg-1 in
the establishment and persistence of S. aureus biofilms using two infection models. The first was
orthopedic implant-associated biofilm infection, which our laboratory has shown is dominated by
MDSCs that express Arg-1 and monocytes polarized towards an anti-inflammatory state (146,
148, 187). No differences in biofilm burdens or leukocyte infiltrates were observed between Arg1fl/fl;Tie-2Cre conditional KO and Arg-1fl/fl;Tie-2null mice over the two-week infection period
(Figure 4.2). We next examined a mouse model of catheter-associated biofilm infection, which is
typified by a more robust macrophage infiltrate, fibrotic response, and Arg-1 expression
compared to the orthopedic implant model (138, 139). Although MDSC infiltrates and bacterial
burdens were significantly increased in catheter-associated tissues of Arg-1fl/fl;Tie-2Cre conditional
KO mice at day 10 post-infection (Figure 4.3), this did not dramatically alter biofilm growth at
later time points (days 14-28; data not shown). No significant differences in arginase activity
were observed in either tissue or femur homogenates from WT and Arg-1fl/fl;Tie-2Cre mice in the
orthopedic implant model (Figure S4.2). This is likely because fibroblasts and other stromal cells
outnumber myeloid cells in these compartments and contribute to the arginase pool at the site of
infection. In addition, we did not observe any dramatic alterations in tissue integrity or collagen
content as determined by H&E and trichrome staining, respectively (data not shown). As a
quantitative means to assess collagen formation, a hydroxyproline assay was performed.
Although hydroxyproline levels were elevated at day 3 post-infection in Arg-1fl/fl;Tie-2Cre mice in
the catheter-associated infection model (Figure S4.3) this was not observed at later time points,
which confirmed the similarities in collagen levels between the two strains. Collectively, these
results indicate that although Arg-1 expression is increased at the site of S. aureus biofilm
infection, the enzyme itself in myeloid cells is not critical for regulating biofilm growth.

136
Figure 4.2

Arginase-1 expression in myeloid cells does not influence S. aureus orthopedic implant
infection. A titanium orthopedic implant was placed in the femur of Arg-1fl/fl;Tie-2null (WT) and
Arg-1fl/fl;Tie-2Cre mice and inoculated with 103 CFU S. aureus LAC. (A-C) Tissue surrounding the
infected implant, femur, and knee joint was collected at the indicated intervals post-infection to
quantify bacterial burdens. (D-F) Infiltrating leukocyte populations in implant-associated tissues
were evaluated by flow cytometry. Results are representative of two independent experiments.
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Figure 4.3

Arginase-1 in myeloid cells does not dramatically affect S. aureus catheter-associated
biofilm infection. Catheter-associated infections were established in Arg-1fl/fl;Tie-2null (WT) and
Arg-1fl/fl;Tie-2Cre mice following challenge with 103 CFU of S. aureus LAC. Animals were
sacrificed at the indicated intervals post-infection, whereupon bacterial burdens in the
surrounding tissue (A) and catheter (B) were determined and infiltrating leukocyte populations
evaluated by flow cytometry (C-E). Results are representative of three independent experiments
*, p < 0.05; **, p <0.01; ***, p < 0.001; unpaired 2-tailed Student’s t-test.
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iNOS expression is increased in biofilm-associated MDSCs from Arg-1fl/fl;Tie-2Cre
conditional KO mice. To establish that the overall lack of differences between Arg-1fl/fl;Tie-2Cre
myeloid conditional KO and Arg-1fl/fl;Tie-2null mice in both the catheter and orthopedic implant
infection models were not due to inefficient Arg-1 deletion in vivo, Arg-1 expression was
examined in myeloid cells recovered from the site of infection. Both MDSCs
(CD45+Ly6GhighLy6C+) and monocytes (CD45+Ly6G-Ly6C+) were isolated by FACS from Arg1fl/fl;Tie-2Cre and Arg-1fl/fl;Tie-2null control mice at days 7 and 14 post-infection, whereupon Arg-1
expression and activity were assessed by RT-qPCR and enzymatic assays, respectively (Figure
4.4). As expected, Arg-1 expression and activity were dramatically reduced in macrophages and
MDSCs from Arg-1fl/fl;Tie-2Cre conditional KO mice compared to Arg-1fl/fl;Tie-2null controls in the
catheter-associated infection model at day 7 and 14 (Figure 4.4A). Because myeloid conditional
Arg-1 deletion was verified in this model, this analysis was not repeated in the orthopedic implant
biofilm model. Interestingly, MDSCs from Arg-1fl/fl;Tie-2Cre myeloid conditional KO mice
showed a dramatic increase in iNOS expression (Figure 4.4A). Since prior studies from our
laboratory have revealed a critical role for MDSCs in attenuating monocyte/macrophage proinflammatory activity and promoting biofilm persistence (12, 14), this suggested that a potential
compensatory mechanism for arginine depletion may exist via upregulation of iNOS by MDSCs
in the absence of Arg-1.
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Figure 4.4

MDSCs and macrophages from Arg-1fl/fl;Tie-2Cre mice express limited arginase-1 in vivo.
Catheter-associated infections were established in Arg-1fl/fl;Tie-2null (WT) and Arg-1fl/fl;Tie-2Cre
mice following challenge with 103 CFU of S. aureus LAC. Animals were sacrificed at days 7 and
14 post-infection, whereupon MDSCs (CD45+Ly6GhighLy6C+) and monocytes (CD45+Ly6GLy6C+) were isolated by FACS for (A) RT-qPCR quantification of Arg-1 and iNOS expression
and (B) arginase activity assay. Results are representative of two independent experiments. **, p
< 0.01; ***, p < 0.001; unpaired 2-tailed Student’s t-test.
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iNOS or reactive oxygen species do not compensate for arginase-1 deficiency in myeloid
cells. Given the observed increase in iNOS expression in MDSCs from Arg-1 myeloid
conditional KO mice, we treated Arg-1fl/fl;Tie-2Cre animals with N6-(1-iminoethyl)-L-lysine (LNIL), a small molecule inhibitor with selectivity for iNOS (cytokine-inducible) over nNOS
(neuronal) and eNOS (endothelial) (342). Both Arg-1fl/fl;Tie-2Cre myeloid conditional KO and
Arg-1fl/fl;Tie-2null control mice received daily administration of L-NIL or vehicle in the S. aureus
orthopedic implant model. No differences in bacterial burdens from the knee, surrounding soft
tissue, or femur, or leukocyte infiltrates were observed with L-NIL treatment (Figure 4.5A-C and
data not shown), suggesting that the observed increase in iNOS expression by MDSCs does not
compensate for reduced myeloid Arg-1. We next examined the potential role of NADPH oxidase
as a redundant pathway for Arg-1 in modulating biofilm persistence, since ROS production by
MDSCs has also been implicated in modulating their suppressive activity (229, 232). Arg1fl/fl;Tie-2Cre myeloid conditional KO and Arg-1fl/fl;Tie-2null control mice were treated with the
small molecule NADPH oxidase inhibitor apocynin, which also revealed no role in limiting the
establishment or persistence of orthopedic implant-associated biofilm infection (Figure 4.5A-C).

141
Figure 4.5

iNOS or reactive oxygen species do not compensate for arginase-1 deficiency in myeloid
cells. S. aureus orthopedic implant infections were established in (A-C) Arg-1fl/fl;Tie-2null (WT),
Arg-1fl/fl;Tie-2Cre or (D-F) C57BL/6 mice, whereupon animals received daily treatments of (A-C)
apocynin (6 mg/kg) and L-NIL (40 mg/kg), or (D-F) DFMO (50 mg/kg) beginning at 5 h prior to
infection. Bacterial burdens were quantified in (A, D) surrounding soft tissues, (B, E) femur, and
(C, F) knee joint at the indicated time points post-infection. *, p < 0.05;***, p <0.001; unpaired
2-tailed Student’s t-test.
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Inhibition of polyamine synthesis promotes bacterial growth in tissues surrounding biofilm
infections. Although our results suggested that myeloid Arg-1 deletion had minimal effects on
biofilm development, we treated WT mice with difluoromethylornithine (DFMO), a small
molecule inhibitor of both arginase and ornithine decarboxylase (ODC), in the orthopedic implant
infection model to examine the potential redundancy of ODC during S. aureus biofilm infection.
Interestingly, bacterial burdens were increased at days 7 and 10 post-infection with DFMO
treatment, but were only manifest in the soft tissue surrounding the biofilm infection site (Figure
4.5D). This finding agrees with an earlier report showing that polyamines are critical for antistaphylococcal responses and resolution of skin abscesses following DFMO treatment (149).
Importantly, our study advances this finding by identifying myeloid cells as a critical source of
Arg-1 during subcutaneous S. aureus abscess formation, since bacterial burdens were
significantly increased in abscesses from Arg-1fl/fl;Tie-2Cre compared to WT mice (Figure 4.6A).
No gross differences in abscess size or dermatonecrosis were observed between Arg-1fl/fl;Tie-2Cre
myeloid conditional KO and Arg-1fl/fl;Tie-2null control mice (Figure 4.6B and data not shown). We
did not explore the effects of DFMO on MDSC function since our data demonstrated that
myeloid-derived Arg-1 does not play a major role during S. aureus biofilm formation.
Collectively, these results demonstrate that myeloid-derived Arg-1 controls S. aureus growth
during planktonic, but not biofilm growth in vivo.
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Figure 4.6
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Myeloid-derived arginase-1 contributes to S. aureus clearance during subcutaneous abscess
infection. Subcutaneous abscesses were established in Arg-1fl/fl;Tie-2null (WT) and Arg-1fl/fl;Tie2Cre mice following inoculation with 107 CFU S. aureus LAC. Animals were sacrificed at days 3,
7, and 10 post-infection, whereupon abscess-associated bacterial burdens (A) and leukocyte
infiltrates (C-F) were determined. (B) Abscess sizes were monitored throughout the course of
infection with calipers. Results are representative of two independent experiments. *, p < 0.05;
**, p < 0.01; unpaired 2-tailed Student’s t-test.
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Supplemental Figure S4.1

LysMCre is not efficient at reducing arginase activity in bone marrow-derived macrophages.
Bone marrow-derived macrophages were unstimulated or treated with rmIL-4 (10ng/mL) for 24
h, whereupon arginase activity in whole cell extracts (20 µg) was measured by the amount of
enzyme that converted 1.0 µmol of L-arginine to ornithine and urea per minute. **, p < 0.01; ***,
p < 0.001; ****, p < 0.0001; one-way ANOVA with Bonferroni’s multiple comparison (ns, not
significant).
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Supplemental Figure S4.2

Arginase activity in whole tissue homogenates is similar between Arg-1fl/fl;Tie-2Cre and Arg1fl/fl;Tie-2null mice. Cell-free homogenates from Arg-1fl/fl;Tie-2Cre conditional KO and Arg1fl/fl;Tie-2null mice were prepared at days 7 or 14 post-infection in the orthopedic implant model
for arginase activity assays. Arginase activity in whole cell extracts from the tissue (A) and femur
(B) was determined by the amount of enzyme that converted 1.0 µmol of L-arginine to ornithine
and urea per minute. Results are representative of three independent experiments.
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Supplemental Figure S4.3

Myeloid derived Arg-1 activity does not play a significant role in collagen deposition during
S. aureus catheter-associated infection. The soft tissues surrounding S. aureus infected
catheters from Arg-1fl/fl;Tie-2Cre conditional KO and Arg-1fl/fl;Tie-2null mice were collected at day
3, 7, or 14 post-infection for hydroxyproline assays. Hydroxyproline content was measured by
colorimetric assay, with results reported as μg of hydroxyproline per mg of tissue. Results are
representative of two independent experiments.
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Discussion
Our laboratory has demonstrated that MDSCs are preferentially recruited to S. aureus
biofilm infections, where they inhibit monocyte pro-inflammatory activity to promote infection
persistence (138, 139, 146-148, 187). MDSCs are the primary source of IL-10 during biofilm
infection and prior studies have established that antibody-mediated depletion of MDSCs and IL10 deficiency both result in reduced S. aureus biofilm burdens (138, 147, 148, 187). However,
bacteria still remain in implant-associated tissues in both of these scenarios, indicating the
existence of additional immunosuppressive mechanisms. Previous reports have shown that
MDSCs and macrophages inhibit innate and adaptive immune responses through extracellular
arginine depletion by Arg-1 (235, 327, 329). Our recent study revealed that Arg-1 expression was
increased in MDSCs during S. aureus orthopedic implant biofilm infection and macrophages
surrounding biofilm infected catheters dramatically upregulate Arg-1 (138, 148, 187, 188).
Furthermore, host polyamine synthesis is important for controlling S. aureus growth in nonbiofilm infection models, such as sepsis and subcutaneous abscesses (149). Arg-1 also plays a
critical role in models of cancer, Alzheimer’s disease, and infection, due to its immune
suppressive properties (268, 322, 337, 338). Based on these observations, we sought to determine
whether myeloid-derived Arg-1 facilitates S. aureus biofilm persistence, which could represent a
viable treatment strategy since the enzyme is currently being explored as a therapeutic target in
Alzheimer’s disease (337).
Despite efficient depletion of myeloid-derived arginase activity from Arg-1fl/fl;Tie-2Cre mice,
minimal differences in bacterial burdens or leukocyte infiltrates were observed in two distinct
device-associated S. aureus biofilm infection models. MDSCs are the primary leukocyte infiltrate
in both orthopedic implant and catheter-associated biofilm infection, whereas few T cells and
neutrophils are present. However, one important distinction is that macrophage infiltrates are
more abundant in catheter-associated infections compared to the orthopedic implant model (138,
146, 148, 187). The finding that leukocyte infiltrates were similar in Arg-1fl/fl;Tie-2Cre myeloid
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conditional KO and Arg-1fl/fl;Tie-2null control mice in both models supports previous reports that
Arg-1 activity regulates cellular activation rather than differential leukocyte recruitment (268,
322, 327, 328, 330). However, cellular activation status was not examined in the current study
since no dramatic differences in biofilm titers were observed.
Interestingly, a marked increase in iNOS expression was observed in MDSCs from Arg1fl/fl;Tie-2Cre myeloid conditional KO animals at both 7- and 14-days following infection. A
previous study reported a similar phenomenon, where deletion of macrophage Arg-1 potentiated
NO production by increasing arginine availability (268). To determine whether this increase in
iNOS expression could compensate for myeloid-targeted Arg-1 depletion, Arg-1fl/fl;Tie-2Cre mice
were treated with L-NIL, a small molecule inhibitor of iNOS. L-NIL had no effect on biofilm
burdens or leukocyte infiltrates in Arg-1fl/fl;Tie-2Cre myeloid conditional KO mice, indicating that
increased iNOS expression is not a significant compensatory mechanism for promoting biofilm
persistence. In addition, unpublished data from our laboratory using iNOS KO mice has
demonstrated that iNOS does not play a role in S. aureus biofilm infections. In contrast, McInnes
et al. reported increased bacterial burdens and mortality during S. aureus septic arthritis in iNOS
KO mice (240), identifying a distinction between biofilm and planktonic infection. In addition,
the current study demonstrates that NADPH does not impact biofilm growth, since apocynin
treatment had no effect on S. aureus burdens. This differs from a recent study by Sun et al. using
NADPH-oxidase deficient mice, which revealed a critical role for ROS in controlling S. aureus
pneumonia (343). Therefore, our study has revealed novel distinctions between S. aureus biofilm
and planktonic infections, since iNOS and NADPH-oxidase do not affect biofilm formation but
do regulate host immunity to planktonic infection.
As another potential point of redundancy, we examined whether ODC contributes to S.
aureus persistence during biofilm infection, since a prior report revealed a critical role for
polyamine synthesis in controlling S. aureus growth in a mouse skin abscess model (149).
Interestingly, treatment of WT animals with the arginase/ODC inhibitor DFMO increased
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bacterial burdens in the soft tissue surrounding infected orthopedic implants at days 7 and 10
post-infection, whereas no changes in bacterial titers were observed in the knee joint, femur, or
implant. The selectivity of DFMO action in the tissue is reminiscent of our findings with the
catheter-associated infection model, where S. aureus burdens were elevated in Arg-1fl/fl;Tie-2Cre
conditional KO mice at day 10 post-infection in the surrounding soft tissues, which possess
planktonic attributes since bacteria have dispersed from the catheter surface. To further
demonstrate the importance of Arg-1 in the context of planktonic infection, we took advantage of
a subcutaneous abscess model, where a role for polyamines in controlling bacterial growth has
been previously shown (149). Importantly, our study advances this finding by identifying myeloid
cells as a critical source of Arg-1 during subcutaneous S. aureus abscess formation, since
bacterial burdens were significantly increased in abscesses from Arg-1fl/fl;Tie-2Cre compared to
WT mice. Collectively, these results demonstrate that myeloid-derived Arg-1 activity and
polyamine synthesis controls S. aureus growth during planktonic, but not biofilm growth in vivo.
The complete repertoire of mechanisms used by MDSCs to inhibit immune function and
promote S. aureus biofilm establishment and persistence is still unknown. Previous studies from
our laboratory have implicated a role for both IL-12 and IL-10 in the indirect recruitment and
immunosuppressive function of MDSCs, respectively (146, 148). In cancer models, myeloidderived Arg-1 has been shown to provide two complementary functions. First, depletion of
extracellular arginine stores modulates the immune response by decreasing NO production,
synthesis of arginine-containing proteins, and T cell activation (302, 322, 332, 333). Second,
arginine metabolism provides precursor molecules for collagen and polyamine synthesis, which
leads to fibrotic tissue deposition, vascular remodeling, and direct antibacterial actions (149, 260,
327, 331-333). Although prior work suggested that myeloid Arg-1 might be important for
promoting S. aureus biofilm infection (146, 148, 187), this study demonstrates that myeloid Arg1 does not directly influence the immune response to S. aureus biofilm infections or induce a
compensatory increase in arginine flux towards RNI/ROS production. However, these
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observations do not provide a specific mechanism by which this occurs. Namely, it does not rule
out potential effects of Arg-1 on arginine bioavailability to support S. aureus growth and fitness
in vivo. For example, previous studies have demonstrated that S. aureus growth and virulence is
dependent on exogenous arginine or arginine biosynthesis via proline (344). Alternatively, S.
aureus biofilm induction of Arg-1 expression in non-myeloid cells, such as fibroblasts or other
mesenchymal cells, could over-ride any potential contribution of myeloid-derived Arg-1 activity
during S. aureus biofilm infection. This would require crossing Arg-1fl/fl with a Cre line directed
by the type I collagen promoter Col1a2 to target gene deletion in fibroblasts (345). Furthermore,
mitochondrial Arg-2 released from dead or dying cells could also contribute to the overall pool of
arginase enzyme activity (341). Additional studies are needed to address these possibilities;
however, this study demonstrates that myeloid-derived Arg-1 has minimal effects on S. aureus
biofilm growth, but instead plays a unique role in controlling S. aureus planktonic infections.
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Chapter 5: Discussion and Future Directions
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Key Findings and Conclusions
The innate immune system is the first line of defense against invading bacterial
pathogens. Specifically, MΦs are a key component of the initial response to pathogens, as they
are resident in all tissues, able to directly kill bacterial pathogens, and function as antigen
presenting cells to effectively link the innate and adaptive immune systems. However, the ability
of S. aureus to form biofilm has endowed it with sophisticated subversion strategies to actively
inhibit immune-mediated clearance mechanisms. S. aureus biofilm infections actively polarize
the innate immune response to promote biofilm establishment and persistence, which is evident
by the influx of MDSCs, paucity of neutrophils and T cells, and the polarization of antiinflammatory MΦs, all of which play a role in the chronicity of S. aureus biofilm infections (145,
146, 148, 187, 226).
Our laboratory has previously determined that the polarization of anti-inflammatory
monocytes/MΦs plays a critical role in promoting S. aureus biofilm persistence. It is known that
MΦs recruited to the site of S. aureus biofilm infections will quickly acquire anti-inflammatory
properties and are subject to toxin-mediated death (139). However, adoptive transfer of in vitroderived pro-inflammatory MΦs into a catheter-associated S. aureus biofilm infection inhibits
biofilm formation and promotes clearance. Our laboratory has also shown that the cytokine milieu
produced by biofilm-associated MDSCs polarizes monocytes to become anti-inflammatory (146,
148, 187, 226). Depletion of MDSCs and neutrophils with α-Ly6G antibody (1A8) transformed
monocytes to a pro-inflammatory state, resulting in reduced biofilm burdens. Depletion of
monocytes and MΦs in addition to MDSCs and neutrophils with α-GR-1 antibody increased
bacterial burdens and worsened the infection, indirectly demonstrating that monocytes and MΦs
are an essential effector cell population to control the S. aureus biofilm bacterial burdens (187).
My dissertation work was centered on elucidating the relationship between leukocyte
metabolism and inflammatory function. The field of immunometabolism focuses on
understanding the link between intrinsic changes in leukocyte metabolism and how it governs,

154
and is governed by, leukocyte inflammatory phenotype. It has been shown that pro-inflammatory
MФs and dendritic cells shift their metabolism towards aerobic glycolysis in order to provide the
necessary carbon flux through the pentose phosphate pathway and provide precursor molecules
for anabolic processes and/or production of reactive oxygen species (256, 257, 260). In contrast,
anti-inflammatory MФs primarily rely on OxPhos to drive their activity, with fatty acid oxidation
also playing a role (256, 289, 290). In MФs, these metabolic switches are facilitated by global
changes in gene expression that will ultimately lead to a shift in metabolism, carbon consumption,
metabolite accumulation, and overall leukocyte phenotype and inflammatory activity.
We demonstrated that leukocyte metabolism, specifically monocyte metabolism, can be
targeted to ultimately promote clearance of the biofilm (Chapter 3). By designing nanoparticle
formulations containing the ATP synthase inhibitor, oligomycin to specifically target Fc-receptor
positive monocytes, we were able to dictate the outcome of biofilm infection. Monocytes isolated
from nanoparticle treated animals displayed an altered intracellular metabolome as compared to
control monocytes. In addition, they exhibited shifts in gene expression that were consistent with
the profile of a pro-inflammatory monocyte. These metabolic and transcriptional changes
translated to sustained decreases in bacterial burdens. Metabolomic and RT-qPCR analysis of
MDSC populations showed significant changes in the intracellular metabolome and
transcriptional profile despite showing no evidence of nanoparticle uptake. While MDSCs are
known to direct the activity and function of other leukocytes, this finding highlights the dynamic
crosstalk that occurs between activated monocytes and MDSCs. Previous work from our
laboratory revealed that S. aureus biofilms cannot be cleared with any treatment regimen,
including antibiotics (146, 148, 187). Surprisingly, nanoparticle administration acted
synergistically with antibiotic treatment to clear the infection. Together this suggests that
targeting monocyte metabolism can polarize monocytes to change the biofilm structure and
milieu to allow for antibiotic-mediated clearance of the infection.
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We investigated Arg-1 in the myeloid compartment to determine whether the metabolic
enzyme plays a role in promoting biofilm persistence. During S. aureus biofilm infection,
MDSCs and MΦs significantly upregulate Arg-1 expression, which catalyzes the conversion of
arginine to ornithine and urea and ultimately regulates the availability of arginine. However,
using Arg-1fl/fl;Tie2Cre conditional knockout animals, we found that myeloid Arg-1 does not play a
critical role in biofilm establishment or persistence in either the S. aureus catheter or implant
biofilm models. While Arg-1 was effectively deleted in Arg-1fl/fl;Tie2Cre MΦs, bacterial burdens
were unchanged. Although Arg-1fl/fl;Tie2Cre conditional knockout animals did display a
compensatory increase in iNOS expression, small molecule inhibitors of iNOS, NADPH oxidase,
or ornithine decarboxylase did not alter the outcome of infection. This indicates that arginine
availability does not dramatically influence S. aureus biofilm infection. Instead, we found that
myeloid-derived Arg-1 does play an important role in controlling planktonic S. aureus, since Arg1fl/fl;Tie2Cre animals had significantly higher bacterial burdens, although this did not translate into
changes in dermatonecrosis or abscess size. This is supported by prior studies that demonstrate a
role for arginine availability for polyamine synthesis in controlling S. aureus growth (149).
In summary, this work has advanced our understanding of the relationship between
leukocyte metabolism and inflammatory phenotype in the context of S. aureus biofilm-associated
infections. Furthermore, these studies also highlight the dynamic host-pathogen interactions in
addition to the host-host interactions that occur in these complex infections. This emphasizes the
challenges that are faced when treating, or trying to prevent S. aureus biofilm infections.
However, it opens up a previously unexplored area of research in the context of leukocyte
metabolism during S. aureus biofilm infections. The method of targeting effector leukocyte
metabolism may ultimately lead to the development of novel therapeutic options for S. aureusassociated biofilm infections and other chronic diseases.
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Future Directions
Genetic approach to targeting MΦ metabolism
Our work has demonstrated that nanoparticle-mediated delivery of metabolic inhibitors
can promote monocyte polarization and clearance of S. aureus biofilms. As a complementary
approach to regulate leukocyte metabolism during S. aureus biofilm infections, we have initiated
studies with a transgenic mouse that possesses a targeted deletion in the electron transport chain.
Nuclear encoded ubiquinone oxidoreductase iron-sulfur protein 4 (Ndusf4) is a non-catalytic
subunit of complex I of the electron transport chain. Deletion of the Ndusf4 gene results in
decreased OxPhos activity, with a corresponding increase in glycolysis (266, 346, 347). Previous
studies have utilized Tie2 (receptor tyrosine kinase Tek)-driven Cre-recombinase expression to
conditionally delete Ndusf4 in MΦs (266, 348). Here we utilized LysM-driven Cre-recombinase
expression to conditionally knockout Ndusf4 in MΦs and monocytes, in addition to other myeloid
cell populations (i.e. MDSCs and PMNs) (269). We hypothesized that these animals would
display a similar phenotype during infection as mice treated with nanoparticles. Specifically, we
predicted that inhibiting the electron transport chain and OxPhos activity in myeloid cells would
enhance their pro-inflammatory activity and lead to biofilm clearance. The fact that Ndusf4 is
deleted in multiple myeloid populations will be important to consider when comparing these
results with monocyte-directed nanoparticles.
Ndusf4fl/fl animals were kindly provided by Dr. Phillip G. Morgan (Seattle Children’s
Research Institute, Seattle WA) and crossed with LysM-driven Cre-recombinase animals.
Preliminary studies measuring the metabolic activity of Ndusf4fl/fl;LysMCre bone marrow-derived
MΦs using Seahorse XF96 metabolic assays, showed that these MΦs have decreased OxPhos and
increased glycolytic activity as expected (Figure 5.1). Specifically, Ndusf4fl/fl;LysMCre MΦs had
significantly less respiratory capacity due to the electron transport chain defect (Figure 5.1A and
5.1C). In addition, Ndusf4fl/fl;LysMCre MΦs showed increased glycolytic activity Compared to
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Ndusf4fl/fl;LysMnull control MΦs, indicating that Ndusf4fl/fl;LysMCre MΦs experienced a glycolytic
shift in their metabolism (Figure 5.1D and 5.1E).
Previous work from our laboratory has shown that MΦs are unable to infiltrate an intact
biofilm in vitro (60, 138, 139). Based on the fact that the loss of Ndusf4 in MΦs pushed their
metabolic activity towards glycolysis, we hypothesized that these cells should display a skewed
phenotype towards pro-inflammatory activity and therefore be able to kill and infiltrate a S.
aureus biofilm. To investigate this possibility, Ndusf4fl/fl;LysMnull and Ndusf4fl/fl;LysMCre MΦs
were co-cultured in vitro with S. aureus biofilms at different stages of growth (Figure 5.2). We
show that bacterial burdens in the biofilm increase over a 4 day period, indicating that upon coculture, MΦs will encounter different bacterial numbers based on biofilm maturity (Figure 5.2).
When MΦs were co-cultured with planktonic bacteria, no differences in bacterial titers were
evident between wildtype and Ndusf4-deficient MΦs throughout a 4 day interval (Figure 5.2B).
Similarly, biofilm burdens were indistinguishable when wildtype and Ndusf4 deficient MΦs were
incubated with biofilms of various levels of maturity (Figure 5.2C–F). Furthermore, confocal
microscopy revealed similar invasion patterns of Ndusf4fl/fl;LysMnull or Ndusf4fl/fl;LysMCre MΦs
into S. aureus biofilms (Figure 5.3).
Since the large numbers of bacteria in a biofilm may overshadow potential differences in
MΦ bactericidal activity, gentamicin protection assays were performed to determine whether
Ndusf4-deficient MΦs were better able to phagocytose and kill planktonic S. aureus (Figure 5.4).
Modest differences were observed between wildtype and Ndusf4-KO MΦs during acute intervals
and were MOI-dependent, which might reflect differences in phagocytic activity. At higher
MOIs, intracellular S. aureus burdens were significantly reduced in Ndusf4-KO MΦs at 24 and 48
h suggesting that indeed, these MΦs possess greater bactericidal activity (Figure 5.4A-B).
Based on our in vitro data showing that Ndusf4-KO MΦs were more glycolytic (Figure
5.1) and better able to kill intracellular S. aureus (Figure 5.4), we next examined the role of
myeloid metabolism in the establishment and persistence of a S. aureus orthopedic implant
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biofilm infection. Our laboratory has shown that this infection model is dominated by MDSC
infiltrates, which play a key role in directing the polarization of anti-inflammatory monocytes and
MΦs. Monocyte and MΦ anti-inflammatory polarization is associated with a bias towards
OxPhos metabolism (146, 148, 187, 226). We predicted that inhibiting the electron transport
chain and OxPhos activity in myeloid cells by Ndusf4 deletion would enhance their proinflammatory activity and lead to biofilm clearance. Surprisingly, despite the increased glycolytic
activity in Ndusf4-KO MΦs in vitro, bacterial burdens were significantly higher in the infected
soft tissues of Ndusf4fl/fl;LysMCre conditional KO animals compared to Ndusf4fl/fl;LysMnull controls
(Figure 5.5A). In contrast, bacterial burdens in the knee joint, femur, and implant were relatively
unaffected (Figure 5.5B-D). Although titers were significantly increased in the femur of
Ndusf4fl/fl;LysMCre conditional KO mice at 7 days post-infection, this was transient and not
observed at later time points (Day 14 and 28). In general, leukocyte infiltrates were not
significantly affected over the 28 day infection interval (Figure 5.5E-H). However, in a few
instances MDSCs were significantly reduced concomitant with increased monocyte and MΦ
populations in Ndusf4fl/fl;LysMCre conditional KO mice. Collectively, these results indicate that
although MΦs from Ndusf4fl/fl;LysMCre animals are more glycolytic and better able to kill
intracellular planktonic S. aureus the broader deletion of Ndusf4 from all myeloid populations
does not translate to a reduction in bacterial burdens in vivo.
Finally, we compared the ability Ndusf4fl/fl;LysMCre and Ndusf4fl/fl;LysMnull mice to control
S. aureus abscess infection, to determine if a distinctions would be observed compared to biofilm
growth (Figure 5.6). While subcutaneous S. aureus abscesses elicit a large MDSC infiltrate, the
infection is generally cleared by the immune system and is not chronic, unlike biofilm (241, 349).
Similar to what was seen during orthopedic implant biofilm infection, Ndusf4fl/fl;LysMCre mice
had significantly higher bacterial burdens (Figure 5.6A), in addition to larger abscesses (Figure
5.6B) and increased dermatonecrosis (Figure 5.6C). No significant differences in leukocyte
infiltrates were observed (Figure 5.6).The increase in bacterial burdens in Ndusf4fl/fl;LysMCre mice
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could suggest that the metabolic state of monocytes/MΦs in these animals is influenced by the
lack of Ndusf4 in other myeloid cells that were also targeted (350).
MΦ/monocyte-specific Ndusf4 conditional knockout
Conditional knockout mouse models allow for the deletion of a gene at a specific time or
in specific tissues by controlling the timing and expression of Cre-recombinase. This strategy
allowed us to specifically delete Arg-1, where the germline knockout is lethal, in MΦ (Tie2)
(339) and myeloid (LysM) populations (Chapter 4) (269). We initiated our metabolic studies
using LysM-driven Cre expression to delete Ndusf4, where LysM is expressed in all myeloid cells
and not monocyte/MΦ-specific. Therefore, in Ndusf4fl/fl;LysMCre mice the Ndusf4 gene is deleted
in monocytes, neutrophils, and MDSCs. Prior studies from our laboratory have shown that the
specificity between targeting monocytes, MDSCs and neutrophils is important (187). Therefore, a
clean, monocyte/-specific, conditional knockout is necessary because of the influence of MDSCs
on other immune cells. Previous studies have shown that glycolysis in MDSCs promotes their
expansion and arrests their maturation, maintaining suppressive activity (351). Therefore, while
Ndusf4fl/fl;LysMCre monocytes are more glycolytic in vitro this effect is possibly mitigated in vivo
by the expanded/activated MDSC population. In addition, LysM expression isn’t observed in all
mononuclear phagocytes, and can vary between mice (268, 270). Therefore, future studies should
be performed with Ndusf4fl/fl;Tie2Cre mice, which more specifically targets monocytes/MΦs over
other myeloid populations. If bacterial burdens are reduced in infected Ndusf4fl/fl;Tie2Cre mice,
this would confirm the modulatory effects of monocyte metabolism in addition to suggesting an
opposing effect of MDSC metabolism in dictating S. aureus biofilm infection outcome.
Alternative floxed mouse models
Ndusf4fl/fl mice were utilized in our work to inactivate OxPhos because prior studies have
shown that they are viable in another bacterial infection model (266). Other floxed animals, such
as Tfamfl/fl (transcription factor A) which is a transcriptional regulator required for synthesis of
ETC genes, have significant viability issues and often develop cancers (352). Although previous
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work noted no changes in MΦ survival, viability could likely be affected once glycolytic
metabolism is accelerated (255, 256, 266, 290). Alternative floxed animals could be utilized in
the future that target complex II or depress ATP-synthase activity. However, to our knowledge
there are not any currently available transgenic mouse models fitting these specifications.
In addition, it is worth noting that floxed animals may contain background mutations that
affect phenotypes. Pertinent to this dissertation work, Ndusf4fl/fl mice had been reportedly
backcrossed to C57BL/6 mice for > 20 generations, yet both Ndusf4fl/fl;LysMCre and
Ndusf4fl/fl;LysMnull control animals exhibited gross changes in their snout morphology compared
to standard C57BL/6 mice. In addition, their skin was loose and very pliable. Integument defects
were previously noted in Ndusf4 complete knockout animals, but had not been reported in the
conditional knockout animals (266). This may partially explain biofilm clearance at later time
points in the knee joint, femur, and implant of both Ndusf4fl/fl;LysMCre and for Ndusf4fl/fl;LysMnull
control mice, which is not observed in C57BL/6 or other mouse strains utilized by our laboratory
(146, 148, 187, 226).
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Figure 5.1

Ndusf4 deletion in MΦs induces a shift in metabolism towards glycolysis. Bone marrowderived MΦs from Ndusf4fl/fl;LysMnull and Ndusf4fl/fl;LysMCre mice were harvested and plated for
24 h in a Seahorse XF96 culture plate, whereupon Seahorse Bioscience assays were performed to
assess (A) OxPhos and (D) glycolysis. (B) Basal respiration, (C) maximal respiration, (E)
glycolytic, and (F) glycolytic capacity were calculated using well-defined algorithms. Data is
presented as the mean (n=3). (*, p < 0.05; Student’s t-test.).
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Figure 5.2

Co-culture of Ndusf4fl/fl;LysMCre MΦs with S. aureus biofilms of various maturation states.
(A) Bone marrow-derived MΦs from Ndusf4fl/fl;LysMnull and Ndusf4fl/fl;LysMCre mice were cocultured with planktonic bacteria (B, Day 0, black) or biofilms of varying maturity levels (C, Day
1, red; D, Day 2, orange; E, Day 3 , green; F, Day 4, blue). Remaining bacterial burdens
following MΦs addition were enumerated daily for 4 consecutive days. Data is presented as the
mean ± SD (n = 9 combined from 3 experiments).
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Figure 5.3
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Confocal imaging of Ndusf4fl/fl;LysMCre MΦ-S. aureus biofilm co-cultures. Bone marrowderived MΦs from Ndusf4fl/fl;LysMnull (wildtype, left) and Ndusf4fl/fl;LysMCre (Ndusf4, right) mice
were stained with CellTracker Blue and co-cultured with GFP expressing S. aureus biofilms that
were 0, 1, or 4 days old at the beginning of the co-culture period. Figures show representative
images of a 3D top-down view of the biofilm-MΦ co-culture.
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Figure 5.4

Ndusf4fl/fl;LysMCre MΦs display increased S. aureus bactericidal activity. Bone marrowderived MΦs from Ndusf4fl/fl;LysMnull and Ndusf4fl/fl;LysMCre mice were plated in a 96-well plate
at 5x104 MΦs per well for 24 h. MΦs were challenged with S. aureus at an MOI of (A) 10 or (B)
100 for 45 min and treated with 100μg/mL gentamicin to kill remaining extracellular bacteria.
MΦs were maintained in medium supplemented with low dose gentamicin (20μg/mL) until the
specified time points, whereupon lysates were plated to enumerate viable intracellular bacteria,
which is reported as CFU/5x104 MΦs. Dashed and dotted lines represent the limit of detection
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(LOD) and the inoculum, respectively. Data is presented as the mean (n=3). (*, p < 0.05;
student’s t-test.).
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Figure 5.5
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Myeloid deletion of Ndusf4 leads to an increase in bacterial burdens during orthopedic
implant infection. A titanium orthopedic implant was placed in the femur of Ndusf4fl/fl;LysMnull
(WT) and Ndusf4fl/fl;LysMCre mice and inoculated with 103 CFU S. aureus LAC. (A-D)Tissue
surrounding the infected implant, knee joint, femur, and implant were collected at the indicated
intervals post-infection to quantify bacterial burdens. (E-H) Infiltrating leukocyte populations in
implant-associated tissues were evaluated by flow cytometry. Results are representative of ≥ 2
independent experiments. (*, p < 0.05; ***, p < 0.001; unpaired 2-tailed Student’s t-test.)
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Figure 5.6
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Myeloid deletion of Ndusf4 leads to an increase in bacterial burdens during subcutaneous
abscess infection. Subcutaneous abscesses were established in Ndusf4fl/fl;LysMnull (WT) and
Ndusf4fl/fl;LysMCre mice following inoculation with 107 CFU S. aureus LAC. Animals were
sacrificed at days 3 and 7 post-infection, whereupon abscess associated bacterial burdens (A) and
leukocyte infiltrates (D-G) were determined. (B) Abscess sizes were monitored throughout the
course of infection with calipers. (C) The presence of dermatonecrosis was noted daily. Results
are from a single experiment. *, p < 0.05; unpaired 2-tailed Student’s t-test.
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Determine what MDSC- or biofilm-derived products mediate the shift in monocyte
metabolism
Biofilm-associated monocytes process signals from a dynamic and complex milieu,
receiving input from both surrounding host cells and the biofilm. Our laboratory has
demonstrated that MDSCs are important for polarizing monocytes toward an anti-inflammatory
state. This was evident following MDSC depletion using a Ly6G antibody, where FACS-purified
Ly6G-Ly6C+ monocytes/MФs exhibited increased iNOS, IL-12p40, and IL-6 expression, which
translated into improved biofilm clearance (187). Meanwhile, the abundance of PAMPs at the site
of infection likely influences monocyte metabolism. In addition, our laboratory has used
proteomic analysis of biofilms to demonstrate the immune inhibitory role of S. aureus toxins,
including Hla and LukAB (60). It is known that Hla facilitates immune evasion by preventing
phagosome-mediated killing, but both Hla and LukAB are able to kill leukocytes by binding to
ADAM10 and CD11b, respectively (60).
Since MDSCs are the primary source of IL-10 during S. aureus biofilm infection, which
can block monocyte NF-κB activation and downregulate cytokine expression, IL-10 is likely a
key mechanism whereby MDSCs polarize biofilm-associated monocytes to an anti-inflammatory
state (148, 187). In addition, monocytes isolated from biofilm infected IL-10 KO mice, showed
increased iNOS, IL-1α, and TNF-α expression, with a concomitant decrease in Arg-1, suggesting
that these monocytes are now pro-inflammatory. IL-10 KO animals have significantly reduced
bacterial burdens, and this is negated by adoptively transferring wildtype, in vitro-derived
MDSCs (148). Therefore, since MDSC IL-10 production significantly influences the
inflammatory phenotype of monocytes, IL-10 likely plays a role in shifting monocyte metabolism
to favor OxPhos. While it is known that IL-10 affects metabolism through the induction of the
mTOR inhibitor DDIT4, this has not yet been examined in the context of S. aureus biofilm
infection (353). It would be interesting to see whether DDIT4-deficient animals would be able to
clear a chronic biofilm infection. In addition, in vivo depletion studies in IL-10 KO animals and
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co-culture experiments of IL-10 KO or WT MDSCs with WT MΦs on a biofilm can help to
determine the role of IL-10 in metabolic skewing.
PAMPs and other bacterial products also likely influence monocyte metabolism and
inflammatory phenotype. Despite the abundance of pro-inflammatory molecules that exist at the
site of infection, the biofilm may produce, or possibly deplete, molecules to bias monocyte
metabolism towards OxPhos to promote anti-inflammatory activity. Specific evidence from MΦ
co-cultures with WT or ΔLuk-AB/Hla S. aureus biofilms show that these molecules kill
leukocytes and affect their inflammatory activity. While MΦ death was mitigated, MΦ skewing
was not completely relieved with the ΔLuk-AB/Hla strain, suggesting that other proteins act
redundantly to alter leukocyte activity and metabolism (60). While the level of redundancy is
unknown, proteomic studies of biofilms co-cultured with both MDSCs and MΦs may be
necessary to fully elucidate the contributing mechanisms utilized by the biofilm vs MDSCs to
shift monocyte metabolism. The S. aureus biofilm infection milieu is complex and dynamic, and
should be studied further to elucidate the mechanism of metabolic-mediated immune polarization
of monocytes, in order to develop novel therapeutics.

Effect of monocyte metabolism on leukocyte longevity
Leukocyte lifespan is tightly regulated to limit self-inflicted injury by activated
leukocytes following the resolution of infection. Several studies have demonstrated that reliance
on OxPhos supports cellular longevity. For example, anti-inflammatory MФs that favor OxPhos
have an increased life span, whereas pro-inflammatory MФs, which rely more on glycolysis are
shorter lived (255). While pro-inflammatory cytokines and PAMPs are abundant in the biofilm
milieu, effector populations are sparse and exhibit anti-inflammatory activity. During biofilm
infection, this suggests that elevated glycolysis-inducing cytokines possibly contribute to biofilm
persistence by eliminating effector cells by glycolysis-induced apoptosis, in addition to biofilmderived PAMPs. Following biofilm establishment and maturation, nutrient deprivation likely also
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prevents glycolysis and monocyte activation. Therefore, we hypothesize that the biofilm takes
advantage of the diminished longevity of glycolytic leukocytes in order to inhibit immune
clearance. Measuring leukocyte metabolism throughout the course of infection will provide
further insight into this aspect of monocyte metabolism, which can be correlated with leukocyte
death.
To directly examine the dynamics of leukocyte OxPhos and glycolysis in vivo,
fluorescent molecules indicative of both events can be used, i.e. JC-1 and 2-NBDG (2-(N-(7Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose). JC-1 is a bi-fluorescent cationic
molecule that accumulates in mitochondria with larger membrane potentials. At low
concentrations, it emits green fluorescence, while at high concentrations it forms J-aggregates that
fluoresce at ~590nm. Cells with more OxPhos activity, will have a more active electron transport
chain and lower mitochondrial membrane potential, which should manifest as a larger green:red
ratio. 2-NBDG is a fluorescent glucose analog that cannot be metabolized, which is used to
monitor glucose uptake and by extension, glycolytic activity. Together these two fluorescent dyes
can be used to characterize the metabolic activity of leukocytes during S. aureus biofilm
infections. Specifically, anti-inflammatory monocytes undergoing more OxPhos will show a
heightened green:red ratio when incubated with JC-1, and decreased 2-NBDG uptake.
Conversely, pro-inflammatory monocytes will show lower green:red ratios with JC-1 and
increased 2-NBDG uptake. My preliminary studies with these dyes have shown that relative to
animals receiving sterile implants at day 7, monocytes from infected animals undergo more
OxPhos and less glycolysis (Figure 5.7). These studies were expanded to examine the metabolic
profiles of leukocytes throughout the first week of infection to identify when monocyte
metabolism becomes permissive to S. aureus biofilm.
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Figure 5.7

Leukocyte metabolism during S. aureus biofilm infection. Tissue homogenates from sterile
and infected mice Day 7 post-orthopedic implant, were stained with JC-1 (A-D) and 2-NBDG (EH) dyes for 30 minutes at 37°C. Cells were washed and stained with antibodies to cell markers
and analyzed by flow cytometry. (A-D) OxPhos activity was determined in JC-1 stained cells by
the Green:Red ratios. (E-H) Glycolytic activity was determined by the percentage of cells that
stained positively for the fluorescent glucose analog. Results are from a single experiment. *, p <
0.05; ***, p < 0.005; ****, p < 0.0005; unpaired 2-tailed Student’s t-test.
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Role of tissue injury in promoting S. aureus biofilm establishment and persistence
Trauma and tissue injury has been shown to disrupt normal immune homeostasis, which
could cause a host to be susceptible to infectious complications. This is due to the fact that the
release of DAMPs are associated with immune suppression and increased susceptibility to
infections (354). Circulating DAMPs released from injured tissues can lead to a decrease in
MHC-II expression and suppression of pro-inflammatory activation (203). Preliminary studies
from our laboratory have demonstrated that the tissue damage associated with orthopedic implant
surgery promotes S. aureus biofilm infection. In particular, in animals receiving a sterile implant
that was allowed to heal for one week prior to S. aureus challenge (i.e. DAMP resolution) had
significantly less bacterial burdens and inflammatory mediator production concomitant with
reduced MDSC and increased monocyte infiltrates compared to animals where infection occurred
at the time of surgery (i.e. time of DAMP release). It would be interesting to determine the
differences in leukocyte metabolism in response to injury using this paradigm. This could be
investigated by complimentary approaches. In vivo, staining with JC-1 and 2-NBDG would
determine how leukocyte metabolism changes following sterile surgery, or cells could be sorted
for intracellular metabolomic analysis. In vitro, MΦs treated with homogenates from a sterile
surgery could be subjected to Seahorse Assays to obtain a real-time measurement of their
metabolic activity. In addition, determining whether specific DAMPs are driving susceptibility to
S. aureus biofilm infection would allow for their targeting to prevent susceptibility to postsurgical infectious complications.

Relationship between myeloid metabolism and bone destruction/formation during S. aureus
biofilm infection
S. aureus orthopedic implant biofilm infections elicit a large degree of osteomyelitis and
bone loss. Prior studies have shown that S. aureus can induce receptor activator of nuclear factor
kappa-B ligand (RANKL) expression and osteoclastogenesis from myeloid precursors (355-357).
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Similar to monocytes and MΦs, osteoclast function and differentiation is intimately related to
metabolic activity. Specifically, high rates of glycolysis are linked to osteoclastogenesis, while
osteoclasts actively resorbing bone will increase the expression of TCA cycle enzymes and
mitochondrial mass and activity (358-360). Furthermore, the reliance of osteoclast bone
resorption activity on OxPhos is supported by the induction or inhibition of OxPhos by pyruvate
or oligomycin, respectively (359). By extension, we hypothesize that bone resorption by
osteoclasts is fueled by OxPhos during S. aureus biofilm infection. Understanding the
mechanisms by which S. aureus can induce OxPhos activity in leukocytes to escape immunemediated clearance may provide insights into how the pathogen regulates bone resorption and
osteolysis. This is important to ultimately determine how to prevent and treat these infections, in
addition to reducing bone-loss during infection.

FINAL CONCLUSIONS
S. aureus biofilms actively polarize a host’s immune response towards an antiinflammatory phenotype which allows for the establishment or chronic infection. The complex
metabolic interactions between S. aureus biofilms and host leukocytes were a previously
unexplored area of research. We have shown that biofilm associated anti-inflammatory
monocytes are biased towards OxPhos metabolism, but can be actively reprogrammed to be proinflammatory and reduce bacterial burdens. However, the direct and indirect mechanisms by
which S. aureus biofilms polarize monocyte metabolism will need to be determined. Furthermore,
the consequences of metabolic polarization and pharmaceutical reprogramming are unknown and
will be investigated with the studies discussed above. Together, these studies will allow for the
development of novel therapeutic options for biofilm infections and other chronic diseases.
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